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Executive summary  
The objective of this deliverable is to summarize the main DRUID results and to extract relevant 
information for different target groups. Part I. discusses the theory of risk communication. Part II. 
summarizes the main DRUID results and Part III. presents the derived extraction per target group.  
 
Part I. describes the theoretic frame of risk communication in a broader perspective (definitions and 
communication theory, risk communication and sources for patients, managing risk communication 
related to driving with impairing substances, risk management framework and risk acceptability). 
Furthermore, it tries to answer the question on how effective are pictograms in communicating risk to 
patients who drive under the influence of medicines? Two studies are presented which evaluated 
different pictograms for risk communication with patients (a triangle and a rating pictogram on 
medicines and driving, each one using 4 different categories, ranging from no or negligible influence to 
major influence on fitness to drive). 
The results of these studies show that both pictograms were effective in communicating risk. Those 
who participated in the studies were able to recognize and understand the risk of driving under the 
influence of medicines and have shown their intention to change their driving behaviour by driving less 
frequently. In both studies, the rating pictogram was preferred over the triangle pictogram.  
 
Part II. presents an overview of the main DRUID results derived from the available DRUID 
deliverables (status 07.09.2011). It is separated into two subchapters: problem situation (mainly 
DRUID WP1-2) and countermeasures (mainly DRUID WP3-7). Eight overview boxes were produced 
to summarize the most relevant information per topic: 
• Alcohol; 
• Illicit drugs;  
• Psychoactive medicines; 
• Enforcement 
• Classification;  
• Rehabilitation; 
• Withdrawal (of driving license);  
• Guidelines/risk communication).  
 
Within Part III., the most relevant issues from Part I. and Part II. were extracted for each target group: 
(1) general public, (2) drivers as patients, (3) young drivers, (4) physicians and pharmacists and (5) 
policy makers on EU and national level. 
 
The following part presents the extraction for policy makers on EU level. This extraction is chosen as 
example within this executive summary, not only because of it’s relevance but also because it gives a 
condensed overview of the main issues mentioned above (in particular the main DRUID results).  
 
Extraction policy makers on EU level 
 
Key elements risk communication 
 
The aim of risk communication addressed to European policy makers is to (i) make them aware that 
the use of psychoactive substances (including some medicines) is not always compatible with car 
driving, (ii) support them to make their own problem definition, according to personal beliefs and 
professional responsibilities within the European context, (iii) provide them opportunities to use risk 
management tools (such as the risk management framework) in discussing risk control with relevant 
European stakeholders, (iii) allow them to decide how to contribute to the management of the risk in 
European society.  
 
For addressing risk communication messages to policy makers on an EU level, the following issues 
need to be considered: 
1. Policy makers need to be addressed with information on risk communication using the risk 
management framework (see table 1, p. 17). This will allow them to understand that DRUID 
outcomes describing the risk of driving under the influence of alcohol, illicit drugs or psychoactive 
medicines, can serve the purpose of discussing EU policy measures, e.g. EU risk control 
measures. 
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2. European stakeholders need to be involved in the development of a risk management framework 
for risk communication aiming at European bodies, such as: 
• Directorate General for Health and Consumer Affairs of the EC (DG SANCO); 
• Directorate-General for Mobility and Transport of the EC (DG MOVE); 
• Trans-European Transport Network Executive Agency of the EC (TEN-T EA); 
• European Transport Safety Council (ETSC); 
• European Parliament; 
• European Commission; 
• European Medicines Agency (EMA); 
• European professional organisation of pharmacists. physicians, psychologists and other 
health professionals; 
• International Alliance of Patients’ Organisations (IAPO); 
• European Association of Pharmaceutical Manufacturers; 
• other bodies… 
 
Extraction of main DRUID results 
 
Alcohol is the most serious problem compared to illicit drugs and psychoactive medicines in traffic in 
all investigated EU Member States (e.g. prevalence, risk estimates and cost-benefit-analysis of 
enforcement measures). Consequently, the first priority of countermeasures should always lie on 
alcohol; other psychoactive substances are second priority.  
 
The results of the DRUID studies in regard to the problem situation can generally be used in selecting 
overall activities and target groups in the policy field of psychoactive substance use in traffic across 
Europe. However, the results indicate, that the prevalence of psychoactive substances by gender, age 
and time period varies largely per country. “Therefore, recommendations for national activities 
regarding, e.g., policy issues, enforcement, education or campaigns, should primarily be based on the 
results of the country reports, rather than on the general report” (D2.2.3, Part I p. 10). 
 
Problem Situation (WP1/2) 
Alcohol  
• Alcohol (≥0.1g/L) is the most frequently detected psychoactive substance in the driving 
population (estimated EU mean 3.48%) (D2.2.3) as well as in the seriously injured (range 
17.7-42.5%) and in killed drivers (range 19.0-44.9%) in Europe (D2.2.5; D2.2.4; D2.3.4).  
• Alcohol was in the general driving population mainly detected among older male drivers, with 
lower BAC levels (D2.2.3).  
• Within the accident involved drivers alcohol was mainly detected among younger male drivers 
with a high BAC level (D2.2.5). 
• Alcohol has a negative impact on driving performance and highly increases accident risk (e.g. 
D1.1.2a, D2.3.2; D2.3.3; D2.3.4; D2.3.5 DRAFT).  
• Based on case- control studies, the relative risk of serious injury or fatality for alcohol (≥0.5 
g/L) is estimated to be significantly increased compared to that of drivers below the DRUID 
cut-off for any substance (D2.3.5) The risk increases dramatically with the alcohol 
concentration. 
• An increased risk was associated with high BAC level, young age and speed (D2.3.3). 
• The risk multiplies with combined use (e.g. cannabis) (D2.3.2). 
• For more details see overview box 1.  
Illicit drugs 
• All DRUID investigations (e.g. D2.2.3, D2.2.5, D2.3.4) show that the prevalence of illicit drugs 
in the driver population (estimated EU mean 1.90%) is lower than the alcohol prevalence 
(estimated EU mean 3.48%) (D2.2.3).  
• Within the accident involved drivers, the majority of drugs appeared to be used in combination 
with other psychoactive substances (mainly alcohol) (D2.2.5). 
• THC is generally the most frequently detected illicit drug, followed by cocaine, but the 
prevalence of the different illicit substances show high national variability (e.g. D2.2.3, D2.2.5, 
D2.3.4). 
• Illicit drugs were in general mainly detected among young male drivers, during all times of the 
day but mainly at the weekend (D2.2.3).  
• Combined use of alcohol and drugs (illicit drugs and/or psychoactive medicine) is in general 
often prevalent among young (<35 years) male drivers during night time hours (D2.2.3).  
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• Multiple drugs (illicit drugs and/or psychoactive medicines) use is in general most common in 
males (D2.2.3).  
• Age groups and time periods vary considerably by country (D2.2.3).  
• Based on case-control studies, the relative risk of serious injury or fatality for different illicit 
substances varies between the substances. For: THC about 1-3 times; benzoylecgonine, 
cocaine and illicit opiates about 2-10 times; amphetamines about 5-30 times as high as that of 
drivers below the DRUID cut-off for any substance (D2.3.5 DRAFT; see also D1.1.2b, D1.2.1, 
D2.3.2). Some of the risk estimates for illicit drugs vary to a high degree among the single 
countries; others are based on few positive cases and/or controls which result in very wide 
confidence intervals. Therefore the estimates are uncertain.  
• Experimental studies have shown that the dose equivalent for BAC 0.5g/L-3.7ng/mL THC 
(range 3.1-4.5ng/mL) for oral administration and 3.8 ng/mL (range 3.3-4.5ng/mL) for smoked 
administration (D1.1.2b, see also D1.4.2 for more information on cut-offs equivalent to BAC 
0.5g/L). 
• The risk multiplies with combined use (e.g. alcohol) (e.g. D2.3.2, D2.3.5).  
• Experimental studies evaluating the effect of stimulants on driving (MDMA and 
dexamphetamine) did not reveal impairing effects on driving performance. However, the 
stimulant effects of MDMA and dexamphetamine are not sufficient to overcome or 
compensate driving impairments produced by concomitant of alcohol use or sleep deprivation 
(D1.1.2b, D1.2.1).  
• For more details see overview box 2.  
Medicines 
• DRUID studies indicate that some selected psychoactive medicines (benzodiazepines, 
medicinal opiates and opioids and Z-drugs) are less prevalent in the driving population 
(estimated EU mean 1.4%) (D2.2.3) as well as is in seriously injured drivers (D2.2.5) 
compared to alcohol (estimated EU mean 3.48%) and illicit drugs (estimated EU mean 
1.90%). Among the killed drivers the presence of benzodiazepines was the second most 
frequent toxicological finding after alcohol (D2.2.5). Psychoactive medicines, such as 
(frequently used) antidepressants, anti-epileptics and antipsychotics, were not included in the 
DRUID studies. Therefore an underestimation of prevalence should be considered. 
• In most countries benzodiazepines were the most common psychoactive medicines in traffic 
but as for illicit drugs the prevalence of the different psychoactive medicines show high 
national variability (D2.2.3, D2.2.5).  
• Epidemiological studies indicate a major increase in the consumption of antidepressants and 
drugs used in addictive disorders in the general population in Europe within the last years 
(D2.1.1).  
• Psychoactive medicines were in general mainly detected among older female drivers during 
daytime hours (D2.2.3).  
• Alcohol impaired driving is the main problem in traffic safety, but also psychoactive medicines 
can constitute a problem in traffic safety. Therefore, both health care providers and patients 
should be properly informed and aware of the potential risks associated with the use of 
psychoactive medicines (link WP4/7). 
• Based on case-control studies, the relative risk of serious injury or fatality for benzodiazepines 
+ Z-drugs and medicinal opioids is estimated to be about 2-10 times (medicinal opioids in the 
upper part of the interval; benzodiazepines + Z-drugs in the lower part of the interval) as high 
as that of drivers below the DRUID cut-off for any substance (D2.3.5). 
• The risk of being involved in an accident for medicine users compared to non-users is highest 
for users of modern antidepressants (1.76, CI: 1.38-2.24), followed by patients who use 
combinations of psychoactive medicines (1.55, CI: 1.20-2.02), and patients using at least one 
psychoactive medication (1.28, CI: 1.12-1.46) (D2.3.1).  
• For more details see overview box 3.  
 
Countermeasures (WP3-7) 
Countermeasures always have to be seen as a comprehensive countermeasure system. 
Enforcement (WP3) 
• DRUID provides guidelines for everyday policy enforcement and installs scientific demands for 
on-side drug screening (e.g. legal frame; basic standards of on-site screening procedure; 
basic standards for on-site screening detection devices).  
• Cost benefit analyses have shown that first enforcement priority should lie on alcohol; other 
psychoactive substances are second priority. 
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• For more details see overview box 4. Furthermore, a detailed evaluation of legal 
countermeasures from the perspective of criminology can be found in D1.4.1  
Classification (of diving impairing medicines) (WP4) 
• DRUID WP4 proposed four level classification and a labelling system regarding the influence 
of medicines on driving performance, from category 0 (no or negligible influence on fitness to 
drive) to category 3 (major influence on fitness to drive). The DRUID WP4 categorization was 
in line with the recent approved SmPC guidelines adopted in September 2009 (which applies 
as from 1st of May 2010) by EMA.  
• DRUID WP4 reviewed over 3000 medicines and over 1500 of them were categorized in 
regard to their influence on fitness to drive: Most of them were Category 0: 50.7%, while 6% 
were Category III (Major influence in fitness to drive). DRUID results are compatible with any 
existing national classification system (e.g. FR, ES) and could be integrated in them. 
• Politicians should promote that the DRUID WP4 categorization and labelling be integrated in 
existing computerized prescribing and dispensing systems for physicians/pharmacists at the 
various EU member states. 
• There is a need to improve information related to effects on driving, particularly in the Patient 
Information Leaflet (PIL). Information to patients who are advised to use medicines that may 
impair driving fitness needs to be improved by simple and patient-centred directions based on 
a clear categorisation system and reflected in the PIL.  
• For more details see overview box 5.  
Rehabilitation (WP5) 
• It should be stated on EU level that Driver Rehabilitation should be an integrated part of a 
comprehensive countermeasure system.  
• Main outlines of rehabilitation procedures should be formulated on EU level (guidelines for 
legal regulations and standardised procedure). DRUID WP5 developed Europe-wide 
standards and recommendations of good practice for DUI/DUID rehabilitation measures, 
which were couched into the form of a user friendly tool (Development of Driver Rehabilitation 
Evaluation Tool, DRET) for implementation, assessment or evaluation of existing or new DR 
systems or programmes. It can be the starting point of a European networking and 
documentation process of DR measures.  
• For more details see overview box 6.  
Withdrawal (of driving license) (WP6) 
• Regulations in European countries regarding withdrawal and accompanying measures should 
be unified. So far, national strategies are very heterogeneous. Hence a clustering of strategies 
or countries is difficult.  
• DRUID WP6 developed Europe-wide recommendations on withdrawal and conditional 
withdrawal for the general driving population and specific problem groups such as DUI/DUID 
drivers, patients in substitution or other long-term treatment with psychoactive medicines (see 
also D1.4.1). 
• For more details see overview box 7.  
Guidelines for health care professionals (WP7) 
• Decision support at the start of a treatment is needed for selecting the least impairing 
medicines. Therefore, guidelines and standards for health care professionals pertaining to 
medicines and driving could be initiated on EU level (D7.2.1).  
• Eight recommendations on improving the procedures for assessing fitness to drive within the 
framework of Council Directive 91/439/EEC (on driving licences) have been formulated within 
DRUID WP7. These suggestions should be discussed in working groups/expert rounds with 
physicians, pharmacists, driving licensing authorities and policy makers in order to reach a 
consensus at European level (D7.2.1). 
• The implementation of existing protocols and guidelines into existing computer software used 
by health care professionals could be stimulated by e.g. incentives for organisations for 
maintaining databases and software companies.  
• For more details see overview box 8.  
Risk communication (WP7) 
• The focus of campaigns (content, target group, media etc.) should be selected according to 
the specific characteristic of problem situation and risk group (D7.1.1, D7.3.1). 
• Campaigns are more successful if they are targeted (specific issues, groups, etc.). Therefore, 
large campaigns should be designed as sets of a larger number of activities on a smaller scale 
(D7.1.1, D7.3.1). 
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• Campaigns should be evaluated (D7.1.1, D7.3.1). The EU project CAST provides guidelines in 
designing and evaluating campaigns (D7.1.1; D7.3.1). 
• Risk communication pictograms on medicine boxes are effective in communicating risk to the 
patient (rating models are preferred over no rating indications) (study: ES NL) (D7.3.2).  
• Prescribing and dispensing guidelines show a positive effect (e.g. reported behaviour, attitude) 
after training and implementation phase (study: BE, ES, NL). Health care professionals 
strongly prefer ICT supporting tools which are integrated in their daily dispensing/prescribing 
software packages (D7.4.2).  
• The emphasis of risk communication towards young people should be given to drink driving 
prevention, targeting the age group 15-24 year. Preventive measures should be differentiated 
into general preventive approaches (e.g. campaigns) and special focussed preventive 
measures for certain smaller subgroups (lifestyle types e.g. personal communication). The 
effectiveness of approaches should be analyzed in-depth based on representative samples 
(according results for e.g. DE will be available at the end of the DRUID project) (D7.4.3Draft).  
• For more details see overview box 8.  
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Part I: Risk communication in a broader perspective 
 
Authors: Han de Gier, Susana Monteiro (RUGPha, University of Groningen, the Netherlands);  
Inmaculada Fierro, F. Javier Álvarez (UVa, University of Valladolid, Spain) 
1 Introduction 
Communication is crucial to the efforts by which governmental agencies, organisations or institutions 
aim to change human behaviour among target groups, such as individuals, communities, populations 
and societies. Efforts related to risk communication by governmental agencies concerning driving with 
impairing substances can have different purposes. The scope is mostly to reduce traffic fatalities and 
injuries caused by driving under the influence of alcohol or other psychoactive substances, whereas 
the assessment of driver fitness and prescribed use of driving impairing medication are considered as 
decisions to maintain mobility of road users with the least but acceptable risk concerning fitness to 
drive. At an individual level the scope is to address the risks and benefits from taking psychoactive 
substances, for example if drivers start to use prescribed medication or decide to use substances that 
might hold risks, e.g. of being impaired while driving. In this Chapter it will be described how 
communication at different levels will have an effect on outcomes of risk communication. It will give a 
broader risk communication perspective by discussing in short how communication theory can help to 
understand changing human behaviour, it will describe definitions and after some focus on the clinical 
context, more information will be presented to understand the management framework for 
stakeholders on how to develop optimal risk communication. Based on this framework risk 
management activities within DRUID will be illustrated and linked to the different sources developed 
within DRUID, which are available as Deliverables. Readers of this Chapter who are more interested 
to know how the management framework has been developed are directly referred to paragraph 4.1.  
2 Definitions and communication theory 
Communication is the production and exchange of information and meaning by use of signs and 
symbols. It involves encoding and sending messages, receiving and decoding them, and synthesizing 
information and meaning (Finnigan & Viswanath, 2011). Risk communication is defined as any two-
way communication between stakeholders about the existence, nature, form, severity, or acceptability 
of risks (McColl, Hicks, Craig, & Shortreed, 2000). This definition clearly points out that stakeholders 
are involved in dialogues, but it also implies that those who are affected by decisions have to follow a 
decision-making process, based in their views and capabilities on the assessments of risk, public 
values, acquired knowledge and perceptions.  
 
Communication theory is the basis for understanding human behaviour in the field of public health by 
using applied communication perspectives. Communication is key for developing health behaviour 
strategies which are based on theories of health behaviour change, such as the health belief model 
and the theories of reasoned action and planned behaviour. According to the health belief model, 
individuals will be likely to change their health-related behaviour if they judge a health risk as 
important, view themselves as susceptible to the risk and regard the benefit of changing their 
behaviour. In the theories of reasoned action and planned behaviour it is considered that behaviour is 
influenced by intentions to change. People’s attitude towards a specific behaviour as well as their 
perceptions of what important referent groups think about the behaviour, will influence their intentions. 
The likelihood to change behaviour in these theories is determined by influencing the individual’s 
perceptions.   
 
For decades health behaviour change strategies have been focused on community-based public 
health interventions and campaigns, where changes in health behaviour (from the individual to the 
community level) are anticipated. Media communication in community-based campaigns, aims to 
achieve an impact on behavioural norms by promoting, discouraging or inhibiting healthy behaviours. 
Media campaigns are seldom effective, if not addressed to the target populations in the right way 
(CAST 2009). One important aspect of media communication is about creating the messages based 
on the definition of a public health problem. The latter will determine how target populations, in 
particular its individuals will be likely to affect the problem.  
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Research on the consequences of media exposure on individuals, groups, institutions and social 
systems has shown that the order of effects on knowledge, behaviour and attitudes depends on where 
individuals or groups are positioned with respect to a given outcome (Chaffee & Roser, 1986). The 
development of the appropriate messages is crucial and should be based on a thorough assessment 
of target group characteristics, social structure and needs. Knowledge and information about health 
issues are not equally distributed across populations. It is well known that people with more formal 
education learn and know more health issues than people with less formal education (Mosteller & 
Moynihan, 1972). As a consequence, groups with higher socioeconomic status are more likely to 
benefit from an increasing flow of information on many issues, including health issues. However, there 
are factors that could reduce the knowledge gap. For example, people might feel that health issues 
are more relevant to them than other issues, also certain groups could experience a greater impact of 
information due to the channel that was chosen, and used more frequently by them (e.g. internet 
applications, newsgroups). It is expected that users of ICT technologies will search the information “on 
demand”, allowing them to control the media technologies and attempts to change their behaviour. 
This, however, is also a risk for widening the knowledge gap, because access could be determined by 
socioeconomic status and necessary skills. Another factor is the ability to use multiple sources, if 
needed. It is suggested that the “power” of any single channel of communication (being mass media or 
interpersonal) may depend on the complexity of the behaviour change being sought. If the change is 
less complex, a single channel of communication may lead to development of the promoted 
behaviour. If, however, the behaviour change is more complex an individual will need the use of 
multiple sources of information and the application of multiple channels of communication  (Bandura, 
1994). 
3 Risk communication and sources for patients    
The definition of risk communication that can be adopted from a clinical context is: one-to-one 
communication in which the intervention includes a stimulus to patients to weigh the risks and benefits 
of a treatment choice or behavioural (risk reducing) change (Edwards & Elwyn, 1999b). The key 
outcomes after such an intervention are in general effects on patient knowledge, risk perception, 
anxiety or behavioural change. However, clinical research outcomes are shifting from traditional 
cognitive and behavioural research outcomes (patient knowledge, risk perception, and compliance) to 
more affective outcomes (assessment of the information provided, shared decision-making, certainty 
about the best option, patient satisfaction). This shift towards affective measures also reflects the 
changing characteristics of patient-provider relationships in health care. The need for this change is 
well illustrated by the fact that approximately 50% of patients in developed countries fail to take their 
medicines properly, despite information that is provided in patient information leaflets. This is partly 
due to a lack of comprehension and estimation of the risks of their medicines, and partly because they 
have no control over planning and conduct of their health care and related safety activities (lack of 
patient empowerment). Patients need a full set of information about anticipated benefits and risks as a 
prerequisite for shared decision making. They need clear guidance how to respond to impairing effects 
of substances by the provision of tailor-made information. Although physicians, pharmacists, nurses 
and pharmaceutical manufacturers play a role in providing comprehensive information to patients, 
sources of information are still unclear and better tools to help patients understand their treatment 
options and associated benefits and risks need to be developed (Ruland, 2004). In Deliverable 7.3.1. 
prototype documents have been developed that might give more information on what the messages 
should be in written and verbal risk communication, to be used by the public, patients, as drivers, 
health care professionals, young drivers and policy makers.  
4 Managing risk communication related to driving with 
impairing substances 
From a broader risk management perspective, it is clear that focus on risk communication is no longer 
limited to concern about how to inform the public about technical aspects, but more on how to start 
and maintain an on-going dialogue among stakeholders (e.g. breweries, drug manufacturers, 
consumers, patients, drivers, health care professionals, academics, traffic safety researchers, 
governmental agencies for road safety, health care and public health media, and policy makers). The 
most preferred way of managing the process of risk communication among all stakeholders is to 
develop a risk management framework to ensure that risk communication will be an integral part of all 
stages of the risk management process. In the next paragraph the risk management framework will be 
explained in more detail.  
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4.1 Risk management framework 
A risk management process aims at defining all steps that need to be addressed in building good risk 
communication. By presenting these steps and describing the risk communication tasks for each step, 
a risk management framework will be developed for effective risk communication in DRUID. By 
showing the link to the various deliverables it will constitute a framework that allows referencing to 
background information as well as a reflection on weak and strong tasks for risk communication. It is 
recommended to address those reflections for improving the risk communication tasks needed to 
stimulate the dialogue among stakeholders. The overview of all necessary steps with risk 
communication tasks (derived after McColl et al., 2000) is presented in table 1. 
 
Table 1: Risk communication tasks in the risk management process 
Risk management step Risk communication task Sources in DRUID Additional comments 
Initiation 
 
Identifying and consulting 
stakeholders, defining the 
scope 
All DRUID partners represent 
some categories: academia 
(psychologists, toxicologists, 
physicians and pharmacists), 
police, traffic safety 
researchers, governmental 
agencies  
 
Task 4.2: regulatory 
agencies/ EMA, patient 
representatives (IAPO),  
Task 7.2.2.: professional 
organisations of GPs and 
pharmacists in Europe 
Task 7.4.3.: young drivers 
who use drugs,  
Groups that did not play a 
significant role in defining the 
scope are  policy makers, 
pharmaceutical industry , 
public health authorities  
Risk identification Developing a stakeholder 
analysis 
During developing tasks in 
various WPs analysis of 
needs, issues of concern, 
level of interest, knowledge 
gaps, trusted sources of 
information, and 
communication preferences 
were conducted. 
A dialogue with the following 
stakeholders is 
recommended:  policy 
makers, pharmaceutical 
industry , public health 
authorities 
Risk estimation 
 
Sources, communicating 
results with stakeholders, 
assess changes in 
knowledge and perceptions 
WP 1 and 2 Deliverables 
 
There will be a need to 
assess stakeholders’ 
knowledge and perceptions 
based on new information 
before messages on risk 
communication can be 
developed. 
Risk evaluation 
 
Perception of risks and 
benefits, assess acceptability 
of risks 
 
WP 1, Task 1.1 evaluated 
dose and blood 
concentrations  related to 
accident risk (compared to a 
standard risk level of 0.5g/L 
blood alcohol concentration) 
There will be a need to 
understand stakeholders’ 
acceptability of risk resulting 
from stakeholders’ 
perceptions   
Risk control 
 
Identifying and evaluating 
control options 
WP 1 identified effective 
legal regulations for 
combating DUI and DUID. 
Deliverables: WP 3, 5 and  6 
for controling DUI drivers and 
WP 4 and 7 for controling 
prescribing and dispensing of 
impairing medicines and 
controling information to 
target groups 
There will be a need to 
assess the stakeholders’ 
acceptance about control 
options provided by various 
DRUID WPs 
Implementation 
 
Communication of risk 
control decisions and 
implementation strategies 
WP 1 recommended how 
cut-off values in biological 
fluids could be defined for 
per se legislations 
WP 3,5 and 6 recommended 
procedures and activities for 
driver rehabilitation 
enforcement and withdrawal 
measures   
WP 4: medicines 
categorization system 
WP 7: prototype documents 
for target groups , 
There will be a need to 
assess the stakeholders 
opportunities to 
communicate the risk control 
options, and possibilities to 
implement these control 
options.  
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prescribing and dispensing 
information & pictogram 
evaluation, evaluation of 
DRUID materials in practice 
& patients responses, 
campaign design for young 
drivers who use drugs
  
Monitoring 
 
Ensure implementation of 
communication strategies, 
monitoring changes in needs 
and concerns of existing and 
new stakeholders 
Recommendations in various 
Deliverables 
There will be a need for 
continuous monitoring of 
changes in needs and 
concerns of (existing and 
new) stakeholders  
 
Step 1: Initiation 
 
During this step identification of stakeholders within DRUID was accomplished by inviting the DRUID 
partners representing academia (psychologists, toxicologists, physicians and pharmacists), police, 
traffic safety researchers, and governmental agencies. The appropriate level of stakeholder 
involvement is situation specific, and each stakeholder’s perspective was described and all activities 
have been developed according to task development schemes with subsequent reporting in 
deliverables. However, some groups did not play a significant role in defining the scope such as policy 
makers, pharmaceutical industry, patient groups and public health authorities. It is recommended to 
involve these groups by informing them about the outcomes of DRUID before the final dissemination 
of the results at the closing of the project. 
 
In various tasks stakeholders were involved who were not contributing as partners: 
• Task 4.2: regulatory agencies (Pharmacovigilance Working Party of EMA), and patient 
representatives (IAPO);  
• Task 7.2.2.: professional organisations of GPs and pharmacists in Europe; 
• Task 7.4.3.: young drivers who use drugs.  
 
Step 2: Risk identification 
 
For each stakeholder group the following information was included in the stakeholder analysis: needs, 
perception and acceptability of risk, knowledge gaps, trusted information sources and communication 
preferences. Since a few stakeholder groups were not involved a dialogue with these groups is 
recommended before finalizing the risk communication messages. In particular verification with policy 
makers, pharmaceutical industry, public health authorities needs to provide the necessary update of 
their considerations in decision-making and communication processes. 
 
Step 3: Risk estimation 
 
Partners have contributed to determining the prevalence of substance use (alcohol, illicit drugs, 
psychoactive medicines), to describing characteristics of impaired drivers using those substances and 
the accident risk for driving. These results are presented in deliverables within WP 1 and 2 (see box 1-
3). However, it is recommended to re-assess stakeholders’ knowledge and perceptions based on new 
information before messages on risk communication can be developed. 
 
Step 4: Risk evaluation 
 
Discussions to determine stakeholder acceptability of the risk associated with DUI related problems 
have resulted in preliminary risk evaluation perspectives for cost and benefits. However, there will be a 
need to understand stakeholders’ acceptability of risk resulting from stakeholders’ perceptions in this 
risk evaluation step before messages on risk communication can be developed. 
 
Step 5: Risk control 
 
It is important to know stakeholders’ acceptability of the residual risk after the implementation of 
proposed risk control options. Within DRUID priorities for police enforcement activities, characteristics 
of the problem situation at national levels, determination of the focus of enforcement, cost-benefits of 
increased drugs and driving enforcement, such as saliva screening in road side testing, and risks of 
cost cutting activities in drink-driving enforcement have been discussed. These results, as well as 
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recommendation of increasing the effectiveness of police enforcement are presented in deliverables 
within WP 3 (see also box 4).  
Risk control can be achieved by implementing legal regulations for effective combating DUI and DUID. 
Identification of effective legal regulations is presented in WP1. 
Another risk control focus has been given to driver rehabilitation activities. Recommendations on 
assignment to driver rehabilitation, the provision of different driver rehabilitation options according to 
offenders’ needs, and quality related requirements are presented in deliverables within WP 5 (see also 
box 6). One important control option, alcohol ignition interlock programmes, has been recommended 
as effective measure for DUI offenders in combination with rehabilitation activities.  
The risk focus for improving the control options in applying withdrawal measures for DUI(D) drivers, 
substitution therapy, conditional licensing based on fitness to drive examinations, is presented in 
deliverables within WP 6 (see also box 7). 
A risk control focus related to medicines that can impair driving is presented by partners involved in 
developing a classification and labelling system. By improving the warnings for patients a better 
decision making process by patients is expected which will contribute a lower the risk of impaired 
driving under the influence of medicines. Recommendations are presented in deliverables within WP 4 
(see also box 5). 
A final focus on control options is given to recommendations for improving prescribing and dispensing 
practices of general practitioners and community pharmacist. In particular the application of 
Information and Communication Technology (ICT) in existing software packages has been 
emphasized for arriving at practical control options everyday medical and pharmaceutical practice. A 
specific control option has been developed in designing a communication pictogram which is linked to 
WP 4 labelling. Recommendations are presented in deliverables within WP 7 (see also box 8). Finally, 
recommendations for improving the procedures for assessing fitness to drive within the framework of 
Council Directive 91/439/EEC (on driving licences) have been developed and are presented in 
Deliverable 7.2.1. (p. 55-59).  
There will be a need to assess the stakeholders’ acceptance about control options provided by various 
DRUID WPs before communication messages can be developed. 
 
Step 6: Implementation 
 
This action step is associated with stakeholder outreach to communicate the risk control decision and 
its implementation involving all possible risk control options that various parties could apply in their 
standard (practice) procedures (see also Step 5).  
There will be a need to assess the stakeholders’ opportunities to communicate the risk control options, 
and possibilities to implement these control options before developing risk communication messages.  
 
Step 7: Monitoring 
 
Monitoring changes in needs and concerns of existing and new stakeholders will be needed as a 
continuous process for ensuring implementation of communication strategies. Recommendations in 
various deliverables are to be followed up in order to know the effects of risk management options on 
desired outcomes. This task will eventually be taken up by national organisations, institutions and 
governmental agencies.  
The effects of new legislations in Member States based on DRUID results and/or developments in 
conjunction with the DRUID project need to be monitored, such as implementation of cut-off values in 
the Netherlands and Norway, as well as the effects of a new rehabilitation system in Slovenia. 
However, there will be one specific task that needs consideration by the European Commission: the 
maintenance of WP 4 procedures to update the medicine lists with categorization, warnings and 
advices to patients, based on the criteria and the framework that has been presented in Deliverables 
4.2. and 4.3. 
Finally, in order to develop risk communication activities in the future, there will be a need for 
continuous monitoring of changes in needs and concerns of (existing and new) stakeholders. 
 
In summary, risk communication tasks within DRUID have been developed with satisfactory results. 
However, the presentation of the risk communication tasks in the risk management process shows 
that there are various needs described for further review in order to be prepared for the development 
of a comprehensive risk communication strategy. In general it boils down to three activities: 
1. Re-assessment of stakeholders’ knowledge, perceptions and risk acceptability based on new 
information as presented in DRUID deliverables; 
2. Assessment of stakeholders’ acceptance of, and opportunities to communicate, the risk 
control options and possibilities to implement the various control options; 
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3. Identifying the (groups of) stakeholders who did not yet show any involvement in the 
development of risk communication tasks where the scope of the problem has been defined, 
e.g. policy makers, pharmaceutical industry and public health authorities.  
 
It is recommended to pay attention to these activities in developing risk communication efforts. 
Stakeholders’ participation remains the key issue in accepting risk management decision; they have 
been heard and are involved, and can better accept the decision even if they continue to dislike the 
decision itself. 
4.2 Risk acceptability 
In many considerations about risk control options, as described in the previous paragraph, risk 
acceptability is mentioned as key issue for developing a successful risk communication messages. It 
would be of interest to determine the acceptability of presenting substance dosages or substance 
blood concentrations which have the same risk of impairment as has been determined for alcohol at a 
blood alcohol concentration of 0.5g/L, which represents an accepted level of risk of impairment in road 
traffic in most countries. 
It is important to realize that accepting risk is guiding people’s behaviour. Several factors affect the 
acceptability of risk, often defined in a narrow technical perspective by experts and in a wider 
psychological, social and cultural perspective by the public. The following list shows some of the 
characteristics of factors that play a role in perceiving and accepting risk (derived after McColl et al., 
2000): 
• Voluntariness (voluntary risk, e.g. smoking is more acceptable than an involuntary risk, eg. air 
pollution); 
• Control (risks not under personal control, e.g. passenger in a vehicle, are perceived more risky 
than those under one’s own control, e.g. driving a car);  
• Credibility (organization or individual: perceived caring and empathy are most important; 
competence and expertise only 15-20% of credibility. Academics are generally ranking higher 
in credibility than industry and governments);  
• Familiarity (high/tech facilities provoke more outrage than familiar risks, e.g. risk at home, 
driving);  
• Diffusion in space and time (rare events such as nuclear accidents are seen as far riskier than 
common ones, e.g. road traffic accidents); 
• Trust (issue is important but organization or individual can not be trusted, feeling to be 
powerless); 
• Morality (what is perceived as risky is seen as attacking core interests and values, e.g. 
children, health, security, the future, certainty). 
 
For driving under the influence of psychoactive substances it seems obvious to address these factors 
carefully in defining messages of risk communication to drivers or patients who drive. A trusted 
organization, credible and with an eye on values and interests that drivers feel important can do a 
proper job in convincing them that, although DUI is a voluntary risk, it will not be completely controlled 
by the person due to the effects of psychoactive substances.   
5 How effective are pictograms in communicating risk to 
patients who drive under the influence of medicines? 
5.1 Abstract 
Introduction: Risk communication is a two way exchange of information, leading to a better 
understanding of risk. Pictograms can be used to communicate risk, helping patients to make 
decisions about using their medicines while driving. Similar studies were conducted in the Netherlands 
and Spain. Despite having common aims, the results obtained in each country are presented 
separately.  
 
Aim: To compare the effectiveness of two pictograms (rating model and triangle model pictograms) in 
communicating risk associated with driving impairing medicines to patients and to assess patients’ 
level of understanding (and comprehensibility, in the Spanish study) and intention to change driving 
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behaviour when looking at various pictograms. The added-value of a explanatory side text was 
investigated as well. 
 
Methods:  Two studies using a 2x3 design were conducted. In the first study, the respondents 
(patients visiting a community pharmacy with a driving license) were exposed to a condition in which 
the pictogram (rating model or homologue triangle model pictogram) and the risk category (category 1, 
2 or 3) were manipulated. In this study, both pictograms were accompanied by the same side-text 
(experiment 1). Additionally, the added value of the side-text was examined (experiment 2). Here, the 
respondents were exposed to the rating model pictogram with or without side-text and again one of 
the three risk categories. 
 
Results:  
 The Netherlands – After observing both rating model and triangle model pictograms, respondents 
recognized the risk of driving while taking driving impairing medicines: 78.8% of the respondents 
were likely to change their behaviour and 36.3% said they would drive less frequently in the 
presence of a medicine with such pictograms. Patients showed preference for the 3 categories 
presented in the rating model pictogram.  
 
Spain – The comprehensibility of the pictograms was good: 90.2% for the rating-model pictogram 
with side-text, 89.3% for the triangle-model pictogram, and 94.8% for the rating-model pictogram 
without side text. 77.7% of the respondents were likely to change their behaviour and 25.4% said 
they would not drive at all in the presence of a medicine with such pictograms. Overall, 
respondents preferred the rating-model pictogram over the triangle-model pictogram, as well as the 
rating-model pictogram with text rather than the same pictogram without text 
 
Conclusion: In the two studies, both pictograms seem to be effective in communicating risk but the 
rating model pictogram was preferred over the triangle model one. In the Dutch study, for the rating 
model pictogram, a clear and direct correlation between the likelihood of changing driving behaviour 
and the level of impairment of a medicine has been observed: the higher the category, the more likely 
to change driving frequency (by driving less frequently). 
5.2 Introduction 
Pictograms for risk communication 
 
Risk communication is central to effective decision making in modern healthcare (Davis et al., 2003; 
Edwards & Elwyn, 1999a; Edwards et al., 2003; Thomson, Edwards, & Grey, 2005) and constitutes 
the basis for informed patient consent (Gordon-Lubitz, 2003; Paling, 2003; Thomson et al., 2005). Risk 
communication can be defined as an interactive process of exchange of information about risk (R. 
Lofstedt, 2002; R. Lofstedt & Perri, 2008; R. Lofstedt, 2008a; R. Lofstedt, 2008b; R. E. Lofstedt, 2007), 
leading to a better understanding and better decisions about clinical management (Edwards, Elwyn, & 
Mulley, 2002; Edwards et al., 2003; Thomson et al., 2005). Risk communication stimulates patients to 
weigh the risks and benefits of a treatment choice or behavioural (risk reducing) change (Edwards & 
Elwyn, 1999a; Edwards et al., 2000). Visual displays of risk information, such as pictograms, are 
known to increase patient understanding of risk (Gordon-Lubitz, 2003; R. Lofstedt, 2008b; Paling, 
2003). Non-verbal symbols, including pictograms, are increasingly being recommended and used to 
convey warnings and other safety-related information (Katz, Kripalani, & Weiss, 2006; Mansoor & 
Dowse, 2004) and are particularly useful to communicate information to patients with low literacy 
(Dowse & Ehlers, 2001; Dowse & Ehlers, 2005; Hill & Roslan, 2004; Houts, Doak, Doak, & Loscalzo, 
2006; Mansoor & Dowse, 2004; Morrell, Park, & Poon, 1990; Ngoh & Shepherd, 1997). 
 
Pictograms are known to enhance comprehension (Dowse & Ehlers, 2001; Dowse & Ehlers, 2005; 
Houts, Witmer, Egeth, Loscalzo, & Zabora, 2001; Houts et al., 2006; Katz et al., 2006; Mansoor & 
Dowse, 2004; Sorfleet, Vaillancourt, Grloves, & Dawson, 2009), recall of information (Dowse & Ehlers, 
2001; Dowse & Ehlers, 2005; Hill & Roslan, 2004; Houts et al., 1998; Houts et al., 2006; Katz et al., 
2006; Mansoor & Dowse, 2004; Sorfleet et al., 2009), adherence (Houts et al., 2006; Katz et al., 2006) 
and communication across language barriers (Lemmon & Hyman, 2006). In order to be effective, 
pictograms should consider the cultural background of the target population and make use of familiar 
objects and symbols (Dowse & Ehlers, 2001; Hill & Roslan, 2004; Ngoh & Shepherd, 1997). The 
design should be simple, realistic and with limited content (Hill & Roslan, 2004) and the pictogram 
should, at all times, be self-explanatory. If these requirements are not considered during the 
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development of pictograms, there is a higher chance that the message and/or concepts will be beyond 
patients’ understanding. 
 
Pictograms in traffic safety 
 
The introduction of a compulsory and harmonised pictogram on the medicines’ packaging, based on 
the European classification of drugs according to their effects, was suggested, in 2005, in the 
European Road Safety Action Programme as part of the “efforts to combat the scourge of drink-driving 
and find solutions to the issue of the use of drugs and medicines” (European road safety action 
program for halving the number of road accident victims in the EU by 2010.) 
. 
 
The development of such categorization system as well as a proposal to communicate the risk of 
driving under the influence of medicines to patients are part of the European DRUID (Driving under the 
influence of drugs, medicines and alcohol) project goals. Therefore, within DRUID, following the 
development of the categorization system (Task 4.3), the need to design appropriate pictograms to 
communicate risk arose (Task 7.3). 
 
In some European Union countries, however, pictograms showing the potential risk of driving when 
taking medicines known to impair psychomotor performance have already been developed. In the 
Netherlands, psychoactive medicines have a yellow warning label that is affixed to the medicines’ 
package (Wolf, Davis, Tilson, Bass, & Parker, 2006). The yellow sticker contains only written 
information that refers to the influence of that medicine in the ability to react adequately as well as the 
increased risk when combining the medicine with alcohol. Another country with warning labels related 
with medicines and driving is Spain, where a red triangle with a black car inside is printed in the box of 
medicines that influence driving ability (Spanish royal decree 1345/2007 of October 11th). 
In France, a country where the categorization system was officially adopted, a graded pictogram was 
designed to be printed on the box of all category 1 to 3 medicines (Orriols et al., 2010) (figure 1).   
 
 
 
Figure 1: Triangle model pictogram (French triangle on medicines and driving) 
 
In Slovenia, medicines with major influence on driving fitness are labeled with a filled red triangle 
whereas medicines with minor to moderate influence are labeled with an empty triangle. In this case, 
three categories have been assigned to impairing medicines: cat. a) no or negligible influence; cat. b) 
minor or moderate influence; cat c) major influence on driving fitness. The symbols are printed on the 
medicine box, making all health care professionals aware of the warnings (Rules on Labelling of 
Medicinal Products and on the Packaging Leaflet (Official Journal of the Republic of Slovenia, no. 
54/06 and the Medicinal Products Act (Official Journal of the Republic of Slovenia, no. 31/06). 
 
The rating model pictogram 
 
In the rating model pictogram, developed within DRUID (figure 2), the various possible risks of 
impairing driving ability are displayed, horizontally, in a bar. From left to right, categories range from 0 
(no impairment) to 3 (severe impairment) and to each category a different colour was attributed. A 
traffic-light colour approach was followed, as people tend to associate the colour red to danger, the 
yellow to caution, and the green to safety (Veldhuijzen et al., 2006). Therefore, green, yellow, orange 
and red colours were chosen to represent each category of the medicine. Finally, the category 
attributed to a medicine is indicated by a triangle with a black car inside, as triangles are commonly 
associated to a warning message and the car is related with driving. A small text on the top of the 
pictogram saying “your risk in traffic” was added to avoid misunderstandings, allowing patients to 
associate the risk of taking a medicine and driving.  
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a)
b)
c)
 
Figure 2: Rating model pictogram. a) category 1; b) category 2; c) category 3 
 
Two studies were conducted in the Netherlands and Spain to evaluate the effectiveness of the two 
pictogram models, as shown above.  
5.3 Dutch study 
5.3.1 Aim 
The primary aims of the present study was to evaluate i) the effectiveness of the rating and triangle 
model pictogram in communicating risk associated with driving impairing medicines to patients and ii) 
to assess patients’ level of understanding and intention to change driving behaviour by looking at 
various pictograms. A comparison between triangle and rating model pictogram was carried out on 
these dimensions. Furthermore, participants were also asked about their preference for one of the two 
models of pictograms on medicines and driving.  
 
A comparison with a similar and already existing (in France) pictogram (figure 1) was made (triangle 
model pictogram). The triangle model pictogram was selected for comparison due to the fact that 
these were the only existing pictograms in which a distinction between different categories or levels of 
impairment was made. 
5.3.2 Methods 
Design 
 
This experimental study involved a 2 (rating model pictogram versus triangle model pictogram) X 3 
(categories of impairment - category 1, 2 and 3) design. The size of the rating model pictogram was 17 
x 46 mm. The pictograms were labelled on “fake” medicines’ boxes created, on purpose, for the study.  
A comparison between the same category of the rating and the triangle pictorial models was 
conducted (experiment 1). The same participants were also asked their preference for one of the 
pictorial models (experiment 2). 
 
In order to analyse the effectiveness of both pictograms and to investigate patients’ level of 
understanding and intention to change behaviour by looking at various pictograms, 9 groups of 30 
patients each, in a total of 270 participants, were created. The order in which the pictograms were 
shown to patients is relevant for the research question (especially in experiment 2) as it might 
constitute a bias. Therefore, 3 main groups of 90 participants (30 per category) were initially asked 
questions related with one category of the triangle model. During the course of the interview, the 
homologue category of the rating model pictogram (with side-text) was shown. Because the order was 
considered to be relevant, 3 other groups were shown pictograms in the reverse order. Three more 
groups were included and firstly shown the rating model (without side-text) and thereafter the triangle 
model. Table 2 gives a brief overview of the groups.  
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Table 2: Pictograms visualized by patients, at the start of the interview and thereafter 
 
Initial pictogram 
(experiment 1) 
Comparison 
(experiment 2) 
A) 
A1 – 30 patients 
A2 – 30 patients 
A3 – 30 patients 
Triangle model 
Category 1 
Category 2 
Category 3 
Rating model with side-text 
Category 1 
Category 2 
Category 3 
B) 
B1 – 30 patients 
B2 – 30 patients 
B3 – 30 patients 
Rating model with side-text 
Category 1 
Category 2 
Category 3 
Triangle model 
Category 1 
Category 2 
Category 3 
C) 
C1 – 30 patients 
C2 – 30 patients 
C3 – 30 patients 
Rating model without side-text 
Category 1 
Category 2 
Category 3 
Triangle model 
Category 1 
Category 2 
Category 3 
 
Setting 
 
A structured interview involving patients visiting a Dutch community pharmacy (location: Groningen) 
and actively participating in traffic with a motorized vehicles was carried out. Participants younger than 
18 years old and those who could not speak nor read Dutch were considered not eligible for the 
interview and, as a consequence, were excluded. 
 
Medical ethical approval  
Since we only performed an interview about interpretation of pictograms among patients in a 
pharmacy (the results of which were anonymized) after explicitly asking their consent, no approval of a 
medical ethics committee was required. 
More in detail: All health care professionals and patients were adequately informed about the nature of 
the study, participated voluntarily and their anonymity was preserved. Patients were interviewed in the 
waiting area of the pharmacy by a research associate who explained that that the interview was aimed 
at evaluating pictograms that could be used to warn patients about driving impairing side effects of 
certain medicines in the near future. Therefore, the therapeutic relationships with their pharmacist 
could not be influenced by the patients’ responses to the interviewer.  
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Experiment 1  
 
In experiment 1, participants were exposed to a condition in which the pictogram (rating model 
pictogram, figure 2 or triangle model pictogram, figure 1) and the risk category (category 1, 2 or 3) 
were manipulated.  Participants were always asked the same questions, regardless the pictogram, 
allowing comparisons between both pictograms (rating and triangle models).   
 
Experiment 2 
 
In experiment 2, the same group of patients were shown one category (1, 2 or 3, depending on the 
category group they were assigned to) presented by both pictorial models. Text that was part of the 
pictogram itself was not shown. Therefore, the rating model pictogram would not have the message 
“your risk in traffic” and the triangle model pictogram did not include side-text. 
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Patients were shown the side-text that belongs to one of the categories separately and they were 
asked which of the pictograms would better reflect the text (understandability) and which one would 
better show the levels of impairment. Figure 3 gives an example on how the pictograms (in this case it 
is exemplified category 1 medicines; the same was done for category 2 and 3 medicines) and the 
side-text were visualised for the patient. 
 
 
Figure 3: Presentation (as an example) in the experiment 2 
 
Structured interview 
 
The interview was carried out in Dutch. All responses were translated into English and transcribed for 
content analysis. The interview consisted of four distinct parts: 1) general knowledge about medicines 
and driving, 2) specific questions about the pictogram, 3) comparison between 2 pictograms, and 4) 
socio-demographic characteristics of the respondent. Below, it is described the questions that were 
asked in each section of the interview and the possible answers. 
 
1. General knowledge about medicines and driving 
a. Can medicines influence the ability to drive? (yes/no/don’t know). 
b. Did you know that certain medicines can influence driving ability? (yes/no/don’t know). 
c. Were you ever informed about the influence of medicines on driving ability? (yes/no). 
If yes, who provided you that information? (pharmacist, general practitioner, read it on 
the patient information leaflet)?  
 
2. Specific questions about the pictogram – here, patients are shown the “fake” medicine’s box 
with the initial pictogram labelled (table 2). The questions in this section were used in 
Experiment 1. 
a. What catches your attention? (open question) 
b. What is your interpretation of the pictogram? (open question) 
c. How likely would it be for you to change your driving behaviour if you would be taking 
a medicine with such a pictogram? (very unlikely (1), unlikely, neutral, likely, very 
likely (5)). 
d. Suppose you are taking a medicine with this pictogram labelled on the box. How often 
you would drive? (equally (1), slightly less often, less often, much less often, not 
anymore (5)).  
e. How would you rate the level of impairment on driving fitness of this medicine? 
(estimation level of danger: harmless (1), safe, not safe/not dangerous, dangerous, 
very dangerous (5)) 
f. How would you rate the pictogram in terms of: 
i. Difficult / easy (7-point Likkert scale ) 
ii. Unclear / clear (7-point Likkert scale ) 
iii. Not informative / informative (7-point Likkert scale ) 
iv. Incomprehensible / Understandable (7-point Likkert scale ) 
v. Complex / not complex (7-point Likkert scale ) 
 
3. Comparison between 2 pictograms (in this section, patients were shown the homologue 
pictogram. The questions in this section were used in Experiment 2. 
a. Which one of the pictograms helps you to better understand the text? (rating model or 
triangle model) 
b. Which one the pictograms give you more insight about levels of impairment? (rating 
model or triangle model) 
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4. Socio-demographic characteristics and use of medicines 
a. What is your gender? (male or female) 
b. What is your age? (age in years).  
c. What is your level of education? (not completed primary school, completed primary 
school, lower vocational training, intermediate vocational training, higher vocational 
training). 
 
Dependent variable construction and statistical analysis 
 
Descriptive analysis was conducted to analyse respondents’ characteristics, such as gender, age and 
education level. For experiment 1, the intention to change behaviour, changes in driving frequency, 
estimation of level of danger and the evaluation of the pictograms was verified. For experiment 2, the 
preference for one of the pictogram models was analysed.   
 
a) Intended change of behaviour 
A 5-point Likert scale was used to analyse participants’ intention to change their driving behaviour (1 = 
very unlikely to 5 = very likely). An ANOVA test was used to measure an interaction effect between the 
fist presented model and the answers given by the respondents. A p-value < 0.05 (95% confidence 
interval) was considered significant. The same approach was carried out in order to investigate 
respondents’ frequency of driving after looking at the pictogram.  
 
b) Estimation of level of danger 
The estimation of the level of danger represented by each category of the pictogram model was 
associated with a 5-point Likert scale (1 = harmless to 5 = very dangerous). Respondents could select 
one of the options given by the Likert scale. However, theoretically, the three categories of the 
pictogram models should be coupled to an answer from the Likert scale as follows: 
Category 1: Likert scale option 3 = not dangerous / harmless;  
Category 2: Likert scale option 4 = dangerous; 
Category 3: Likert option 5 = very dangerous.  
 
An independent T-test was executed to determine the correlation effect between the first presented 
pictogram model and the answers given by the respondents. A p-value < 0.05 was considered 
significant.  
 
c) Evaluation of the pictograms 
A 7-point Likert scale was used to evaluate the pictograms in six different parameters: 
Clarity:    1 = unclear to 7 = clear;  
Level of information:  1 = not informative to 7 = informative;  
Understandability:  1 = not understandable to 7 = understandable;  
Complexity:   1 = complex to 7 = not complex;  
Level of difficulty:  1 = difficult to 7 = easy;  
Level of ambiguity:  1 = ambiguous to 7 = unambiguous. 
A p-value < 0.05 (95% confidence interval) was considered significant. The Cronbach’s alpha value of 
0.899 proves the reliability of the scale. 
 
d) Pictograms preference (experiment 2) 
To investigate respondents’ preference for the pictogram that would better explain the side-text and 
the levels of impairment, a χ2 – Test was performed in order to compare the differences between 
pictograms and between the categories of each pictogram. A p-value < 0.05 was considered 
significant.  
5.3.3 Results 
A total of 270 participants, assigned to 9 different groups, were interviewed. In order to reach the 
required number of participants, 360 patients were approached. Thirty-two participants (75% females) 
did not possess a driving license and, for that reason, could not be part of the study. Fifty-eight 
participants (62.1% females) did not want to take part of the study (non-respondents) for several 
reasons: no time (44.8%), no interest (29.3%), not feeling fit due to illness (12.1%), and other reasons 
(13.8%). 
 
The relevant characteristics of the study population are summarised in table 3. The total study 
population (n = 270) was equally distributed in terms of gender (n=137; 50.7% males). The mean age 
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of the participants was 48.4 years-old and the majority of the respondents had a university degree (n = 
123; 45.6%). No statistical significant differences were found between gender, age or education level 
between pictograms (rating model with and without side-text and triangle model).  
 
Table 3: Characteristics of the respondents, stratified per pictogram 
     
Rating Model 
without side-
text (n=90) 
Rating Model 
with side-text 
(n=90) 
Triangle Model 
with side-text 
(n=90) 
Gender N %  N %  N %  
Male 45 50.0 50 55.6 42 46.7 
Female 45 50.0 40 44.4 48 53.3 
For ‘Gender’ a χ2 – Test was calculated: P-value=0.484 
Age (in years) 
   
Mean 49.23 48.19 47.78 
Minimum 20 20 21 
Maximum 78 75 78 
For ‘Age’ an ANOVA test was executed: P-value=0.785 
Educational level: N  %  N  %  N %  
Low 19 21.1 15 16.7 20 22.2 
Intermediate 29 32.2 34 37.8 30 33.3 
High 42 46.7 41 45.6 40 44.4 
For ‘Education Level,’ a χ2 – Test was calculated: P-value=0.614 
 
Almost all respondents were aware of the fact that some medicines can influence both reaction time (n 
= 261; 96.7%) and driving ability and (n = 264; 97.8%). Of the respondents, 48.5% received 
information about the influence of medicines on driving against 49.3% who did not. For those who 
received information, pharmacists were the preferable source of information (64.4%), followed by the 
patient information leaflet (12.1%). General practitioners were only mentioned by 7.6% of the 
respondents who received information about the influence of medicines on driving ability.  
 
Experiment 1  
 
The pictogram, with no distinction between the rating model and the triangle model, caught 84.8% of 
the respondents’ attention right after looking at the medicines’ boxes for the first time.  
 
Respondents were asked to interpret the pictogram they were shown. Answers were divided in right or 
wrong. Those related to traffic without any reference to the category were still considered as correct 
answers. As illustrated in figure 4, 72.2% of the participants that were shown one of the triangle model 
pictograms (n = 90) did not make any reference to any category of impairment, against 46.7% and 
36% of the respondents who looked at the rating model pictogram with and without side-text, 
respectively. With the rating model pictograms, more fully correct answers (traffic related with 
reference to categories of impairment) were obtained. Education level did not have a statistically 
significant influence in the correct interpretation of the pictograms. References to risk of driving under 
the influence of medicines were often made by participants who saw the rating model pictograms.  
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Figure 4: Respondents’ interpretation of the starting pictogram (n=270; 90 respondents per 
pictogram group) 
 
The estimated level of danger was assessed with a scale ranging from harmless to very dangerous. A 
significant difference (p-value = 0.033) between the rating model and the triangle model was found. A 
significant difference in category 1 pictograms was fond as well (p-value = 0.027), meaning that, by 
looking at category 1 from the rating model, respondents think it is safer than the homologue category 
form the triangle model. According to participants’ perspectives, categories 2 and 3 of the rating model 
were those associated, although not significantly, with more dangerous situations (figure 5).  
 
 
Figure 5: Estimation level of danger was assessed by asking the following question: “How 
would you rate the level of impairment on driving fitness of this medicine?” Every dot 
represents the mean estimation of risk value of 30 participants belonging to each category of 
the rating and triangle models pictogram 
 
The estimation level of danger was assessed by asking the following question: “How would you rate 
the level of impairment on driving fitness of this medicine?”. Every dot represents the mean estimation 
of risk value of 30 participants belonging to each category of the rating and triangle models pictogram. 
 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
30 
The likelihood of changing driving behaviour by looking at pictograms was also investigated, by using 
a scale ranging from very unlikely to very likely. The likelihood to change driving behaviour is 
significantly higher (p-value = 0.022) with the rating model pictograms than with the triangle model. 
Figure 6 represents the likelihood to change driving behaviour according to the category of the 
pictogram. It is shown that, the higher the category (or risk level) the bigger the likelihood to change 
driving behaviour and that, respondents who saw category 1 pictograms are significantly more likely to 
change their behaviour with the triangle model than with the rating model (p-value = 0.004). 
 
 
Figure 6: Respondents’ likelihood to change driving behaviour was assessed by asking the 
following question: “How likely would it be for you to change your driving behaviour if you 
would be taking a medicine with such a pictogram?” Every dot represents the mean likelihood 
value of 30 participants belonging to each category of the rating and triangle models pictogram 
 
The respondents’ likelihood to change driving behaviour was assessed by asking the following 
question:. “How likely would it be for you to change your driving behaviour if you would be taking a 
medicine with such a pictogram?” Every dot represents the mean likelihood value of 30 participants 
belonging to each category of the rating and triangle models pictogram. 
 
Participants (36.3%; n = 270) stated they would be likely to change their driving behaviour by driving 
less frequently. No statistically significant differences (p-value = 0.100) were found between both types 
of models (figure 7). However, a statistically significant difference was found in category 1 pictograms 
(p-value = 0.037). Similarly to what was found with the likelihood to change behaviour, respondents 
who saw category 1 pictograms significantly drive less with the triangle model than with the rating 
model. 
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Figure 7: Respondents’ changes in driving behaviour (frequency) was assessed by asking the 
following question: “Suppose you are taking a medicine with this pictogram labelled on the 
box. How often you would drive?”. Every dot represents the mean change in driving behaviour 
value of 30 participants belonging to each category of the rating and triangle models pictogram 
 
The respondents’ changes in driving behaviour (frequency) were assessed by asking the following 
question: “Suppose you are taking a medicine with this pictogram labelled on the box. How often you 
would drive?”. Every dot represents the mean change in driving behaviour value of 30 participants 
belonging to each category of the rating and triangle models pictogram. 
 
40.7% of the respondents (n = 270), would change their driving behaviour by not driving anymore. 
Refrain from driving is advised whenever a category 3 medicine is prescribed. 60% (n = 90) of the 
respondents who first saw category 3 pictograms from the rating model would not drive anymore, 
against 43.3% of those who saw the homologue triangle model.  
 
All pictograms (different categories from the two models) were found to be clear, informative, easy, 
understandable, not complex, and not ambiguous, as it is shown in table 4. For all determents, 
category 2 pictograms had lower mean scores than other categories. Education level did not influence 
respondents evaluation of the pictograms (p-value = 0.136). 
 
Table 4: Mean scores (± standard deviation) for the evaluation of the pictograms. For each 
characteristic, a 7 point Likkert scale was used (1 – negative; 7 – positive).  
 
Rating model  
without side-text 
Rating model  
with side-text 
Triangle model  
with side-text 
Cat 1 Cat 2 Cat3 Cat 1 Cat 2 Cat3 Cat 1 Cat 2 Cat3 
Unclear - clear 5.73 (±1.55) 
5.23 
(±1.65) 
6.37 
(±1.22) 
5.57 
(±1.43) 
5.13 
(±1.55) 
6.20 
(±1.40) 
4.83 
(±1.82) 
4.63 
(±1.96) 
5.37 
(±1.52) 
Not informative 
- informative 
4.97 
(±1.59) 
5.13 
(±1.57) 
5.57 
(±1.69) 
5.27 
(±1.62) 
5.07 
(±1.08) 
6.07 
(±1.28) 
5.03 
(±1.56) 
4.77 
(±1.87) 
5.50 
(±1.28) 
Difficult - easy 5.77 (±1.38) 
5.63 
(±1.33) 
6.10 
(±1.49) 
5.87 
(±1.38) 
5.87 
(±1.07) 
6.47 
(±0.97) 
5.83 
(±1.17) 
5.70 
(±1.53) 
5.97 
(±1.22) 
Not 
understandable 
- 
understandable 
5.77 
(±1.28) 
6.13 
(±0.94) 
6.20 
(±1.45) 
5.87 
(±1.31) 
5.90 
(±1.12) 
6.40 
(±1.04) 
5.57 
(±1.22) 
5.57 
(±1.32) 
5.90 
(±1.21) 
Complex – not 
complex 
5.93 
(±1.23) 
5.83 
(±1.39) 
6.30 
(±1.42) 
5.90 
(±1.32) 
5.77 
(±1.22) 
6.40 
(±1.10) 
5.93 
(±0.98) 
5.93 
(±1.33) 
6.13 
(±1.11) 
Ambiguous –  
Unambiguous 
5.67 
(±1.21) 
5.27 
(±1.80) 
6.17 
(±1.51) 
5.53 
(±1.59) 
5.33 
(±1.47) 
5.83  
(±1.58) 
5.70 
(±1.32) 
5.70 
(±1.73) 
5.77 
(±1.63) 
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Experiment 2 
 
Respondents were asked which one of the models would better explain the side-text (that differs 
depending on the category) and which one of the pictograms would better show the levels of 
impairment. Table 5 illustrates participants’ preferences, according to their age, gender, starting 
pictogram and education level.  
 
Table 5: Participants pictogram preferences for explaining a side-text and levels of impairment  
 Preference for understanding the warning 
in the side-text 
Preference for showing the levels of 
impairment 
 Rating Model Triangle Model P-value Rating Model Triangle Model P-value 
Category 1 76.7% 23,3% <0.001 86.7% 13.3% <0.001 
Category 2 81.1% 18.9% <0.001 84.4% 15.6% <0.001 
Category 3 65.6% 34.4% <0.001 76.7% 23.3% <0.001 
Total 74.1% 25.6% <0.001 82.6% 17.4% <0.001 
 
A correlation between age and preference for one of the pictograms was found: older participants 
were more in favour of the triangle model than younger participants, who prefer the rating model 
(figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Participants’ preference for a certain pictogram according to their age. a) Preferred 
pictogram for explaining better the side-text. b) Preferred pictogram to show better levels of 
impairment.  
a) 
a) 
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5.3.4 Discussion 
The pictograms that were compared were effective in communicating risk. Respondents who 
participated in this study were able to recognize the risk of driving under the influence of medicines 
and showed their intention to change their driving behaviour by driving less frequently. For the rating 
model pictogram a direct correlation was shown between the likelihood of changing driving behaviour 
and the level of impairment of a medicine. The added value of the side-text was demonstrated. 
 
Respondents had a high education level and were well aware of the fact that medicines can influence 
both reaction time and driving ability. Pharmacists were the preferable source of information in relation 
to receiving information about medicines. 
 
Both pictograms, rating and triangle models, seemed to be eye-catching. This is an important factor 
because it is the first step to catch patients’ attention which might stimulate patients to attend to the 
information that is on the pictogram (Davis et al., 2003). Respondents were able to interpret correctly 
the meaning of the pictogram, regardless of the category. It was considered that the correct 
interpretation needed to focus on risk in traffic (minor, moderate or severe risk). From the answers that 
were given, those who looked at the rating model pictograms gave more answers related to risk than 
those who looked at the triangle model. This could be due to the fact that the rating model has a small 
line of text stating “your risk in traffic”. The authors believe that the sentence is of relevance to the 
correct interpretation of the pictogram. This line of text might also have contributed to the better 
estimation of danger that was associated with the rating model. Higher risk categories (category 2 and 
3) were significantly more dangerous than the homologue from the triangle model. However, the lower 
category (category 1) of the triangle model had a higher mean score for the estimation of danger than 
the same category from the rating model. This could be due to the fact that the triangle model does 
not make any reference to the number of categories, which means that it is difficult to perceive the 
exact risk.  
 
The risk message associated with both pictorial models (risk of driving) was well understood by the 
respondents as the intention to change driving behaviour, by driving less frequently, was mentioned by 
the majority of the respondents. A direct and significant correlation between likelihood to change 
driving behaviour and category was seen with the rating model: the higher the risk, the bigger the 
likelihood to change driving behaviour. As mentioned before this is believed to be due to the fact that 
the triangle model stands as a single pictogram, not giving the idea of the total range of categories 
and, therefore, missing the risk concept as a whole.  
  
Respondents found both pictograms clear. However, for all three categories of risk, the rating model 
was found to be significantly clearer than the triangle model. The presence of all categories of risk that 
exist and the text “your risk in traffic” might be a reasonable explanation for this fact. In general, both 
pictograms were classified as informative, easy, understandable, not complex, and not ambiguous, 
meaning that pictograms were well designed.  However, category 2 pictograms were not so well 
accepted, as category 2 pictograms had lower score rates. Considering that a great proportion of the 
medicines fell in this category, it is of great importance that category 2 pictograms have a message 
that leaves no doubt.  
 
With no doubts, the rating model pictogram was, in respondents’ opinion, the one explaining better the 
side-text that was shown as well as the levels of impairment. Despite the rating model was always 
preferred, the elderly respondents shown preference for the triangle model. It could be hypothesised 
that the triangle model has a more conservative design. A triangle with a car with a traffic-light-like 
colour system background seems to be enough to transmit the warning message to elderly patients.  
 
The results of this study should be considered in the light of some strengths and limitations. The study 
population had a higher education level which could have contributed to the correct interpretation of 
the pictograms’ message and to the relatively degree of acceptation. Pictograms are often used as a 
message vehicle for low literate populations. Therefore, it is important to make sure that patients with 
low education levels can understand the risk message. However, these pictograms are targeted to 
those who drive which certainly imply a certain level of education and literacy.  
 
There are several studies that show the relevance of pictograms in health care (Dowse & Ehlers, 
2001; Dowse & Ehlers, 2005; Hill & Roslan, 2004; Houts et al., 1998; Houts et al., 2001; Houts et al., 
2006; Katz et al., 2006; Lemmon & Hyman, 2006; Mansoor & Dowse, 2004; Morrell et al., 1990; Ngoh 
& Shepherd, 1997; Sorfleet et al., 2009; Wolf et al., 2006). Still, not so much can be retrieved from the 
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field of medicines and driving (Veldhuijzen et al., 2006). For that reason, the DRUID partners believe 
in the novelty of the findings and are confident that the implementation of pictograms related with the 
influence of medicines on driving ability will be a substantial contribution to campaign development. 
5.4 Spanish study 
5.4.1 Aim 
The aim of the Spanish study was to evaluate i) the comprehensibility of the triangle model and the 
rating model pictograms (with and without side-text) in communicating the risk associated with driving 
impairing medicines to patients; ii) the intention to change driving behaviour by looking at these 
pictograms; iii) to assess patients’ preference: Comparison between the Rating model and the 
Triangle model, both with side-text (Study 1); Comparison between the Rating model with side-text 
and the Rating model without side-text (Study 2). 
5.4.2 Methods 
Target population 
The target population was made up of “health service users”. Throughout the current text, they shall 
be referred to as “patients”. However, it should be taken into account that what we really mean by this 
term is people who come into contact with the National Health Service through Primary Care, Hospital-
Specialized Attention or as consumers in pharmacies. 
 
The “health service users“ included in the study correspond to three different health service levels: i) 
Pharmacies; ii) Primary Care; iii) Hospital-Specialized Attention. The study was aimed at both patients 
with a driving license and those without. 
 
Sample size 
The study included a total of 736 patients. 541 patients were included in the Study 1, which compared 
the triangle-model pictogram and the rating-model pictogram. Study 2, which compared the rating-
model pictogram, with and without text, included 195 patients. 
 
Design 
To evaluate “The comprehensibility of the triangle model and the rating pictogram (with and without 
side-text) in communicating the risk associated with driving impairing medicines to patients” and “The 
intention to change driving behaviour by looking at these pictograms” (first and second objectives), the 
answers about the first pictogram shown were used (annex 1, p. 129). Approximately one third of the 
sample was shown each one of the three DRUID categories (Categories I, II and III).This same 
proportion was maintained for each of the models of pictogram (triangle model with side-text and 
rating model pictogram with and without side-text). ISO 9186-1:2007 was the reference for testing the 
comprehensibility of the different pictogram models. 
 
Both in Study 1 (Comparison between the Rating model and the Triangle model (both with side-text) 
and Study 2 (Comparison between the Rating model with side-text and the Rating model without side-
text), on evaluating the preference for one model of pictogram or the other, the possible influence of 
the order in which they were shown was considered. In order to avoid this possible effect, the sample 
was stratified in such a way that, for each category and model of pictogram, half of those interviewed 
were first shown the category and model that was shown second to the other half. 
 
Setting 
2.  
3.  
4.  
The study was carried out in different health care environments within the Province of Valladolid.  
 
The patients were interviewed in:  
1. Primary Care facilities by nursing staff,  
2. In pharmacies by trained survey personnel, 
3. In Specialist Attention (pre-anesthesia visits in the “Hospital Clínico” in Valladolid) by trained 
survey personnel. 
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Questionnaire 
A questionnaire was created for this purpose, which can be seen in annex 1. It has been analysed as 
was agreed by the partners of task 7.4.  
 
Medical Ethical approval 
The study was approved by the Clinical Research Ethics Committee of the Faculty of Medicine at the 
University of Valladolid and by the Research Commission of the “Hospital Clínico Universitario” of 
Valladolid. All the health professionals and patients were adequately informed of the nature of the 
study, participated voluntarily and their anonymity was preserved. 
 
Statistical analysis  
The data gathered from the study have been recorded in a database of the statistical package PASW 
Statistics 18. The results are shown as mean ± standard deviation and/or median for the quantitative 
variables and percentages for the categorical variables. Also, respectively, the T-test and the Squared 
Chi test have been used to analyze the results. Values of P ≤ 0.05 were considered statistically 
significant.   
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5.4.3 Results 
The study included a total of 736 patients. Study 1, which compared the triangle-model pictogram and 
the rating-model pictogram included 541 patients. Study 2, which compared the rating-model 
pictogram, with and without text, included 195 patients. 
 
Table 6 shows the distribution according to gender, educational level and mean age of the patients 
included in the study according to the pictogram they were shown first, independently of whether they 
were from study 1 or 2. As the Spanish study has included both drivers and non-drivers, table 6 shows 
the distribution according to whether or not they had a driving license. 
 
Table 6: Characteristics of the respondents, stratified per pictogram  
  
Triangle Model 
(with side-text) 
N (%) 
Rating Model 
(with side-text) 
N (%) 
Rating Model 
(without side-text) 
N (%) 
Gender  Male 140 (53.2) 177 (47.1) 48 (49.5) Female 123 (46.8) 199 (52.9) 49 (50.5) 
Educational 
 level 
 
Did not finish primary school 4 (1.5) 13 (3.5) 1 (1.0) 
Finished primary school 79 (30.0) 139 (37.1) 36 (37.1) 
Finished secondary school 46 (17.5) 44 (11.7) 5 (5.2) 
Completed “A” level (age 18) 58 (22.1) 73 (19.5) 29 (29.9) 
University degree/diploma 76 (28.9) 106 (28.3) 26 (26.8) 
Driver licence Yes 240 (91.3) 324 (86.2) 79 (81.4) No 23 (8.7) 52 (13.8) 18 (18.6) 
Age: Mean ± SD (N) 49.03 ± 14.20 (263) 49.85 ± 14.64 (376) 50.04 ± 13.88 (97) 
Total 263 (100.0) 376 (100.0) 97 (100.0) 
 
The meaning the pictogram on driving has for the patient 
 
To analyse the meaning the patient gives to the pictogram on driving on the medicine packaging, all 
the patients were asked the following question: In your opinion, what is the meaning for you of the 
pictogram on driving? 
 
The question was formulated openly and the answers were then codified into the 7 levels proposed in 
the norm ISO 9186: 
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Level 1: Correct understanding of the symbol is certain (estimated probability of correct 
understanding over 80%); 
Level 2: Correct understanding of the symbol is very probable (estimated probability of correct 
understanding between 66% and 80%); 
Level 3: Correct understanding of the symbol is very probable (estimated probability of correct 
understanding between 50% and 65%); 
Level 4: The meaning which is stated is the opposite to that intended; 
Level 5: Any other response; 
Level 6: The response given is “Don’t know”; 
Level 7: No response is given. 
 
The criterion established for understanding was: “It may negatively affect driving or put the driver at 
risk” + “reference to the definition of each category” 
 
The definition is different for each of the three categories, but the same for each of the three types of 
pictogram. 
Category I: “Be careful: Read carefully the patient leaflet before driving”; 
Category II: “Be very careful: Take advice from a physician or pharmacist before driving”; 
Category III: “Danger: do not drive: seek medical advice before driving again”. 
 
Table 7 shows the answers obtained for each of the pictograms. 
 
Table 7: The meaning the pictogram on driving has for the patient, according to pictogram type 
 
Triangle Model 
(with side-text) 
N (%) 
Rating Model 
(with side-text) 
N (%) 
Rating Model 
(without side-text) 
N (%) 
Level1: Correct understanding (p>80%) 13 (4.9) 23 (6.1) 0 (0.0) 
Level 2: Correct understanding (66%<<80%) 139 (52.9) 192 (51.0) 80 (82.5) 
Level 3: Correct understanding (50%<<65%) 74 (28.1) 118 (31.4) 12 (12.4) 
Level 4: Opposite meaning 6 (2.3) 1 (0.3) 2 (2.1) 
Level 5: Any other answer 18 (6.8) 18 (4.8) 1 (1.0) 
Level 6: Don’t know 3 (1.1) 17 (4.5) 2 (2.1) 
Level 7: No response is given 10 (3.8) 7 (1.9)  0 (0.0) 
Total 263 (100.0) 376 (100.0) 97 (100.0) 
 
Percentages are calculated for all level except cases where no response is given. Figure 9 shows the 
distribution of responses by patients for the first 6 levels of the norm ISO 9186. As indicated in the 
norm ISO 9186, these percentages have been calculated excluding the no response cases (category 
7). 
 
Having grouped together the correct answers with a probability of above 50%, the comprehensibility of 
the three models of pictogram is Good: 90.2% in the group of the rating-model pictogram with text, 
89.3% in the triangle-model pictogram, and 94.8% for the rating-model pictogram without side text. 
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Figure 9: Norm ISO 9186: Comprehension test  
 
Overall scores for each pictogram were obtained by weighting and summing the percentages of 
responses in the different categories. Weighting algorithm (Percentage X Weight):  
% Category 1 X 1.0 
% Category 2 X 0.75  
% Category 3 X 0.50 
% Opposite X -1.0 
% Wrong X 0.0  
 
Table 8 shows comprehension scores for the three models of pictogram after summing weighting 
percentages to obtain comprehension score (the percentage of total comprehension). 
 
Table 8: Comprehension scores for the three models of pictogram  
 Weight 
Triangle Model 
(with side-text) 
Rating Model 
(with side-text) 
Rating Model 
(without side-text) 
% % score % % score % % score 
Correct understanding (p>80%) 1.00 5.1 5.1 6.2 6.2 0.0 0.0 
Correct understanding (p: 66%-
80%) 0.75 54.9 41.2 52.0 39.0 82.5 61.9 
Correct understanding (p: 50%-
65%) 0.50 29.2 14.6 32.0 16.0 12.4 6.2 
Opposite meaning -1.00 2.4 -2.4 0.3 -0.3 2.1 -2.1 
Wrong 0.00 8.3 0.0 9.5 0.0 3.1 0.0 
% Comprehension score   58.5  60.9  66.0 
 
The International Organization for Standardization (norm ISO 9186) recommends a critical level of 
correct comprehension of at least 67% for signs and symbols. Thus, none of these three pictograms 
would pass the comprehensibility criterion, the rating-model without side text being the closest to this 
score (66.0%). 
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Estimation of the level of danger 
 
The estimation of the level of danger represented by the pictogram model was studied by means of a 
4 point Likert scale (0= very harmless to 3 = very dangerous). As shown in table 9 for each category (I 
to III), the mean scores do not differ within the three types of pictograms. In general, an increase in the 
risk perceived by the patients (increase in the average score) can be seen as the category of the 
medicine increases, for both the triangle-mode pictogram and the rating-model pictogram (either with 
or without side-text). However, as can be seen in figure 10, relatively higher scores tend to be given in 
categories I and II (average scores over 1.00 and 2.00 points respectively) and to underestimate the 
risk/danger in category III. Even with this effect, significantly different scores concerning the danger 
can be seen in all three models of pictogram between categories I and II. The same can be seen 
between categories II and III, except for the triangle–model pictogram, in which the average score 
given to the risk factor of categories II and III do not differ in any significant way (table 9). 
 
Table 9: How would you evaluate the degree of influence of this medicine on driving, i.e., the 
risk you run using this medicine when driving? 
 
Category I Category II Category III (cat I/II) T [95% IC]; p 
 N Mean±SD N Mean±SD N Mean±SD (cat II/III) T [95% IC]; p 
Triangle Model 
(with side-text) 81 1.88±0.75 84 2.54±0.65 80 2.69±0.57 
-6.06 [-0.87,-0.44]; 
p<0.0001 
1.60 [-0.34,0.04]; p>0.05 
Rating Model 
(with side-text) 130 1.78±0.77 111 2.35±0.63 107 2.77±0.52 
-6.31 [-0.74,-0.39]; 
p<0.0001 
-5.31 [-0.57,-0.26]; 
p<0.0001 
 
Rating Model 
(without side-text) 31 1.58±0.67 31 2.39±0.62 34 2.76±0.43 
-4.93 [-1.13, -0.48]; 
p<0.0001 
-2.84 [-0.64, -0.11]; 
p<0.01 
Total sample 242 1.79±0.75 226 2.42±0.64 221 2.74±0.53   
 F= 1.75; p>0.05 F= 2.09; p>0.05 F= 0.57; p>0.05   
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Figure 10: Risk of driving under the effects of a medicine (Mean±SD) according to its category. 
 
Intended change of behaviour 
Two questions in a 5 points Likert scale was used to analyse participants’ intention to change their 
driving behaviour. 
 
Question 1: “Supposing you were prescribed this medicine which has the pictogram 
concerning driving on the packaging. How frequently would you drive during the period in 
which you were taking the medicine?” 
 
The interviewed patients were asked the following question: “Supposing you were prescribed this 
medicine which has the pictogram concerning driving on the packaging. How frequently would you 
drive during the period in which you were taking the medicine?” The question had 5 possible answers: 
the first answer would imply no change in attitude –“With the same frequency”- while the other four 
present a growing degree of change –“Less frequently”; “A lot less frequently”; “I would hardly drive at 
all” and “I would not drive at all”.  
 
There were significant differences in the answers concerning the change in frequency of driving 
depending on the different pictograms (Χ28=19.393; p<0.05) (table 10, figure 11).  
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
40 
 
Comparing the answers given for each pictogram, significant differences can be seen between the 
triangle-model pictogram and the rating-model pictogram without text (Χ24=10.225; p<0.05) and 
between the rating-model pictogram with and without text (Χ24=15.836; p<0.01). However, no 
significant differences were found between the triangle-model pictogram and the rating-model 
pictogram with side-text (Χ24=3.596; p>0.05).  Thus, the triangle-model pictogram and the rating-model 
pictogram, both with side-text would have a similar influence at the time of deciding whether to reduce 
the frequency of driving while taking a medicine with one of these pictograms on the packaging; while 
the rating-model pictogram without side-text would, on the evidence of the results, have a significantly 
lower influence. 
 
Table 10: Supposing you were prescribed this medicine which has the pictogram concerning 
driving on the packaging. How frequently would you drive during the period in which you were 
taking the medicine? 
 
With the same 
frequency 
N (%) 
Less 
frequently N 
(%) 
A lot less 
frequently 
N (%) 
I would hardly 
drive at all 
N (%) 
I would not drive at 
all 
N (%) 
Triangle Model 
(with side-text) 34 (13.4) 62 (24.4) 39 (15.4) 60 (23.6) 59 (23.2) 
Rating Model 
(with side-text) 45 (12.2) 88 (23.8) 61 (16.5) 70 (18.9) 106 (28.6) 
Rating Model 
(without side-text) 26 (27.1) 24 (25.0) 10 (10.4) 18 (18.8) 18 (18.8) 
Total 105 (14.6) 174 (24.2) 55 (7.5) 148 (20.6) 183 (25.4) 
 Χ
2
8=19.393; p<0.05  
 
 
Figure 11: How frequently would you drive during the period in which you were taking the 
medicine? 
 
Question 2: What are the probabilities that you would change your driving habits if you were 
prescribed or dispensed a medicine with this pictogram about medicines and driving on the 
packaging? 
 
No significant differences were observed in the probability of changing driving habits when the 
interviewee was prescribed or dispensed a medicine with the pictogram, irrespective of the type of 
pictogram (table 11 and figure 12). 
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Table 11: What are the probabilities that you would change your driving habits if you were 
prescribed or dispensed a medicine with this pictogram about medicines and driving on the 
packaging? 
 
Very improbable 
N (%) 
Improbable 
N (%) 
Neither probable/nor 
improbable 
N (%) 
Probable 
N (%) 
Very probable 
N (%) 
Triangle Model 
(with side-text) 12 (4.7) 23 (8.9) 16 (6.2) 88 (34.1) 119 (46.1) 
Rating Model 
(with side-text) 15 (4.0) 19 (5.1) 31 (8.3) 148 (39.6) 161 (43.0) 
Rating Model 
(without side-text) 2 (2.1) 9 (9.3) 8 (8.2) 37 (38.1) 41 (42.3) 
Total 29 (4.0) 51 (7.0) 55 (7.5) 273 (37.4) 321 (44.0) 
 Χ
2
8=7.826; p>0.05  
 
 
Figure 12: Probability of changing driving habits according to the type of pictogram on the 
prescribed/dispensed medicine 
 
Evaluation of the pictograms 
 
A 10-point scale was used to evaluate the pictograms in four parameters: 
 
Utility:               1 = unnecessary to 10 = useful;  
Level of information:  1 = not informative to 10 = informative;  
Understandability:  1 = not understandable to 10 = understandable;  
Complexity:   1 = complex to 10 = not complex. 
 
Table 12 shows the mean scores (±SD) given to different aspects of the pictogram (utility, information, 
understandability and simplicity) for each of the types of pictogram. Of these characteristics, the best 
score was, in all three cases, for utility (8.37 ± 1.75 points for the triangle-model, 8.31 ± 1.74 for the 
rating-model with side-text and 7.75 ± 1.95 for the rating-model without side-text). 
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Table 12: Evaluation of the pictograms by pictogram type 
 
Triangle Model 
(with side-text) 
Rating Model 
(with side-text) 
Rating Model 
(without side-text) F; p 
 N Mean±SD N Mean±SD N Mean±SD 
Utility 243 8.37±1.75 345 8.31±1.74 95 7.75±1.95 4.57; p<0.05 
Information 241 8.11±1.84 346 8.10±1.82 95 7.40±2.00 5.94; p<0.005 
Understandability 239 7.91±2.00 344 7.87±1.98 95 7.20±2.09 4.86; p<0.01 
Simplicity 240 7.88±2.05 345 7.75±2.10 95 7.20±2.09 3.76; p<0.05 
 
Comparing the replies given for each pictogram (Student’s t test for independent samples), no 
significant differences were found between the average scores for any of the evaluated aspects of the 
triangle-model pictogram and the rating-model pictogram (both with side-text). Comparing the triangle-
model pictogram  and the rating-model pictogram without text, significant differences (p<0.05) were 
observed in the averages of all the scores; all of them being favorable (highest scores) to the triangle-
model pictogram. Comparing the rating-model pictogram with and without text, significant differences 
(p<0.05) were found in the average scores given to utility and level of information; favorable to the 
rating-model pictogram with side-text. Therefore, it seems that it is the text rather than the design 
which increases the four scores significantly. 
 
Pictograms preference  
 
STUDY 1: Comparison between the Rating model (with side-text) and the Triangle model (with 
side-text) 
 
A total of 541 questionnaires were done for this study. After the questions about the first pictogram, 
whose answers are shown in the previous paragraphs, the interviewee was shown a second 
pictogram and his/her preference for one or the other was analysed, taking into account two aspects, 
depending on their opinion:   
i) Question 1: Which of the two stickers helps you to understand the text better? and, 
ii) Question 2: Which of the two stickers gives you the best insight into the degree of 
impairment? 
 
Question 1: For the question “Which of the two stickers helps you to understand the text better?”  517 
replies were obtained. 63.4% of the answers (n= 328) pointed to the rating-model (with side-text) 
sticker as the best option, while the remaining 36.6% (n=189) preferred the triangle model (with side-
text)( Χ2=3.932; p<0.05).  
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Figure 13: “Which of the two stickers helps you to understand the text better?” Answer 
percentages 
 
Question 2: For the question “Which of the two stickers gives you the best insight into the degree of 
impairment?” 511 replies were obtained, of which 69.1% (n= 353) pointed to the rating-model (with 
side-text) pictogram as the best option, while the remaining 30.9% (n=158) preferred the triangle 
model (with side-text) (Χ2=10.992; p<0.001).  
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Figure 14: “Which of the two stickers gives you the best insight into the degree of 
impairment?” Answer percentages 
 
We have performed logistic regression analysis to identify which of the sociodemographic 
characteristics of the patient (age, gender, educational level, and having a driving license or not) has 
an influence on the opinion given. 
 
Regarding Question 1: Which of the two stickers helps you to understand the text better? Those who 
have a driving license were more likely (OR= 2.011, 95% IC 1.074-3.765] to select the rating-model 
pictogram. 
 
Regarding Question 2: Which of the two stickers gives you the best insight into the degree of 
impairment?, those who have a driving license (OR= 2.682, 95% IC 1.405-2.704) and those with a 
higher educational level (OR= 1.288, 95% IC 1.090-1.523),were more likely to select the rating-model 
pictogram. Showing a pictogram in second place (irrespective of which one it was) increased the 
probability of its being chosen (OR= 1.816, 95% IC 1.219-2.704).  
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STUDY 2: Comparison between the Rating model (with side-text) and the Rating model (without 
side-text)  
 
A total of 195 questionnaires were carried out for this study. As with Study 1, after the questions 
concerning the first pictogram shown, the interviewee was shown a second pictogram and his/her 
preference for the first or second one was analyzed, taking into account two aspects, according to 
his/her opinion (as in Study 1):  
i) Question 1: Which of the two stickers helps you to understand the text better? and,  
ii) Question 2: Which of the two stickers gives you the best insight into the degree of impairment? 
 
Question 1: For the question “Which of the two stickers helps you to understand the text better?”  189 
answers were obtained, of which 97.4% (n= 184) pointed to the rating-model (with side-text) sticker as 
the best option and only the remaining 2.6% (n=5) pointed to the rating-model (without side-text) 
sticker (Χ2=5.082; p<0.05). 
 
 
Figure 15: “Which of the two stickers helps you to understand the text better?” Answer 
percentages 
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Question 2: For the question “Which of the two stickers gives you the best insight into the degree of 
impairment?” 180 answers were obtained, of which 99.4% (n= 179) pointed to the rating-model (with 
side-text) pictogram as the best option and only the remining 0.6% (n=1) pointed to the rating-model 
(without side-text) pictogram (Χ2=1.075; p>0.05).  
 
 
Figure 16: “Which of the two stickers gives you the best insight into the degree of 
impairment?” Answer percentages 
5.4.4 Discussion 
If we group together the replies considered correct (over 50% probability), the understandability of the 
three models of pictogram may seem to be good (for the rating-model pictogram with text: 90.2%, for 
the triangle-model pictogram: 89.3%, and for the rating-model pictogram without side text: 94.8%), in 
fact, none of them surpasses the understandability criteria of the Norm ISO 9186 (overall score 
>67%), the best option being the rating-model pictogram without side-text (overall score = 66%). 
 
According to the scores given to the estimation of the level of danger of the pictograms, an increase in 
the risk perceived by the patients (increase in the mean scores) in line with the increase in the 
category of the medicine can be seen, both for the triangle-model pictogram and the rating-model 
pictogram (either with or without side-text). The triangle-model (with side-text) pictogram would be the 
least adequate for distinguishing between categories II and III (the mean score given to the risk of 
these categories does not differ significantly). 
 
The triangle-model pictogram and the rating-model pictogram, both with side-text, would have a 
similar influence at the time the patient is deciding whether to reduce driving frequency while taking a 
medicine with one of these pictograms. On the other hand, the rating-model pictogram without side-
text would, in view of the results, have significantly less influence 
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The rating-model pictogram and the triangle model pictogram did not differ regarding how patients 
evaluate the two pictograms with respect to Utility, Level of information, Understandability, and 
Complexity.  However, both pictograms with text are better rated (have higher scores) by patients than 
the rating-model pictogram without text.  
 
The studies on Pictograms preference showed that overall patients preferred the rating-model 
pictogram to the triangle-model pictogram, as well as the rating-model pictogram with text rather than 
this pictogram without text. 
 
Having a driving license was associated with understandability of the text of the pictogram, while 
having a driving license, educational level and the order in which the pictograms are shown to the 
patients are associated with the reported insight of the patient’s about the degree of impairment. 
5.5 Overall conclusion 
By carrying out these 2 separate studies with the same aims, it can be concluded that both the rating 
model and the triangle model were effective in communicating risk. Those who participated in the 
studies were able to recognize and understand the risk of driving under the influence of medicines and 
have shown their intention to change their driving behaviour by driving less frequently. The rating 
model pictogram showed a direct correlation between the likelihood of changing driving behaviour and 
the level of impairment of a medicine (category-related). 
 
In both studies, the rating model pictogram was preferred over the triangle model pictogram.  
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Part II. Main DRUID results 
Authors: Uta Meesmann, Sofie Boets (IBSR-BIVV, Belgium), F. Javier Alvarez (UVa, University of 
Valladolid, Spain), Han de Gier (RUGPha, University of Groningen, the Netherlands), Anja Knoche, 
Markus Schumacher (BASt, Germany), Inger Marie Bernhoft, Tove Hels (DTU, Denmark), Sjoerd 
Houwing (SWOV, the Netherlands), Kristin Thorsteinsdottir (LMU, Germany), Alain Verstraete and 
Sara-Ann Legrand (University of Gent, Belgium) 
1 Introduction  
The European Commission set up an ambitious target to increase road safety in the EU and to reduce 
road accidents fatalities by 50% by 2010 (White Paper). DRUID (Driving under the Influence of Drugs, 
Alcohol and Medicines) aimed to combat the problem of driving under the influence of psychoactive 
substances by providing a solid scientific base for European policy makers. It brought together 
experienced organisations in Europe to assemble a coordinated set of data resources and measures.  
 
The DRUID consortium is composed of a total of 37 partners from 19 States (18 EC Member States 
and NO, see figure 17). As the majority of the participating institutions are members of FERSI they 
have a broad experience in road safety.  
 
Figure 17: Geographic coverage of the EU project DRUID 
 
DRUID is an integrated European research project which consisted of different sub-projects (Work 
Packages; see figure 18) that were aimed at different topics such as the prevalence and risk of 
psychoactive substances, enforcement, classification of medicines, rehabilitation of offenders and 
withdrawal of driving licenses (www.druid-project.eu) (D2.2.3 PART I p. 3). 
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Figure 18: Overview of the different DRUID work packages  
 
The objectives of the DRUID project are:  
• “to conduct reference studies of the impact on fitness to drive for alcohol, illicit drugs and 
(psychoactive) medicines and give new insights to the real degree of impairment caused by 
psychoactive substances and their actual impact on road safety; 
• to generate recommendations for the definition of analytical and risk thresholds;  
• to analyse the prevalence of alcohol and other psychoactive substances in accidents and in 
general driving, set up a comprehensive and efficient epidemiological database; 
• to evaluate "good practice" for detection and training measures for road traffic police allowing 
a legal monitoring of drivers; 
• to establish an appropriate classification system of medicines affecting driving ability, give 
recommendations for its implementation and create a framework to position medicines 
according to a labelling system, 
• to evaluate the efficiency of strategies of prevention, penalisation and rehabilitation, 
considering the difficulties of appropriate evaluation strategies for combined substance use 
and recommend "good practice";  
• to define strategies of driving bans, combining the road safety objectives with the individual´s 
need for mobility; 
• to define the responsibility of health care professionals for patients consuming psychoactive 
substances and their impact on road safety, elaborate guidelines and make information 
available and applicable for all European countries” (DRUID TA p. 1f.). 
2 Method 
The summary of the main DRUID results is based on a review of the executive summaries and 
conclusion parts of finalized DRUID deliverables (WP1-7 until 07.09.2011) and the draft version of the 
DRUID case-control study (D2.3.5), presentations of the WP leaders at the DRUID general meeting 
(2010), input of the WP leaders to the coordinator for the annual periodic activity reports to the EC and 
the technical annex of the DRUID project. Outcomes in regard to legal limits (e.g. D1.4.2 “Methods of 
defining cut of values for zero tolerance”) could not be included in this report as these results will only 
be available at the end of the DRUID project (October 2011).  
 
It was decided to separate the presentation of the main DRUID results into two main parts: (1) 
problem situation, which mainly focuses on input of WP1/2 and (2) countermeasures which is mainly 
summarizing results of WP3-7. Furthermore, a detailed evaluation of legal countermeasures from the 
perspective of criminology can be found in D1.4.1. 
 
The authors of D7.3.2 provided a describing text and a summarizing overview table per WP. These 
texts and summaries were discussed in two rounds, first with the DRUID coordinator and WP7 
partners (work sessions: 14.01.11 Madrid, 03.03.11 Brussels, 29.03.11 Thessaloniki, 23.05.11 Gent) 
and secondly with WP leaders and authors of main deliverables (via email until 07.09.11). 
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The reviewing WP leaders and main authors of the summarized WP texts were:  
• Problem situation (WP1/2): Anja Knoche, Markus Schumacher (BASt); Inger Marie Bernhoft, 
Tove Hels (DTU), Sjoerd Houwing (SWOV), Kristin Thorsteinsdottir (LMU), Alain Verstraete 
and Sara-Ann Legrand (UGent); 
• Enforcement (WP3): Sjoerd Houwing and and Marjan Hagenzieker (SWOV); 
• Classification (WP4): Javier Alvarez (UVa) and Han de Gier (RUGPha); 
• Rehabilitation (WP5): Monika Pilgerstorfer (KfV), Sofie Boets and Uta Meesmann (IBSR) ; 
• Withdrawal (WP6): Simone Klipp (BASt); 
• Guidelines and risk communication (WP7): Han de Gier (RUGPha). 
3 Problem situation and risk group characteristics (WP1/2) 
The DRUID project (WP1/2) aimed at assessing the situation regarding the prevalence and risk of the 
use of alcohol, illicit drugs, and (psychoactive) medicines by drivers in Europe. Within WP2, two of the 
main investigations to obtain these insights were the DRUID roadside survey (D2.2.3) and the DRUID 
hospital study on seriously injured and killed drivers (D2.2.5) which were melded together in the 
DRUID case-control study (D2.3.5). These three investigations form the main base within this 
deliverable to scratch the problem situation (prevalence and risk) and risk group characteristics of 
driving under influence of alcohol (1), illicit drugs (2) psychoactive medicines (3).  
 
This deliverable (D7.3.2) focuses on the general results assessing the situation in Europe, but since 
there is huge between-country variability in the results, any recommendation for national activities 
regarding, e.g., policy issues, enforcement, education or campaigns, should primarily be based on the 
results of the country reports, rather than on the general reports. Furthermore it should be taken into 
account, that the estimated EU prevalence means of the road side survey (D2.2.3) are based on the 
analyses of different body fluids. DRUID WP2 tried to compensate for this by using equivalent cut-offs 
to correct for differences in sample collection method. The presented prevalence values of the hospital 
studies are based on blood samples. 
 
WP1 focused on experimental studies evaluating the effect of psychoactive substances on driving 
performance (e.g. D1.1.2a-c, D1.2.1, D1.2.2). A synthesis of the experimental and epidemiological 
results on risk estimates for single and combined use of psychoactive substances will be available at 
the end of the DRUID project (October 2011, D1.3.1). Furthermore, a detailed evaluation of legal 
counter measures can be found in D1.4.1. Recommendation on methods of defining cut-off values for 
per se legislation, are to be expected at the end of the DRUID project (D1.4.2). 
 
In the following parts methodological information of the different DRUID studies in WP1/2 are 
summarized for more details see the according deliverables.  
 
DRUID roadside survey (D2.2.3) 
 
Within the DRUID roadside survey (D2.2.3), thirteen countries participated in a large scale prevalence 
study by conducting roadside surveys according to a general design. In total almost 50,000 randomly 
selected drivers participated between January 2007 and July 2009. In most countries the results are 
based on saliva samples (exceptions are: LT only blood and BE, IT, and NL saliva and blood 
samples). The non-response rate varied between 0% and 52%. The following table gives an overview 
of the number of included samples, the used body-fluid and the non-response rate per country. The 
prevalence of drivers tested positive for at least one psychoactive substance ranged between 2.32% 
(HU) and 15.01% (IT). An overview of the different illicit drug- and medication groups included in this 
study can be found in the annex 2. Table 13 presents an overview of the number of included samples, 
body-fluid, non-response rate and prevalence rate for all psychoactive substances of DRUID roadside 
survey. European means were estimated based on the prevalence of psychoactive substances in 
these thirteen different European countries. To estimate this means weight factors were used, based 
on the number of inhabitants of the EU countries (since data on driver kilometres were not available 
for all European countries) and on the European region that they represented. 
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Table 13: Overview of number of included samples, body-fluid, non-response rate and 
percentage of positive toxicological finding of DRUID roadside survey (D2.2.3) 
Country Number of included samples Body fluid Non-response rate Toxicological 
finding positive 
BE 2949 Saliva/blood 52% 10.65% 
CZ 2037 Saliva 23% 2.80% 
DK 3002 Saliva 5% 4.48% 
ES 3174 Saliva 2% 14.85% 
FI 3841 Saliva 48% 2.85% 
HU 2738 Saliva 10% 2.32% 
IT 1310 Saliva/blood 0%* 15.01% 
LT 1264 Blood 24% 5.51% 
NL 4822 Saliva/blood 5% 5.51% 
NO 9236 Saliva 6% 2.97% 
PL 4005 Saliva 1% 2.37% 
PT 3965 Saliva 3% 9.99% 
SE 6199 Saliva 38% 1.34** 
Total  48542   
 
*mandatory test in IT; **no alcohol included in SE results 
 
DRUID hospital study (D2.2.5) 
 
The DRUID hospital study (D2.2.5) sampled 2,492 seriously injured drivers (cars and vans) in 6 
countries (BE, DK, FI, IT, LT and NL) between October 2007 and April 2010 (in both studies with 
different collection periods in the participating countries) and 1,118 killed drivers (cars and vans) in 4 
countries (FI, NO, PT, SE) between January 2006 and December 2009*. Almost all studies are based 
on blood samples (see exceptions FI, IT and SE below). The non-response rate varied between 0% 
and 8.5% for the seriously injured drivers (not known in DK and NL). Within the killed driver studies, 
post-mortem examinations are mandatory in PT, FI and SE for all people killed in road traffic 
accidents. “However, in practice less than 100% of the cases are analysed. For this reason these 
three countries have a lower percentage of missing cases compared to Norway where sampling is not 
mandatory” (D2.2.5 p. 27). The percentage of missing cases varied between 5.7% and 41%.. Within 
the hospital studies the percentage drivers tested positive for at least one psychoactive substance 
ranged among the seriously injured drivers between 28% (LT) and 53% (BE) and among the killed 
drivers between 31% (SE) and 48% (PT). An overview of the tested substance classes, groups and 
analytical findings within the DRUID hospital studies can be found in the 3. Tables 14 and 15 give an 
overview of the number of included samples, the used body-fluid and the non-response rate, 
percentage/number of missing cases and percentage of positive toxicological finding per country for 
both hospital studies 
 
Table 14: Seriously injured drivers - number of included samples, used body-fluid, non-
response rate, percentage/number of missing cases and percentage of positive toxicological 
finding per country (based on D2.2.5) 
SERIOUSLY INJURED DRIVERS 
Country N of included 
samples Body-fluid Non-response rate Missing cases 
Toxicological 
finding positive 
BE 348 Blood 5.4% 105  52.6% 
DK 840 Blood Unknown* 60 30.3% 
FI 54 Blood/oral fluid 8.5% No missing cases 
reported 44.7% 
IT 676 Blood/Urine 0% No missing cases 
reported** 32% 
LT 387 Blood 0% No missing cases 
reported 27.8% 
NL 187 Blood Unknown No missing cases 
reported 33.9% 
Total 2492     
* No registration of the patients that refused is available; ** Lack of accident data such as road type, accident type,.   
 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
52 
Table 15: Killed drivers - number of included samples, used body-fluid, non-response rate, 
percentage/number of missing cases and percentage of positive toxicological finding per 
country (based on D2.2.5) 
KILLED DRIVERS 
Country N of included 
samples Body-fluid Non-response rate Missing cases 
Toxicological 
finding positive 
FI 483 Blood n.a. 5.7% 42.3% 
NO 193 Blood n.a. 41% 40% 
PT 285 Blood n.a. 21% 47.7% 
SE 157 Blood/Urine/Muscle tissue n.a. 6% 30.5% 
Total 1118     
 
While comparing the prevalence values of the hospital studies and the roadside survey it has to be 
clear that studies refer to different populations. The roadside survey focuses on the general driving 
population while the hospital studies concentrates on seriously injured and killed drivers. Moreover, 
the presented prevalence values within the roadside survey mainly represent single substance use 
(exceptions are pointed out) and within the hospital studies both, single and combined use.   
 
DRUID case control study (D2.3.5) 
 
The results of the roadside survey and hospital studies were melted together in the DRUID case-
control study (D2.3.5) in which the substance distribution over hospital cases (D2.2.5) were compared 
with the substance distribution over a representative sample of control drivers in the national general 
road user population (D2.2.3), resulting in calculations of the relative risk of being seriously injured in 
an accident while tested positive for alcohol and/or other psychoactive substances (DRUID TA p. 84). 
These risk calculations have been carried out in 6 different European countries (BE, DK, FIN, IT, LT 
and NL). D2.3.5 DRAFT will be finalized by the end of the DRUID Project (October 2011), but data on 
seriously injured drivers from BE, DK, FI, IT, LT and NL and data on killed drivers from FI, NO, PT and 
SE could already be included in this deliverable.  
 
Other included accident risk estimate studies (D2.3.1, D2.3.2, D2.3.3, D2.3.4) 
 
Furthermore, the following DRUID studies estimating the relative risk of accident involvement for 
drivers impaired by alcohol and other psychoactive substances were included in this deliverable.  
• D2.3.1 describes the results of a pharmacoepidemiological approach estimating the risk for 
traffic accident involvement of patients using psychoactive medicines in NL.  Medication 
records were obtained under controlled conditions (regarding privacy) from community 
pharmacies and were linked to accident data from the same patient groups. Cases were 
defined as adults, who had a traffic accident between 2000 and 2007 and were driving, and 
received medical assistance. Controls were defined as adults, who had a driving license and 
had no traffic accident during the study period. In total 3963 cases and 18828 matched 
controls were selected for the case-control analysis (D2.3.1). 
• D2.3.2 investigated the responsibility risk of positive tested car drivers for psychoactive 
substances, involved in fatal accidents in FR. About 7,500 car drivers were sampled from a 
database of approximately 10,000 drivers who were involved in a fatal road accident between 
October 2001 and September 2003 in FR. By means of a method adapted from a 
responsibility analysis developed by Robertson and Drummer (1994) car drivers were 
assessed as either responsible for the accident (4946 cases) or not responsible (1986 
controls). After taking the toxicological analysis of each subject into account the relative risk 
for a car driver of being responsible for a fatal crash while driving under the influence of 
psychoactive substances were calculated.  
• D2.3.3 investigated the responsibility risk of positive tested drivers for psychoactive 
substances who were killed in accidents based on in depth data of fatal motor vehicle 
accidents in FI. From a database of the Traffic Accident Investigation Teams in Finland 
accidents taking place between 2002 and 2006 were sampled and analyzed (in total 1,108 
killed drivers). The focus lay on the influence of (legal) medications and alcohol. Killed drivers 
tested positive for alcohol (n=211) or legal (prescribed) medicines (n=46) were compared with 
those of sober killed drivers (n=689). In order to calculate relative risk for crash responsibility 
four different exposed groups were compared to their matched non-exposed groups.  
• D2.3.4 compared the responsibility risk of positive tested drivers for psychoactive substances 
who were killed in accidents in DE, HU, LT and SK. “Data of killed drivers was sampled 
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prospectively by means of a database established within the DRUID-framework in the years 
2008 and 2009 and increased by retrospective data. The analysis included 483 subjects, 18 
years and older, killed within 10 hours after being involved in a traffic accident. Responsibility 
analysis was conducted with the method proposed by Robertson and Drummer (1994) which 
allocated the 483 subjects in 419 cases and 64 controls. Subsequently a toxicological analysis 
was carried out where the 23 DRUIID-core substances as well as several other additional 
substances were screened for. An in–depth analysis of 20 killed drivers was carried out by 
means of a systematic accident causation catalogue” (D2.3.4 p. 4). 
 
Experimental studies on the effect of psychoactive substances on driving performance 
(D1.1.2a-c, D1.2.1) 
  
• D1.1.2a: Since many experimental studies on the effects of alcohol on human performance 
and driving have been published, a meta-analysis was conducted (D 1.1.2a). 450 papers 
published between 1950 and 2007 were included in which a total of 5,300 findings of alcohol 
effects on (driving) performance, social behaviours or mood are reported. The meta-analytic 
procedure determines for each BAC group how often significant effects were reported in these 
studies.  
• D1.2.1 investigates the influence of stimulant drugs, their interaction with sleep deprivation 
and with alcohol, on actual and simulated driving. Experimental studies were designed to 
asses the effect of 3,4-methylmethamphetamine (MDMA; 25, 50 and 100mg ) and 
dexamphetamine (10, 40mg) on actual and simulated driving performance.  
• D1.2.2 investigates the influence of psychoactive medicines (hypnotics, analgetics, 
antipsychotics) on actual and simulated driving.  
• D1.1.2b is a meta-analysis of empirical studies concerning the effects of medicinal and illegal 
drugs on safe driving. In addition detailed information about pharmacokinetics of these drugs 
is given.  
• D1.1.2c is a meta-analysis summarizing studies on psychomotor relevant performance (1) 
after single dose administration of opioids, narcoanalgesics and hallucinogens to drug naïve 
subjects (2) in patients treated chronically with morphine or methadone / buprenorphine. 
3.1 Alcohol (DUI) 
3.1.1 Prevalence of alcohol in relation to road safety  
Alcohol (≥0.1g/L) is the most frequently detected psychoactive substance in the driving 
population (estimated EU mean 3.48%) (D2.2.3) as well as in the seriously injured (range 17.7-
42.5%) and in killed drivers (range 19.0-44.9%) in Europe (D2.2.5; D2.2.4; D2.3.4).  
 
General driving population 
 
The DRUID roadside survey showed that: Alcohol is the most frequently detected psychoactive 
substance in Europe. The estimated EU mean prevalence for single alcohol use (≥0.1g/L) was 3.48%, 
highest in IT (8.59%) followed by BE, PT, ES and LT and lowest in HU (0.15%). No alcohol 
information was available in SE (see figure 19 and 20).  
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Figure 19: Geographical presentation of alcohol (≥0.1g/L) use by car drivers in the EU (D2.2.3 
PART I p. 7) 
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Figure 20: Prevalence of alcohol alone ≥0.1g/L by country; prevalence in percentages (D2.2.3 
Part I p. 45) 
 
The legal alcohol limit was in most countries 0.5 g/L (only CZ and HU have a zero tolerance limit for 
alcohol and PL, NO and SE have legal limit of 0.2g/L). Even with a cut-off level of 0.5 g/L, alcohol 
would still have been the most prevalent substance in European traffic with an average prevalence of 
1.49%. IT (5.23%) has over twice the prevalence of the second and third ranked countries, LT (2.31%) 
and BE (2.16%), respectively (see figure 21). The prevalence for single alcohol use at ≥1.2g/L is 
highest in LT and IT (both around 1.4%). The according European average prevalence is about 0.4% 
(see figure 22).  
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Figure 21: Prevalence of alcohol alone ≥0.5g/L by country; prevalence in percentages (D2.2.3 
Part I p. 45) 
Figure 22: Prevalence of alcohol alone ≥1.2g/L by country; prevalence in percentages (D2.2.3 
Part I p. 46) 
 
Single alcohol use is in general mainly prevalent in the Southern part of Europe. The highest 
prevalence for the TOTAL alcohol use (single + combined use) is found in IT (9.6%) followed by PT 
and BE (both: 6.73%) and lowest in FI (0.18%) (see table 16). The estimated EU mean for TOTAL 
alcohol use is 3.87%.  
 
Table 16: Prevalence of alcohol alone and alcohol in combination with other psychoactive 
substances; prevalence in percentages (based on D2.2.3 PART I p. 46) 
 
  BE  CZ  DK  ES  FI  HU  IT  LT  NL  NO  PL  PT SE 
Alcohol 
alone 6.42 0.99 2.53 3.92 0.64 0.15 8.59 3.86 2.15 0.32 1.47 6.42 NA 
Alcohol in 
combination 0.31 0.05 0.10 1.14 0.08 0.03 1.01 0.03 0.24 0.07 0.00 0.31 NA 
Total 6.73 1.04 2.63 5.06 0.72 0.18 9.60 3.89 2.39 0.39 1.47 6.73 NA 
 
Seriously injured or killed drivers 
 
In the DRUID hospital study (D2.2.5) alcohol (≥0.1g/L) was the most common toxicological finding, 
both in the seriously injured (range 17.7% (LT) - 42.5% (BE)) and in the killed drivers (range 19% (SE) 
- 44.9% (PT)). Respective findings for alcohol intoxication at ≥0.5g/L were 16.1% (LT) - 38.2% (BE) for 
seriously injured drivers and 16.3% (SE) – 35.1% (PT) for killed drivers. Among the positives, most 
had a high BAC: 90.5% of injured drivers and 87% of killed drivers had a BAC ≥0.5g/L (mean and 
median values of ethanol were respectively 1.59 g/L and 1.60 g/L, and 1.61g/L and 1.67g/L) (see table 
17 and figure 23-24).  
 
Table 17: Distribution of positive alcohol findings by BAC-group among seriously injured and 
killed drivers (based on D2.2.5)  
 Seriously injured drivers Killed drivers 
BAC group Frequency Percent Frequency Percent 
0.1 ≤ BAC < 0.5 g/L  58 9.5 45 12.7 
0.5 ≤ BAC < 0.8 g/L  48 7.9 26 7.3 
0.8 ≤ BAC <1.3 g/L  103 16.9 33 9.3 
BAC ≥ 1.3 g/L  400 65.7 250 70.6 
Total  609 100.0 354 100.0 
 
Alcohol was the only substance among the ones tested for that appeared more often alone than in 
combinations. When alcohol was combined with other psychoactive substances, benzodiazepines and 
cannabis (THC and/or THCCOOH) were the most common associated findings (D2.2.5).  
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Figure 23: Seriously injured drivers – Alcohol (≥0.1 g/L) prevalence: detail of toxicological 
findings (D2.2.5 p. 60) 
 
 
Figure 24: Killed drivers – Alcohol (≥0.1 g/L) prevalence: detail of toxicological findings (D2.2.5 
p. 93)  
 
Based on a fatal accidents database analysis in FR (N approx. 7,000), alcohol is the most prevalent 
psychoactive substance with 29% of drivers (n=1997) involved in a fatal crash tested positive for 
alcohol. The majority (n=1257, 63%) of positively tested drivers were severely intoxicated (blood 
alcohol concentration ≥1.2g/L)  
 
In the responsibility study (D2.3.4) carried out in DE, LT, HU and SK (n=483) 33% of the killed drivers 
were tested positive for alcohol (alcohol ≥0.1 g/L) as a single psychoactive substance. 67% (n=107) of 
positively tested drivers were severely intoxicated (BAC ≥1.2 g/L), a condition more frequently found in 
East-European samples (D2.3.4 p. 4). 
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3.1.2 Characteristics of drivers tested positive for alcohol 
Alcohol was in the general driving population mainly detected among older male drivers, with 
lower BAC levels (D2.2.3). Within the accident involved drivers alcohol was mainly detected 
among younger male drivers with a high BAC level (D2.2.5). 
 
General driving population  
 
Alcohol was found to be more present in male than in female drivers in all investigated countries 
except in NO, where the same prevalence was found for both genders and IT were more female than 
male drivers were tested positive (≥0.1g/L). In most countries the proportion of alcohol-positive 
(≥0.1g/L) drivers (male and female) was the highest for the two oldest age groups (35-49 and 50+), 
except in PT where this was more present in young drivers (18-24) (D2.2.3). “In general, alcohol use is 
higher during night time hours than during day time hours. However, in some Eastern European 
countries such as HU, LT and PT this was not the case. The highest prevalence was detected in BE 
during weekday nights (21.05%) and weekend nights (16.60%). The 95% confidence intervals are 
very large for some countries; therefore it is difficult to assign exact differences between time periods 
for the participating countries. The proportion of alcohol use was in general the lowest at weekdays 
during daytime hours. However, in PT the proportion of alcohol drivers was higher during weekday 
hours than during weekday nights. Despite a general large proportion of high BAC drivers, no alcohol 
use was found during weekend nights in LT. In HU no alcohol was found at all during night time hours” 
(D2.2.3 PART I p. 54f). 
 
In the general driving population the largest prevalence for alcohol is in general present at the lower 
BAC categories. Within the DRUID roadside survey in DK even 81% of the alcohol drivers had a BAC 
between 0.1 and 0.5g/L. However, in LT almost 40% of all alcohol intoxicated drivers had a BAC level 
of 1.2g/L or higher, while for most other countries this proportion is below 15% (D2.2.3). Among the 
seriously injured and killed drives the percentage of high alcohol levels was much higher (see 
following chapter). 
 
The DRUID investigation on the motives behind impaired driving (D2.2.1) carried out in SE and HU 
showed that drivers do not think that alcohol impairs their performance and that within this study drink 
drivers feel more ashamed than drug drivers. The feeling of shame appeared not to be related to a 
feeling that the act itself could result in an accident, but somewhat related to if their friends and 
relatives disapproved. Drivers whose drinking and driving was related to problems with alcohol argue 
that losing the licence or even to be imprisoned would not have helped them to stop re-offending; 
instead, they argue that the treatment programme had helped them by providing a greater insight into 
their own problems (D2.2.1). 
 
Seriously injured or killed drivers 
 
In both hospital studies significant differences were found between both gender and age groups. In 
general, the prevalence in males was higher than in females, with a percentage ratio approximately 
70/30 in the seriously injured drivers and 83/17 in the killed drivers. The age group distribution was 
different in the two hospital studies, with the age group 50 and above accounting for approximately 
19% of the sample in the injured drivers study and approximately 36% of the sample in the killed 
drivers study. In men, the two first age groups, 18-24 and 25-34, accounted for approximately 55% of 
the sample in the injured drivers study, and for approximately 42% of the sample in the killed drivers 
study. For the same two female age groups, the distribution was approximately equal to 49% in the 
seriously injured drivers study and to 32% in the killed drivers study.  
 
In general, the prevalence in males was higher than in females, with a percentage ratio approximately 
70/30 in the seriously injured drivers and 83/17 in the killed drivers. 
 
The majority of seriously injured or killed drivers tested positive for alcohol within the hospital study 
had a high BAC level; 90.5% of injured drivers (87% of killed drivers) had a blood alcohol 
concentration ≥0.5g/L and 65.7%-injured drivers of 70.6% killed drivers a BAC of ≥1.3g/L (D2.2.5).  
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Within the responsibility study (D2.3.4) carried out in DE, LT, HU and SK the majority of subjects who 
consumed alcohol were severely intoxicated (BAC ≥1.2 g/L), a condition more frequently found in 
East-European samples (D2.3.4). 
3.1.3 Accident risk for driving with alcohol 
Alcohol highly increases accident risk (e.g. D2.3.2; D2.3.3; D2.3.4; D2.3.5 DRAFT).  
Based on case- control studies, the relative risk of serious injury or fatality for alcohol (≥0.5g/L) 
is found to be significantly increased compared to that of drivers below the DRUID cut-off for 
any substance (D2.3.5). An increased risk was associated with high BAC level, young age and 
speed (D2.3.3). The risk increases drastically with combined use (e.g. cannabis) (D2.3.2). 
 
According to the French study (D2.3.2), for drivers positive for alcohol (≥0.1g/L), the risk of being 
responsible for a fatal crash is about 8 times as high as that of sober drivers (adjusted OR 8.39 [95% 
CI 6.95-10.11]). For alcohol ≥1.2 g/L this risk increased about 19 times (adjusted OR 19.32 [95% CI 
13.99-26.69]). Combined use of alcohol and cannabis multiplies the risk of causing a fatal accident 
(8.39*1.89=15.86) (D2.3.2).  
 
In the Finnish study (D2.3.3) killed drivers, positive for alcohol (≥0.5 g/L), had a risk of about 7 times 
as high as that of sober drivers being responsible for a fatal accident (adjusted OR 6.55 [95% CI 1.83 
– 31.75]). They were more often young drivers (<36 years) and more often car than bus or lorry 
drivers. Significant variables associated with the responsibility were: age of the driver, driver’s BAC 
level and speed (D2.3.3).  
 
In the responsibility study carried out in DE, LT, HU and SK (D2.3.4) a significant increase of the 
relative risk for drivers who were killed in an accident of being responsible for the accident was found 
for an alcohol concentration of ≥0.1g/L (adjusted OR 4.57 [95% CI 2.02-10.38]) and for ≥1.2 g/L this 
was 20.84 [95% CI 3.10-140.16]. The corresponding confidence intervals are wide and therefore the 
precision of estimate is poor.  
 
Table 18 gives an overview of the above mentioned results of the different responsibility studies 
carried out in DRUID. 
 
Table 18: Overview of the adjusted OR estimating the risk for a driver of being responsible for a 
fatal accident (D2.3.2) and the risk for a killed driver of being responsible for the accident 
(D2.3.3; D2.3.4) when driving under the influence of alcohol. 
 
Reference 
 
Included country 
 
BAC concentration in g/L 
≥0.1 ≥1.2 
Adjusted OR 95% CI Adjusted OR 95% CI 
D2.3.2 FR 8.39 6.95-10.11 19.32 13.99-26.69 
D2.3.3 FI 6.6 1.83-31.75 14.96 2.00-111.89 
D2.3.4 DE, LT, HU, SK 4.57 2.02-10.38 20.85 3.10- 140.16 
 
Although the study designs of the single DRUID risk estimation studies do not allow precise 
comparison of the calculated accident risks, their results show similar effects regarding the relative risk 
of being responsible for a fatal accident driving under the influence of alcohol. 
 
The DRUID case-control study (D2.3.5) calculated the risk of being seriously injured or killed based 
on control data from the roadside survey (D2.2.3) and case data from the hospital study and study on 
killed drivers (D2.2.5). Odds ratios for different alcohol concentrations have been calculated by means 
of data from BE, DK, FI, IT, LT and NL (seriously injured drivers) and for FIN, NO and PT (killed 
drivers) separately for each country and for all countries as a whole. The odds ratios are adjusted for 
age and gender and the controls were weighted with the traffic distribution in eight time periods over 
the week. Table 19 shows the calculated OR (alcohol) for getting seriously injured and table 20 for 
getting killed based on aggregated data (D2.3.5). 
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Table 19: Overview of OR (alcohol alone) for getting seriously injured based on aggregated 
data (D2.3.5) 
Reference Included 
country OR + CI 
BAC concentration in g/L 
0.1 – 0.5 0.5 – 0.8 0.8 – 1.2 ≥1.2 
D2.3.5 
DRAFT 
BE, DK, 
LT, NL 
Crude OR  
95% CI 
1.05 
0.73-1.53 
3.80 
2.48-5.82 
13.97 
8.75-22.29 
55.27 
39.52-77.31 
Adjusted OR 
95% CI 
1.18 
0.81-1.73 
3.64 
2.31-5.72 
13.35 
8.15-21.88 
62.79 
44.51-88.58 
Finland and Italy have been left out of the calculations of OR for alcohol and alcohol-drug(s) because of bias in collecting data 
for the control samples. 
 
Table 20: Overview of OR (alcohol alone) for getting killed based on aggregated data (D2.3.5) 
Reference Included 
country OR + 95% CI 
BAC concentration in g/L 
0.1 – 0.5 0.5 – 0.8 0.8 – 1.2 ≥1.2 
 D2.3.5 
DRAFT NO, PT 
Crude OR  
95% CI 
9.23 
6.07-14.05 
42.94 
21.99-83.86 
34.81 
16.02-75.65 
450.37 
224.06-905.25 
Adjusted OR 
95% CI 
8.01 
5.22-12.29 
45.93 
23.02-91.66 
35.69 
15.68-81.22 
500.04 
238.07-inf. 
Finland has been left out of the calculations of OR for alcohol and alcohol-drug(s) because of bias in collecting data for the 
control sample.  
 
The results indicate a significant increase of the relative risk of serious injury or fatality for an alcohol 
concentration of ≥0.5g/L. Overall, the relative injury risk is estimated to be slightly increased of about 
1-3 times for alcohol concentrations of 0.1-0.5g/L, medium increased of about 2-10 times for alcohol 
concentrations of 0.5-0.8g/L, highly increased of about 5-30 times for alcohol concentrations of 0.8-
1.2g/L and extremely increased of about 20-200 times for alcohol concentrations ≥1.2 g/L compared to 
the risk for drivers below the DRUID cut-off for any substance. The results are based on calculations 
of odds ratios adjusted for age and gender. The controls were weighted with the traffic distribution in 
eight time periods over the week. Including all alcohol concentrations at and above the DRUID cut-off 
(≥0.1g/L) the relative injury risk for alcohol is estimated to be about 5-10 times as high as that of 
drivers below the DRUID cut-off for any substance. 
3.1.4 Results from experimental studies on the effect of alcohol on 
driving performance  
Alcohol has a negative impact on driving performance and on skills related to driving (e.g. 
D1.1.2a). Driving tests are important to estimate impairment effects, as unspecific measures of 
psychomotor performance do not fully represent the driving performance decrements caused 
by alcohol (e.g. D1.1.2a).   
 
The main outcomes of the DRUID meta-analysis of empirical studies concerning the effects of alcohol 
on safe driving (D1.1.2a) are illustrated in the following two figures. As can be seen in figure 25 there 
is an increase in the subjective feeling of being intoxicated already at very low BAC level: at 0.4g/L 
BAC 80% of the findings show a significant effect. Subjective feelings of fatigue increase with 
increasing BAC. There are performance decrements at BAC of 0.5g/L in 30% of the findings. At BAC 
of 0.8g/L about 50% of the findings are significant (see figure 26). Taking a closer look at only those 
findings based on driving performance assessed in driving simulators, it becomes obvious that 
complex tasks like driving are more affected by alcohol than simple tasks, especially at low BACs.  
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Figure 25: Subjective intoxication – percentage of significant findings per BAC group (D1.1.2a, 
p. 69) 
Figure 26: Impairment in driving simulator tasks vs. in general – percentage of significant 
findings per BAC group (D1.1.2a, p.76). 
 
Therefore it is important to conduct driving tests to estimate the impairing effects of alcohol on driving. 
Especially at low BACs unspecific measures of psychomotor performance do not fully represent the 
driving performance decrements caused by alcohol. Impairments in driving performance become 
obvious already at much lower BACs than in cognitive skills related to driving (D 1.1.2a). 
3.1.5 Overview box – alcohol 
Box 1: Summary of main DRUID results – ALCOHOL 
Prevalence of alcohol in relation to road safety: 
• Alcohol (≥0.1g/L) is the most frequently detected psychoactive substance in the driving 
population (estimated EU mean 3.48%) (D2.2.3) as well as in the seriously injured 
(range 17.7-42.5%) and in killed drivers (range 19.0-44.9%) in Europe (D2.2.5; D2.2.4; 
D2.3.4).  
• General driving population (D2.2.3): 
o Alcohol alone (≥0.1g/L): most frequently detected substance in most countries; 
estimated EU mean prevalence 3.48% (range 0.15-8.59%); prevalence ranking from 
all investigated substances #1; main EU region: Southern Europe; 
o Alcohol alone (≥0.5g/L): estimated EU mean prevalence 1.49% (range 0.07-5.23%): 
prevalence ranking from all investigated substances #2; 
o Alcohol alone (≥1.2/L): estimated EU mean prevalence about 0.40% (range 0.01-
1.47%); prevalence ranking from all investigated substances #6; 
o Total alcohol (single + combined): estimated EU mean prevalence about 3.87% 
(range 0.18-9.6%). 
• Seriously injured and killed drivers (D2.2.5; D2.2.4; D2.3.4): 
o Hospital study: alcohol (≥0.1g/L) was the most common toxicological finding, both in 
the seriously injured (range 17.7-42.5%) and in killed drivers (range 19.0-44.9%); 
Respective findings for alcohol (≥0.5 g/L) were 16.1-38.2% for seriously injured 
drivers and 16.3– 35.1% for killed drivers (D2.2.5);  
o Fatal accident database FR (D2.2.4): prevalence rate of alcohol 25% (followed by 
THC, opiates, amphetamines and cocaine) (D2.2.4); 
o Responsibility study in DE, LT, HU, SK (D2.3.4): about 37% of all tested drivers were 
under the influence of alcohol.  
Characteristics of drivers tested positive for alcohol: 
• Alcohol was in the general driving population mainly detected among older male 
drivers, with lower BAC levels (D2.2.3).  
• Within the accident involved drivers alcohol was mainly detected among younger male 
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drivers with a high BAC level (D2.2.5). 
• General driving population (D2.2.3): 
o Most prevalent in the two oldest age groups (35-49 and 50+); 
o More prevalent in male than in female drivers;  
o Main prevalent periods: weekday nights and weekends; 
o In general the largest prevalence for alcohol is present at low BAC level (exception: 
LT were 40% of alcohol drivers had BAC >1.2g/L) (D2.2.3). 
• Seriously injured and killed drivers (D2.2.5, D2.2.4): 
o Most prevalent in young drivers (25-35 years) (D2.2.5); 
o More prevalent in male than in female drivers (about 70/30 in seriously injured and 
83/17 in the killed drivers) (D2.2.5); 
o Majority of seriously injured or killed drivers tested positive for alcohol had a high BAC 
level; 90.5% of injured drivers (87% of killed drivers) had BAC ≥0.5g/L (D2.2.5); 
majority of positive tested drivers for alcohol were severely intoxicated (BAC ≥1.2 g/L) 
(D2.2.4). 
• Motives behind impaired driving (D2.2.1):  
o Drivers do not think that alcohol impairs their performance; 
o Drivers whose drinking and driving was related to problems with alcohol argue that 
losing the licence or even to be imprisoned would not have helped them to stop re-
offending; instead, they argue that the treatment programme had helped them by 
providing a greater insight into their own problems. 
Accident risk for driving with alcohol: 
• Alcohol highly increases accident risk (e.g. D2.3.2; D2.3.3; D2.3.4; D2.3.5 DRAFT).  
• Based on case- control studies, the relative risk of serious injury or fatality for alcohol 
(≥0.5g/L) is found to be significantly increased compared to that of drivers below the 
DRUID cut-off for any substance (D2.3.5).  
• An increased risk was associated with high BAC level, young age and speed (D2.3.3).  
• The risk increases drastically with combined use (e.g. cannabis) (D2.3.2). 
• The results of the DRUID accident risk studies reveal:  
o Responsibility studies (D2.3.2, D2.3.3, D2.3.4): the risk of being responsible for a fatal 
crash is 5-8 times higher for a driver driving under the influence of alcohol ((≥0.1g/L) 
than for a sober driver; severely intoxicated drivers (alcohol ≥1.2 g/L) have a 15-21 
times higher risk of being responsible for a fatal crash compared to sober drivers.  
o Case control study (D2.3.5): relative risk of serious injury or fatality for a driver when 
positive for alcohol (≥0.1g/L)  is estimated to be about 5-10 times (for: 0.1-0.5g/L -> 1-
3 times; 0.5-0.8g/L  -> 2-10; 0.8-1.2g/L  -> 5-30 times; and ≥1.2 g/L  -> 20-200 times) 
as high as that of drivers below the DRUID cut-off for any substance. 
Results from experimental studies on the effect of alcohol on driving performance: 
• Alcohol has a negative impact on driving performance and on skills related to driving 
(e.g. D1.1.2a). 
• Driving tests are important to estimate impairment effects, as unspecific measures of 
psychomotor performance do not fully represent the driving performance decrements 
caused by alcohol (e.g. D1.1.2a).   
3.2 Illicit drugs (DUID) 
3.2.1 Prevalence of illicit drugs in relation to road safety 
All DRUID investigations (e.g. D2.2.3, D2.2.5, D2.3.4) show that the prevalence of illicit drugs in 
the driver population (estimated EU mean 1.90%) is lower than the alcohol prevalence 
(estimated EU mean 3.48%) (D2.2.3). Within the accident involved drivers, the majority of drugs 
appeared to be used in combination with other psychoactive substances (mainly alcohol) 
(D2.2.5). THC is generally the most frequently detected illicit drug, followed by cocaine, but the 
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prevalence of the different illicit substances show high national variability (e.g. D2.2.3, D2.2.5, 
D2.3.4).  
 
General driving population 
 
Within the DRUID roadside survey illicit drugs were, as a whole, most frequently detected in Southern 
and Western Europe. The highest prevalence was found in ES where 8.20% of all tested drivers 
(approximately 1 in 12) were positive for one or more illicit drugs (followed by IT: 3.92%; NL: 2.51% 
and PT: 1.80%). In Northern and Eastern Europe the prevalence was on average below 1% (range 
0.22% SE – 0.94% BE) (see figure 27). The different estimated EU mean prevalence of the 
investigated substances were: THC 1.32, cocaine 0.42, amphetamine 0.08, illicit opiates 0.07% 
(D2.2.3).  
 
 
Figure 27: Geographical presentation of illicit drug use by car drivers in the EU (D2.2.3 PART I 
p. 6) 
 
The results of the DRUID roadside survey in regard to different illicit drugs and combined use have 
been summarized as follows (D2.2.3, p. 137f): 
 
“THC1 was the most frequently detected illicit drug in traffic (D2.2.3, 2.2.5, D2.2.4) (estimated 
European mean: 1.32%). It was mainly used in ES where the prevalence was almost four times higher 
than in the second ranked country, NL. On average between 20% and 30% of THC use was in 
                                                 
1
 The THC substance group is formed by THC only. THC-COOH was detected as well in blood, but this inactive metabolite of 
THC will be regarded as negative. 
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combination with other psychoactive substances. Combinational THC use was the highest in the 
Southern European countries (IT, ES, PT) and NL (No THC was detected in LT) (see figure 28). 
 
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
8.00
BE CZ DK ES FI HU IT LT NL NO PL PT SE
THC
European mean
0.00
0.50
1.00
1.50
2.00
2.50
BE CZ DK ES FI HU IT LT NL NO PL PT SE
Cocaine
European mean
 
Figure 28: Prevalence of THC alone by country; prevalence in percentages (D2.2.3 Part I p. 70) 
Figure 29: Prevalence of cocaine alone by country; prevalence in percentages (D2.2.3 Part I p. 
63) 
 
Cocaine2 was the second most frequently detected illicit drug among drivers was cocaine 
(estimated European mean: 0.42%). The highest prevalence for cocaine was found in ES and IT. (No 
cocaine was detected among drivers in CZ, DK, LT, PO and SE.) On average around half of the 
cocaine was detected in combination with other substances. Only in FI and HU cocaine was 
solely detected in single drug use (see figure 29). 
 
Amphetamines3 were far less frequently detected than THC and cocaine. The prevalence of 
amphetamines is very low in most of the 13 countries (estimated European mean: 0.08%). The CZ 
has the highest proportion with 0.38% which is almost the double of the proportion of the countries 
that are ranked second and third: LT and NL with 0.22% and 0.19% respectively. Most countries have 
a prevalence which is lower than 0.10%. In general amphetamines are equally often detected alone as 
in combinations…(No single amphetamines were detected in BE, HU, IT and PT.) (see figure 30) 
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Figure 30: Prevalence of amphetamines alone by country; prevalence in percentages (D2.2.3 
Part I p. 56) 
Figure 31: Prevalence of illicit opiates alone by country; prevalence in percentages (D2.2.3 Part 
I p. 79) 
 
Illicit opiates4 were barely prevalent in European traffic (estimated European mean: 0.07%). IT 
has the highest proportion with 0.3%. In the Northern European countries no illicit opiates were 
detected among drivers. In the Eastern European countries illicit opiates were only detected in PL. 
Illicit opiates were relatively frequently used in combination with other psychoactive substances. 
In IT the prevalence of illicit opiates in combination with other substances was 0.71% which was far 
higher than the single use (0.3%) (see figure 31)”. 
 
                                                 
2
 The cocaine group includes both drivers with cocaine and with its metabolite benzoylecgonine. 
3
 The amphetamine drugs group consisted of amphetamine, metamphetamine, MDMA, MDA, and MDEA. 
4
 The illicit opiates group includes drivers that were positive for heroin (6-acetylmorphine) or the combination of morphine and 
codeine where the concentration of morphine is equal to or higher than the concentration of codeine. If the concentration of 
codeine is higher than that of morphine, the use was regarded as medicinal opiates and opioids use. 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
64 
Alcohol-drug5 combinations. The Northern and Eastern European countries all had lower 
prevalence for the combined use of alcohol and drugs than the European average (estimated EU 
mean: 0.37%). In Western Europe the prevalence was around the average, while relatively the most 
drivers positive for alcohol and drugs were detected in Southern Europe. The highest prevalence was 
detected in ES (1.14%) and IT (1.01%) with prevalence rates just over the 1%. (In all other countries 
the prevalence varied between 0.00% in PL and 0.42% in PT. No information on the combined use of 
alcohol and drugs was available for SE.)  
The relative proportion of alcohol in combination with drugs as a total of all alcohol use varies between 
0% (HU) and 23% (ES). Countries with higher prevalence for single alcohol and single drug use have, 
as expected, higher prevalence for combined use of alcohol and drugs. 
The total of single alcohol use and combined use with illicit drugs and/or psychoactive medicines is 
mainly prevalent in the Southern part of Europe, highest in IT (9.6%) followed by PT and BE (both: 
6.73%) and lowest in FI (0.18%)) (see figure 32). 
 
 
Figure 32: Geographical presentation of alcohol and drugs combinations by car drivers in the 
EU (D2.2.3 PART I p. 8) 
 
Drug-drug6 combinations. The prevalence of drug-drug combinations among drivers was the highest 
in IT and ES, which were the only two countries with a prevalence higher than the European mean of 
                                                 
5
 The group alcohol and drug (combination) consist of alcohol 0.1 g/L in combination with one or more other psychoactive 
substances, excluding THC-COOH which is regarded as negative. 
 
6
 The group drug-drug combinations consist of the combination of two or more other psychoactive substances other than 
alcohol from at least two different groups of drugs, excluding THC-COOH which is regarded as negative. 
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0.39%. Most commonly used drugs in multi-drug combinations are THC, cocaine, and 
(sometimes illicitly used) benzodiazepines, which are also the most frequently detected single 
psychoactive substances after alcohol. 
The proportion of multi-drug use is on average around 10% of all drug use. IT had the highest 
proportion of multi-drug use: 22% of the drug using had been using two or more different drugs (see 
figure 33)”. 
 
 
Figure 33: Geographical presentation of drug-drug combinations by car drivers in the EU 
(D2.2.3 PART I p. 8) 
 
Seriously injured and killed drivers 
 
Within the DRUID hospital study no clear picture of the distribution of illicit drugs among injured and 
killed drivers could be identified, as the prevalence of different substances showed great national 
variability (D2.2.5). In the prevalence of use among all seriously injured drivers, THC (range 0.5% (NL) 
- 7.6% (BE)) was the second most frequently detected substance after alcohol. Amphetamine use 
appears to be more common in northern Europe, while cocaine use seems to be more prevalent in 
southern Europe. No cases of cocaine/benzoylecgonine were recorded in FI. In BE approximately 
9.9% of the seriously injured drivers tested positive for cannabis (THC and/or THCCOOH).  
 
In the prevalence of use among all killed drivers THC was number four (range 0% - 6.1%), after 
alcohol, benzodiazepines and amphetamines. NO had the highest percentage of positive findings for 
THC (6.1%) and PT (0.0%) the lowest. Among the killed drivers subjects positive for THC (alone or in 
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the presence of THCCOOH) were only found in males (D2.2.5). In PT no subjects were found positive 
for the amphetamine group and illicit opiates.  In FI no drivers tested positive for cocaine. In both 
groups the majority of drugs appeared to be used in combination with other psychoactive substances 
(mainly alcohol) (D2.2.5).  
 
In the FR accident databases (D2.2.4) 6.9% of all drivers involved in fatal accidents were tested 
positive for THC, 0.6% for amphetamines, 0.5% for cocaine and 0.9% for opiates (D2.2.4).  
 
Within the responsibility study in DE, LT, HU and SK (D2.3.4) 10% of killed drivers with a positive 
toxicological screening were tested positive for illicit drugs. This corresponded to 4.3% of the whole 
sample7 (n = 483). The most common substance was cannabis (2.5% of the whole sample) (D2.3.4). 
 
Combined use (alcohol-drug and drug-drugs) within seriously injured drivers (D2.2.5). The 
group of seriously injured drivers testing positive for a combination of “alcohol-drug” were within the 
DRUID hospital studies the second most represented group in all countries apart from Lithuania 
(“alcohol only” represent largest group in all six countries). The combined use of “drug-drug” represent 
either the third (Belgium, Denmark, Finland, Italy) or the fourth (Lithuania, The Netherlands) biggest 
group for percentage of positive subjects” (D2.2.5 p. 118) 
 
In general, 75.7% of all positive tested seriously injured drivers (including all countries) used a single 
psychoactive substance (mainly alcohol). 17.8% tested positive for 2 substance groups (D2.2.5). 
 
Combined use (alcohol-drug and drug-drugs) within killed drivers (D2.2.5). Within all countries 
the group of tested positive killed drivers for a combination of alcohol-drug was the second most 
represented group (“alcohol only” represent largest group in all six countries). Within the SE sample 
the same percentage was found for subjects testing positive for the “combination” and for the “drug-
drug combination (D2.2.5).  
 
In general, 78.7% of all positive tested killed drivers (including all countries) used a single 
psychoactive substance (mainly alcohol). 18.4% tested positive for 2 substance groups (D2.2.5). 
3.2.2 Characteristics of drivers tested positive for illicit drugs 
Illicit drugs were in general mainly detected among young male drivers, during all times of the 
day but mainly at the weekend (D2.2.3). Combined use of alcohol and drugs (illicit drugs and/or 
psychoactive medicine) is in general often prevalent among young (<35 years) male drivers 
during night time hours (D2.2.3). Multiple drugs (illicit drugs and/or psychoactive medicines) 
use is in general most common in males (D2.2.3). Age groups and time periods vary 
considerably by country (D2.2.3).  
 
General driving population 
 
Within the DRUID roadside survey the following substance specific characteristics of drivers positive 
for illicit drugs have been identified (D.2.2.3, p. 137f):  
 
“THC. In general drivers who had been using THC were males younger than 35 years. THC was 
prevalent at all days of the week during all hours of the week in most countries. However, in BE, 
CZ, DK, IT and, single THC use was mainly detected during the weekend. The trend of THC use in 
weekends by young male drivers was confirmed by the logistic regression analysis. 
 
Cocaine. Almost all cocaine users were younger than 50 and predominantly male. However, it should 
be taken into account that female drivers in Spain have a higher prevalence for cocaine than most 
male users in other countries. Cocaine was detected during all time periods. However, large 
differences in the distribution by time period exist on a country level. In FI and HU cocaine was only 
detected at weekdays during daytime hours. In ES it was frequently detected during all time periods. 
In IT it was detected frequently in all time periods except in the weekend at daytime hours. In NL 
single cocaine use was primarily detected during weekend nights, while in BE it was more frequently 
                                                 
7
 Whole sample: all killed car drivers (N=483); Responsibility analysis was conducted with the method proposed by Robertson 
and Drummer (1994) which allocated the 483 subjects in 419 cases and 64 controls. Subsequently a toxicological analysis was 
carried out where the 23 DRUIID-core substances as well as several other additional substances were screened for. 
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detected during weekday nights. The results of the logistic regression …based on the data of BE, NO, 
HU and PT, suggest that the highest prevalence would be found among the age group 25- 34. 
 
Amphetamines are mainly used by drivers younger than 35; (in NL and SE however, the largest 
proportion was formed by drivers aged 35-49 years). It is in some countries more prevalent among 
male drivers and in other countries more among female drivers. In LT the prevalence of 
amphetamines among female drivers was almost 20 times higher than for male drivers. This large 
difference could partially be caused by the small sample size of female drivers (n = 121). The 
distribution of amphetamines by time period differs per country. In NL and NO amphetamines are 
mainly used in night time periods. In SE it is detected during night times as well, but only on 
weekdays. In DK and FI amphetamine use was only detected during weekend days and in CZ and ES 
it was detected primarily in the weekend both during the day and during the night. In LT 
amphetamines were only detected in traffic during weekday hours. 
 
Illicit opiates. Most users of illicit opiates are between 35 and 49 years old, except for BE where 
most users were younger than 25. Illicit opiate use was not detected among drivers from Northern 
European countries (DK, FI, NO, SE) and from CZ, LT and HU. Illicit opiates are mainly used by male 
drivers. Illicit opiates were not found during weekday nights in any of the 13 countries. In IT and PT the 
prevalence was the highest during weekend nights, in BE, NL and ES during weekend days and in PL 
at weekdays during daytime”. 
 
Alcohol and drugs combination. In general the prevalence for alcohol-drug combinations for male 
drivers is higher than for female drivers. The only exceptions are NO, where the prevalence of alcohol 
among male drivers was equal to that of female drivers, and Italy where the prevalence of alcohol 
among female drivers was even higher than that in men. 
Most drivers who used alcohol and drugs in combination with each other were younger than 35 years 
old, except for IT, where the drugs-alcohol combination was relatively more prevalent among drivers 
over 35 years old. 
The combined use of alcohol and drugs was mainly detected during night time hours. However, in 
FI, CZ and BE the prevalence during daytime hours was relatively high as well. 
 
Drug-drug combinations were most frequently detected among drivers younger than 50 years. The 
distribution over the four age groups varies largely though over the different countries. 
In general multi-drug use is more common among male than among female drivers. However, in CZ, 
SE, and especially in HU, the proportion of female users is larger. 
The distribution of multi-drug use by time period varies considerable between the different countries. 
In Southern European countries and in NO the prevalence of drug-drug combinations was relatively 
high during night time hours at weekdays. The prevalence during daytime hours at weekdays was the 
highest in Italy and HU. The results of the logistic regression analysis also indicate no significant 
overall trend of time period”. 
 
The DRUID investigation on motives behind drug impaired driving (D2.2.1) carried out in SE and HU 
showed that addicted drivers did not believe that they would be stopped by the police. Furthermore, 
they did not believe that alcohol or drugs would impair their driving and therefore they did not perceive 
any real risks of driving (D2.2.1).  
Findings of the smartphone study in DE indicate that especially moderate substance users can 
realistically judge their intoxication and are responsible-minded concerning drugs in traffic (D2.2.2).  
 
Seriously injured or killed drivers 
 
In both DRUID hospital studies (seriously injured and killed drivers) the distribution of gender and age 
groups of those subjects tested positive for illicit drugs showed high national variability. Illicit drugs 
were in general mainly detected among male seriously injured/killed drives and consumption tends to 
drop in the age group 50 and over. The majority of drugs appeared to be used in combination with 
other psychoactive substances (mainly alcohol) (D2.2.5 p. 63 ff): 
3.2.3 Accident risk for driving with illicit drugs 
Based on case-control studies, the relative risk of serious injury or fatality for different illicit 
substances varies between the substances. For: THC about 1-3 times; benzoylecgonine, 
cocaine and illicit opiates about 2-10 times; amphetamines about 5-30 times) as high as that of 
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drivers below the DRUID cut-off for any substance. Some of the risk estimates for illicit drugs 
vary to a high degree among the single countries; others are based on few positive cases 
and/or controls which result in very wide confidence intervals. Therefore the estimates are 
uncertain. (D2.3.5; see also D1.1.2b, D1.2.1, D2.3.2). The risk multiplies with combined use (e.g. 
alcohol) (e.g. D2.3.2, D2.3.5). 
 
Although the study designs of the single DRUID risk estimation studies do not allow precise 
comparison of the calculated accident risks (e.g. case-control studies for the risk of responsibility, 
case-control studies for injury risk), they point into the same direction.  
 
The FR responsibility study indicates a significant dose effect for cannabis: risk of about twice that of 
drivers not positive for cannabis (≥1 ng/ml) (the risk for alcohol is 8 times that of drivers not positive for 
alcohol (<0.01g/L)). The increased risk effect of responsibility in fatal accidents remains significant 
after adjustment for age, sex and alcohol (adjusted OR 1.89 [95% CI 1.43-2.51]).  There is no 
interaction between alcohol and cannabis on the higher risk of causing road crashes; in other words, 
there is merely a multiplicative effect between the two (8.39*1.89=15.86). For amphetamines, cocaine 
and opiates no significant increase/decrease of risk of being responsible in a fatal accident could be 
observed (D2.3.2). 
 
The findings of the DRUID case-control study (D2.3.5) underline the results mentioned above. Odds 
ratios for different illicit substances have been calculated by means of data from BE, DK, FI, IT, LT 
and NL (seriously injured drivers) and data from FI, NO, PT and SE (killed drivers) separately for each 
country and for all countries as a whole. The odds ratios are adjusted for age and gender and the 
controls were weighted with the traffic distribution in eight time periods over the week. Table 21 shows 
the calculated OR (illicit drugs) for getting seriously injured and table 22 for getting killed based on 
aggregated data (D2.3.5). The results indicate an increase of the relative risk of being seriously injured 
in an accident of about 1-30 times, with a slightly increased risk for driving with THC (of about 1-3 
times), a medium increased risk for driving with benzoylecgonine, cocaine and illicit opiates (of about 
2-10 times) and a highly increased risk for driving with amphetamines (of about 5-30 times) compared 
to the risk for drivers below the DRUID cut-off for any substance. Note that some of the risk estimates 
for illicit drugs vary to a large degree among the single countries; others are based on few positive 
cases and/or controls which result in wide confidence intervals. Therefore these estimates are 
uncertain. Equivalent data for combined use are presented in table 23 and 24. 
 
Table 21: Overview of OR (illicit drugs alone) for getting seriously injured based on aggregated 
data (D2.3.5) 
Reference  Included 
country OR + CI 
Illicit drugs 
Amphetamines Benzoylecgonine Cocaine** THC*** Illicit opiates 
D2.3.5 
DRAFT 
BE, DK, 
FI, IT, LT, 
NL 
Crude OR  
95% CI 
9.66* 
4.80-19.46 
5.36* 
2.53-11.34 
3.41* 
1.61-7.21 
1.86* 
1.20-2.88 
4.03* 
1.32-12.32 
Adjusted 
OR 95% CI 
8.35 
3.91-17.83 
3.70 
1.60-8.57 
3.30 
1.40-7.79 
1.38 
0.88-2.17 
2.47 
0.50-12.10 
* In the case of 0 counts in one of the groups: Positive cases, negative cases, positive controls and negative controls, 0.5 was 
added to all four cells in the data from each such country when calculating crude OR (Greenland et al., 2000); ** Cocaine or 
cocaine + benzoylecgonine; *** THC or THC + THCCOOH 
 
Table 22: Overview of OR (illicit drugs alone) for getting killed based on aggregated data 
(D2.3.5) 
Reference  Included 
country 
OR   
95% CI 
Illicit drugs 
Amphetamines Benzoylecgonine Cocaine** THC*** Illicit 
opiates 
D2.3.5 
DRAFT 
FI, NO, 
PT, SE 
Crude OR  
95% CI 
25.44* 
10.81-59.90 
6.87* 
1.49-31.76 
22.34* 
3.66-136.53 
1.80* 
0.73-4.44 
10.04* 
2.04-49.32 
Adjusted 
OR 95% CI 
24.09 
9.72-59.71 n.a. n.a. 
1.33 
0.48-3.67 n.a. 
* In the case of 0 counts in one of the groups: Positive cases, negative cases, positive controls and negative controls, 0.5 was 
added to all four cells in the data from each such country when calculating crude OR (Greenland et al., 2000); ** Cocaine or 
cocaine + benzoylecgonine; *** THC or THC + THCCOOH  
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Table 23: Overview of OR (combined use) for getting seriously injured based on aggregated 
data (D2.3.5) 
Reference  Included 
country OR + CI 
Combined use 
Alcohol-drug(s) Multiple drugs 
D2.3.5 
DRAFT 
BE, DK, 
LT, NL 
Crude OR  
95% CI 
31.97 
20.76-49.25  
Adjusted 
OR 95% CI 
28.82 
18.41-45.11  
D2.3.5 
DRAFT 
BE, DK, 
FI, IT, LT, 
NL 
Crude OR  
95% CI  
8.64* 
5.85-12.75 
Adjusted 
OR 95% CI  
8.01 
5.34-12.01 
Finland and Italy have been left out of the calculations of OR for alcohol and alcohol-drug(s) because of bias in collecting data 
for the control samples 
* In the case of 0 counts in one of the groups: Positive cases, negative cases, positive controls and negative controls, 0.5 was 
added to all four cells in the data from each such country when calculating crude OR (Greenland et al., 2000)  
 
Table 24: Overview of OR (combined use) for getting killed based on aggregated data (D2.3.5) 
Reference  Included 
country 
OR   
95% CI 
Combined use 
Alcohol-drug(s) Multiple drugs 
D2.3.5 
DRAFT NO, PT 
Crude OR  
95% CI 
41.22 
22.59-75.24  
Adjusted OR 
95% CI 
31.52 
16.83-59.05  
D2.3.5 
DRAFT 
FI, NL, 
PT, SE 
Crude OR  
95% CI  
16.77 
9.95-28.27 
Adjusted OR 
95% CI  
18.51 
10.84-31.63 
Finland has been left out of the calculations of OR for alcohol and alcohol-drug(s) because of bias in collecting data for the 
control sample. Sweden did not include alcohol positive drivers in the control sample.  
3.2.4 Results from experimental studies on the effect of illicit drugs on 
driving performance  
Experimental studies have shown that the dose equivalent for BAC 0.5g/L-3.7ng/mL THC 
(range 3.1-4.5ng/mL) for oral administration and 3.8 ng/mL (range 3.3-4.5ng/mL) for smoked 
administration (D1.1.2b, see also D1.4.2 for more information on cut-offs equivalent to BAC 
0.5g/L). Experimental studies evaluating the effect of stimulants on driving (MDMA and 
dexamphetamine) did not reveal impairing effects on driving performance. However, the 
stimulant effects of MDMA and dexamphetamine are not sufficient to overcome or compensate 
driving impairments produced by concomitant of alcohol use or sleep deprivation (D1.1.2b, 
D1.2.1).  
 
Stimulants. The experimental studies on stimulants (D1.2.1) in WP1 showed that 3,4-
methylmethamphetamine (MDMA; 25, 50 and 100mg ) and dexamphetamine (10, 40mg) did not 
reveal impairing effects or increased risk caused by the drug consumption itself (low doses of 
stimulant drugs produce neutral or even stimulating effects on a range of psychomotor functions). It 
should be noted that doses of stimulants administered in the studies conducted within DRUID have 
been relatively low for (some) recreational drug users. But it was not possible to assess high doses 
due to medical and ethical constraints.  
As stimulant drug consumption is often combined with sleep deprivation and/or concomitant alcohol 
use experimental studies investigated these effects. Sleep deprivation itself generates the same 
degree of impairment as BAC 0.8g/L. An increased risk taking behaviour could be observed only in 
combination with additional alcohol consumption. Stimulant effects of MDMA and amphetamine are 
not sufficient to overcome or compensate driving impairments produced by concomitant alcohol use or 
by sleep deprivation. The pharmacological effects of stimulants and the effects of drug use setting 
(e.g. poly-drug use, concomitant alcohol use and sleep deprivation) are closely intertwined and 
significantly contribute to degree of driver impairment. Very often users of stimulating drugs are not 
aware of post acute fatigue effects. They need to be educated about this effect and its possible 
implications on driving safety (D1.2.1). 
 
Based on meta-analyses of experimental studies (D1.1.2b) no negative influence of stimulants on the 
fitness to drive can be stated. In summary there are more findings of performance improvements than 
of performance impairments. Dexamphetamine is the agent on which most studies are available 
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(dosage 1mg to 36 mg). Recent studies focused on the impact of designer amphetamine MDMA 
(ecstasy) on performance. In those studies more improvements than impairments were found, as well. 
Accordingly there is no performance decrement during the time of action after consumption of “normal” 
doses (40mg to 125mg) (D1.1.2b).  
 
Cocaine has similar acute effects as amphetamines. From a meta-analysis of experimental studies no 
negative influence on the fitness to drive could be stated. Only some case-reports and non-
experimental publications revealed negative effects. But overall there is a lack of studies focusing on 
impairments during the post acute phase (D1.1.2b).  
 
On Cannabis (THC) 21 studies with 482 effects in total (doses 7.5 to 39mg) were included into a 
meta-analysis of the effects of oral administration of THC on performance (D 1.1.2b). This analysis 
reveals that the impairment caused by 3.7ng/mL THC (range 3.1 to 4.5ng/mL) is equal to that caused 
by 0.5g/L BAC. An additional meta-analysis on the effects of smoking of THC on performance leads to 
a comparable result. 78 studies with a total of 888 effects (doses 1 to 52 mg) were included in that 
meta-analysis. The dose equivalent to 0.5g/L BAC is 3.8ng/mL (range 3.3 to 4.55ng/mL). Therefore 
the results of both meta-analyses are in agreement (D1.1.2b). 
3.2.5 Overview box – illicit drugs 
Box 2: Summary of main DRUID results – ILLICIT DRUGS 
Prevalence of illicit drugs in relation to road safety: 
• All DRUID investigations (e.g. D2.2.3, D2.2.5, D2.3.4) show that the prevalence of illicit 
drugs in the driver population (estimated EU mean 1.90%) is lower than the alcohol 
prevalence (estimated EU mean 3.48%) (D2.2.3).  
• Within the accident involved drivers, the majority of drugs appeared to be used in 
combination with other psychoactive substances (mainly alcohol) (D2.2.5). 
• THC is generally the most frequently detected illicit drug, followed by cocaine, but the 
prevalence of the different illicit substances show high national variability (e.g. D2.2.3, 
D2.2.5, D2.3.4). 
• General driving population (D2.2.3): 
o Illicit drugs: estimated EU mean for one or more illicit substances 1.90% (range 0.22-
8.20%); main EU region: Southern Europe; 
o THC alone: estimated EU mean prevalence 1.32% (range 0-5.99%); prevalence 
ranking from all investigated substances #3; main EU region: Southern Europe; on 
average 20-30% of THC use was in combination with other psychoactive substances;  
o Cocaine alone: estimated EU mean prevalence 0.42%, (range 0-1.49%); prevalence 
ranking from all investigated substances #5; main EU region: Southern Europe; on 
average around 50% of cocaine use was in combination with other psychoactive 
substances;  
o Amphetamine alone: estimated EU mean prevalence 0.08%; (range 0-0.38%); 
prevalence ranking from all investigated substances #11; main EU region: no specific 
region; on average around 50% of amphetamine use was in combination with other 
psychoactive substances; 
o Illicit opiates alone: estimated EU mean prevalence 0.07%; (range 0-0.30%); 
prevalence ranking from all investigated substances #12; main EU region: Southern 
Europe; illicit opiates were relatively frequently used in combination with other 
psychoactive substances; 
o Alcohol (≥0.1g/L) - drug combinations: estimated EU mean prevalence 0.37% (range 
0.0-1.14%); prevalence ranking from all investigated substances #8; main EU region: 
Southern Europe; relative proportion varies between 0-23%; Countries with higher 
prevalence for single alcohol and single drug use have, as expected, higher 
prevalence for combined use of alcohol and drugs; 
o Drug-drug combinations: estimated EU mean prevalence 0.39% (range 0-1.22%); 
prevalence ranking from all investigated substances #7; main EU region: Northern 
Europe; most commonly used drugs in multi-drug combinations are THC, cocaine, 
and benzodiazepines; proportion of multi-drug use is on average around 10% of all 
drug use (highest in IT where 22% of the drug using had been using two or more 
different drugs. 
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• Seriously injured and killed drivers (D2.2.5; D2.2.4; D2.3.4): 
o Hospital study: no clear picture of the distribution of illicit drugs among injured and 
killed drivers could be identified, as the prevalence of different substances showed 
great national variability. Seriously injured drivers: THC (range 0.5-7.6%) second most 
common toxicological finding after alcohol. Amphetamine use more common in 
northern Europe; cocaine use more prevalent in southern Europe.  Killed drivers:  
THC was number four (range 0- 6.1%), after alcohol, benzodiazepines and 
amphetamines. Combined user (alcohol-drug and drug-drugs): The majority of drugs 
appeared to be used in combination with other psychoactive substances (mainly 
alcohol). The group of alcohol-drug combined users were within the seriously injured 
drivers and killed drivers second most represented group in almost all countries. The 
combined use of “drug-drug” represent either third or fourth biggest group for 
percentage of positive subjects among seriously injured drivers (D2.2.5). 
o Responsibility study in DE, LT, HU, SK (D2.3.4): about 4.3% of all tested drivers were 
under the influence of illicit drugs (mainly cannabis).   
Characteristics of drivers tested positive for illicit drugs: 
• Illicit drugs were in general mainly detected among young male drivers, during all times 
of the day but mainly at the weekend (D2.2.3).  
• Combined use of alcohol and drugs (illicit drugs and/or psychoactive medicine) is in 
general often prevalent among young (<35 years) male drivers during night time hours 
(D2.2.3).  
• Multiple drugs (illicit drugs and/or psychoactive medicines) use is in general most 
common in males (D2.2.3).  
• Age groups and time periods vary considerably by country (D2.2.3).  
• General driving population (D2.2.3): 
o Cannabis in drivers in traffic (D2.2.3): 
 Most prevalent among young drivers (18-34 years); 
 2-3 times more prevalent in male than in female drivers;  
 Main time period differs per country. 
o Cocaine in drivers in traffic (D2.2.3): 
 Almost all cocaine users younger then 50 years; within logistic regression 
(BE, NO, HU PT) highest prevalence would be found among the age group 
25- 34; 
 2 times more prevalent in male than female drivers; 
 Main time period differs per country. 
o Amphetamines in drivers in traffic (D2.2.3): 
 Most prevalent among young drivers (18-35 years);  
 The gender effect differs by country; 
 Main time period differs per country. 
o Illicit opiates (D2.2.3): 
 Most prevalent among middle aged drivers (35-49 years); 
 More prevalent in male than in female drivers;  
 Main time period differs per country.  
o Alcohol and drugs combination (D2.2.3): 
 Most prevalent among young drivers (18-34);  
 More prevalent in male than in female drivers;  
 Most commonly detected in night-time hours. 
o Drug-drug combination (D2.2.3): 
 Mainly detected in middle aged drivers (<50); 
 More prevalent in male than in female drivers;  
 Main time period differs per country. 
• Seriously injured and killed drivers (D2.2.5): 
o Most prevalent in young and middle aged drivers (<50 years), 
o More prevalent in male than in female drivers;  
o The majority of drugs appeared to be used in combination with other psychoactive 
substances (mainly alcohol).   
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• Motives behind impaired driving (D2.2.1; D2.2.2):  
o Addicted drivers did not believe that they would be stopped by the police (D2.2.1) 
o They did not believe that alcohol or drugs would impair their driving and therefore they 
did not perceive any real risks of driving (D2.2.1). 
o Findings indicate that especially moderate substance users can realistically judge 
their intoxication and are responsible-minded concerning drugs in traffic (D2.2.2).  
Accident risk for driving with illicit drugs:  
• Based on case-control studies, the relative risk of serious injury or fatality for different 
illicit substances varies between the substances. For: THC about 1-3 times; 
benzoylecgonine, cocaine and illicit opiates about 2-10 times; amphetamines about 5-
30 times) as high as that of drivers below the DRUID cut-off for any substance. Some of 
the risk estimates for illicit drugs vary to a high degree among the single countries; 
others are based on few positive cases and/or controls which result in very wide 
confidence intervals. Therefore the estimates are uncertain. (D2.3.5; see also D1.1.2b, 
D1.2.1, D2.3.2).  
• The risk multiplies with combined use (e.g. alcohol) (e.g. D2.3.2, D2.3.5). 
• DRUID accident risk studies:  
o Responsibility study FR (D2.3.2): drivers involved in fatal accidents and positive for 
cannabis (≥1 ng/ml), had a risk of about twice as high as that of drivers not positive for 
cannabis (adjusted OR 1.89 [95% CI 1.43-2.51]) (in comparison alcohol: 8 times as 
high (adjusted OR 8.39 [95% CI 6.95-10.11]). Combined use of alcohol and cannabis 
multiplies the risk of causing a fatal accident (8.39*1.89=15.86). 
o Case control study (D2.3.5): relative risk of serious injury or fatality for a driver when 
positive for different illicit substances is estimated to be about 1-30 times (for: THC -> 
1-3 times; benzoylecgonine and cocaine -> 2-10; amphetamines 5-30 times) as high 
as that of drivers below the DRUID cut-off for any substance. 
Results from experimental studies on the effect of illicit drugs on driving performance  
• Experimental studies have shown that the dose equivalent for BAC 0.5g/L-3.7ng/mL 
THC (range 3.1-4.5ng/mL) for oral administration and 3.8 ng/mL (range 3.3-4.5ng/mL) for 
smoked administration (D1.1.2b, see also D1.4.2 for more information on cut-offs 
equivalent to BAC 0.5g/L). 
• Experimental studies evaluating the effect of stimulants on driving (MDMA and 
dexamphetamine) did not reveal impairing effects on driving performance. However, 
the stimulant effects of MDMA and dexamphetamine are not sufficient to overcome or 
compensate driving impairments produced by concomitant of alcohol use or sleep 
deprivation (D1.1.2b, D1.2.1).   
3.3 Medicines  
3.3.1 Prevalence of psychoactive medicines in relation to road safety 
DRUID studies indicate that some selected psychoactive medicines (benzodiazepines, 
medicinal opiates and opioids and Z-drugs) are less prevalent in the driving population 
(estimated EU mean 1.4%) (D2.2.3) as well as is in seriously injured drivers (D2.2.5) compared 
to alcohol (estimated EU mean 3.48%) and illicit drugs (estimated EU mean 1.90%). Among the 
killed drivers the presence of benzodiazepines was the second most frequent toxicological 
finding after alcohol (D2.2.5). Psychoactive medicines, such as (frequently used) 
antidepressants, anti-epileptics and antipsychotics, were not included in the DRUID studies. 
Therefore an underestimation of prevalence should be considered. In most countries 
benzodiazepines were the most common psychoactive medicines in traffic but as for illicit 
drugs the prevalence of the different psychoactive medicines show high national variability 
(D2.2.3, D2.2.5). Epidemiological studies indicate a major increase in the consumption of 
antidepressants and drugs used in addictive disorders in the general population in Europe 
within the last years (D2.1.1).  
 
General driving population 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
73 
 
Within the DRUID roadside survey the prevalence rates for psychoactive medicines were in most 
countries (7 out of 13) between 1.4 - 1.8% (estimated EU mean 1.36%). The highest prevalence was 
found in BE and PT just below 3% and the lowest in PL (0.17%) (see figure 34). In general 
benzodiazepines were the most prevalent psychoactive medicine in traffic (estimated European mean: 
0.90%). Medicinal opiates and opioids were less prevalent (estimated European mean: 0.35%) and Z-
drugs were very seldom detected in EU countries (estimated European mean: 0.09%), except in NO 
where they were detected among 0.69% of all drivers.  
 
 
Figure 34: Geographical presentation of psychoactive medicine use by car drivers in the EU 
(D2.2.3 PART I p. 7) 
 
The prevalence of different psychoactive medicines shows high national variability. The according 
results have been summarized within the DRUID roadside survey as follows (D2.2.3 PART I p. 141f)):  
 
“Benzodiazepines8 were detected in all 13 countries. The highest prevalence was detected in PT, 
followed by BE, HU, ES and LT. The average European mean was 0.90%. Benzodiazepines were not 
often used in combination with other psychoactive substances. In most countries the proportion was 
around 15%. However in IT almost half of all benzodiazepines were used in combination (see figure 
35). 
 
                                                 
8
 The benzodiazepines group consists of diazepam, nordiazepam, oxazepam, lorazepam, alprazolam, flunitrazepam, and 
clonazepam. 
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Figure 35: Prevalence of benzodiazepines alone by gender; prevalence in percentages (D2.2.3 
Part I p. 86) 
 
Medicinal opiates and opioids9 (estimated European mean: 0.35%).The highest prevalence was 
found in DK followed by BE, SE, FI and IT. No medicinal opiates and opioids were detected among 
drivers in LT.)  In HU, IT and PT medicinal opiates and opioids are relatively often used in combination 
with other psychoactive substances. In CZ, ES and PL only single use was detected (see figure 36). 
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Figure 36: Prevalence of medicinal opiates and opioids alone by country; prevalence in 
percentages (D2.2.3 Part I p. 102) 
Figure 37: Prevalence Z-drugs alone by country; prevalence in percentages (D2.2.3 Part I p. 95) 
 
Z-drugs10 were not commonly detected among European drivers (estimated European mean: 
0.09%). The prevalence is the highest in the Northern European countries (NO, FI, DK, SE), followed 
by BE, HU and the NL. In all other countries no Z-drugs were detected among drivers. Z-drugs were 
relatively often combined with other psychoactive substances in FI and HU. In DK only single use of Z-
drugs was detected. In BE, NO, SE and NL the relative proportion of combinational use of Z-drugs 
varied between 9% and 26% (see figure 37)”.  
 
Seriously injured and killed drivers 
 
Within the hospital study the prevalence use among all seriously injured drivers, of benzodiazepines 
(range 0-10.2%) was third most frequent finding after alcohol  (range 17.7-42.5%) and THC (range 
0.5-7.6%). The highest prevalence was found in FI (10.2%) and lowest in NL (0.0%). The prevalence 
of amphetamines ranged between 0.1 % (IT) and 4.2% (DK) and those for cocaine and/or 
benzoylecgonine between 0.0% (FI) and 5.4% (IT). No positive findings for Z-drugs were recorded in 
IT and LT. LT had almost a double amount of positive subjects for medicinal opioids compared with 
the other countries in the study.   
Within all killed drivers benzodiazepines (range 1.8% (PT) - 13.3% (FI)), were the second most found 
substance group after alcohol ((≥0.1g/L; range 19.0 - 44.9%), followed by amphetamine (range 0.0% 
(PT) – 7.4% (NO)). However, it should be noted that three of the participating countries (FI, NO and 
SE) are part of the Scandinavian area where the use of amphetamines is generally higher than in the 
southern European countries. SE had a double amount of subjects positive for medicinal opioids 
compared with the other three countries (D2.2.5).  
 
                                                 
9
 The medicinal opiates and opioids group consists of morphine, codeine, methadone and tramadol. 
10
 The Z-drugs group consists of zolpidem and zopiclone. 
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Within the responsibility study in DE, LT, HU and SK (D2.3.4) 13% of the killed drivers positive for 
psychoactive substances were tested positive for psychoactive medicines which represented 5.6% of 
the whole sample (n=483). The most common substances were benzodiazepines (3.7% of the whole 
sample11) (D2.3.4). 
3.3.2 Characteristics of drivers tested positive for psychoactive 
medicines  
Psychoactive medicines were in general mainly detected among older female drivers during 
daytime hours (D2.2.3). 
 
General driving population 
 
Within the DRUID roadside survey the following specific characteristics of drivers impaired by 
psychoactive medicines have been identified (D.2.2.3, p. 139f). The information in regard to drivers 
impaired by Z-drugs is based on a very small sample and was not included within this Deliverable.   
 
“Benzodiazepines. The highest prevalence for single benzodiazepine use was detected among 
drivers aged 35 years and older. However, in IT most benzodiazepines were used by young drivers 
aged 18-24. Unlike for illicit drugs, benzodiazepine use is relatively more frequently detected among 
female drivers. Especially in LT the proportion of female drivers was much higher than that of male 
drivers. In DK, FI and PL the proportion of benzodiazepine use was higher among male drivers 
though. Benzodiazepines were most commonly detected during daytime in many of the countries. 
Only in PL and PT relatively more drivers were positive for the use of benzodiazepines during night 
time hours. This trend was generally confirmed by the logistic regression analysis. 
 
Medicinal opiates and opioids were mainly detected among drivers of 35 years and older. 
In most countries the proportion of female drivers is larger, except for ES, FI, NO, and PT where the 
proportion of male drivers positive for medicinal opiates and opioids was larger. The logistic regression 
results indicate a general higher prevalence among female drivers as well. The distribution over the 
four different DRUID time periods varies largely, but in general highest prevalence was detected 
during daytime hours. In DK though, most medicinal opiates and opioids were detected in weekend 
nights and in FI during weeknights”. 
 
Seriously injured or killed drivers  
 
In both DRUID hospital studies (seriously injured and killed drivers) the distribution of gender and age 
groups of those subject positive for psychoactive medicines showed high national variability. 
Psychoactive medicines were in general mainly detected among male seriously injured/killed drive.  
The percentage of positives appeared to be generally higher in older age groups (>35 years). The 
majority of psychoactive medicines within seriously injured/killed drivers appeared to be used in 
combination with other psychoactive substances (mainly alcohol and benzodiazepines) (D2.2.5 p. 86 
ff): 
3.3.3 Accident risk for driving with psychoactive medicines 
Alcohol impaired driving is the main problem in traffic safety, but also psychoactive medicines 
can constitute a problem in traffic safety. Therefore, both health care providers and patients 
should be properly informed and aware of the potential risks associated with the use of 
psychoactive medicines (link WP4/7). Based on case-control studies, the relative risk of 
serious injury or fatality for benzodiazepines + Z-drugs and medicinal opioids) is estimated to 
be about 2-10 times (medicinal opioids in the upper part of the interval; benzodiazepines + Z-
drugs in the lower part of the interval) as high as that of drivers below the DRUID cut-off for 
any substance (D2.3.5). 
 
Although the study designs of the single DRUID risk estimation studies do not allow precise 
comparison of the calculated accident risks, they point into the same main direction.  
 
                                                 
11
 Whole sample: all killed car drivers (N=483) 
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Within NL relative accident risk study of patients using psychoactive medicines (D2.3.1) an increased 
traffic accident risk was also seen in: new (inexperienced) users, intermediate and long half-life 
benzodiazepine users, female users, and young/middle-aged users (these associations were not 
always statistically significant). The risk of being involved in an accident is highest for users of modern 
antidepressants (1.76, CI: 1.38-2.24), followed by patients who use combinations of psychoactive 
medicines (1.55, CI: 1.20-2.02), and patients using at least one psychoactive medication (1.28, CI: 
1.12-1.46) (D2.3.1).  
 
In the DRUID case-control study (D2.3.5) odds ratios for different medicines have been calculated by 
means of data from BE, DK, FI, IT, LT and NL (seriously injured drivers) and data from FI, NO, PT and 
SE (killed drivers) separately for each country and for all countries as a whole. The odds ratios are 
adjusted for age and gender and the controls were weighted with the traffic distribution in eight time 
periods over the week. Table 25 shows the calculated OR (medicine) for getting seriously injured and 
table 26 for getting killed based on aggregated data (D2.3.5). 
 
Table 25: Overview of OR (medicine) for getting seriously injured based on aggregated data 
(D2.3.5) 
Reference Included 
country 
OR 
95% CI 
Medicine 
Benzodiazepines  
+ Z-drugs 
Medicinal  
opioids 
D2.3.5 
DRAFT 
BE, DK, 
FI, IT, LT, 
NL 
Crude OR  
95% CI 
1.73 
1.19-2.51 
7.99* 
5.73-11.15 
Adjusted 
OR 95% CI 
1.99 
1.36-2.91 
9.06 
6.40-12.83 
* In the case of 0 counts in one of the groups: Positive cases, negative cases, positive controls and negative controls, 0.5 was 
added to all four cells in the data from each such country when calculating crude OR (Greenland et al., 2000)  
 
Table 26: Overview of OR (medicine) for getting killed based on aggregated data (D2.3.5) 
Reference Included 
country 
OR 
95% CI 
Medicine 
Benzodiazepines  
+ Z-drugs 
Medicinal  
opioids 
D2.3.5 
DRAFT 
FI, NO, 
PT, SE, 
Crude OR  
95% CI 
5.11 
3.72-7.02 
4.82 
2.61-8.88 
Adjusted 
OR 95% CI 
5.40 
3.90-7.46 
4.82 
2.60-8.93 
 
The results of the DRUID case-control study (D2.3.5) indicate a medium increased relative risk of 
being seriously injured in an accident for benzodiazepines + Z-drugs and for medicinal opioids of 
about 2-10 times higher than that of drivers below the DRUID cut-off for any substance. There is, 
however, a tendency that the risk for benzodiazepines + Z-drugs lies in the lower part of the interval 
whereas the risk for medicinal opioids lies in the upper part of the interval. 
3.3.4 Results from experimental studies on the effect of psychoactive 
medicines on driving performance  
Psychoactive medicines can impair driving performance (e.g. D1.2.2, D1.1.2b, D1.1.2c). Besides 
the agent itself there are many factors influencing the degree of impairment (e.g. galenics, 
route of administration, dose, time period between administration and driving, concomitant use 
of other (medicinal) drugs, habituation).  Zopiclone (7.5mg) and alprazolam (0.5mg) produced 
significant driving impairment in patients as well as in healthy controls during morning driving 
10-11 hrs after drug intake (D1.2.2). The impairing potential of Codiliprane® varies with age 
(D1.2.2). Single doses (10 and 20mg) of Dronabinol (Marinol®) impaired road tracking 
performance of occasional cannabis users (representing acute effects of Dronabinol) during 
on-the-road driving tests in a dose related manner. Those impairments were bigger than the 
impairment caused by BAC of 0.5g/L (D1.2.2). After habituation transdermal application of 
opioid analgesics as well as oral administration of slow release formulations of opioid 
analgesics caused no impairment in patients suffering from chronic pain (D1.2.2). Even at low 
dosages methadone and buprenorphine caused impairment when given as a single dose to 
healthy subjects. No clear evidence exists if patients under maintenance treatment are able to 
drive safely. Many maintenance patients use other substances in addition, so it is 
recommended that a screening for other substances is done if a maintenance patient should 
be allowed to drive (D1.1.2c). 
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The main results of D1.2.2 can be summarized as follows:  
 
Standardized driving tests demonstrated that nocturnal intake of zopiclone (7.5mg) and alprazolam 
(0.5mg) produced significant driving impairment in patients as well as in healthy controls during 
morning driving 10-11 hrs after drug intake. Whereas chronic users did not experience any sedative 
effects of zopiclone and alprazolam, infrequent users and healthy users reported feelings of reduced 
alertness and sleep. This lack of awareness of the (residual) sedative effects of zopiclone and 
alprazolam may lead insomnia and anxious patients to the false belief that car driving is safe during 
treatment with these drugs.  
Codiliprane® is a combination of codeine and paracetamol available on the European market. 
Results of the driving test data indicate that the impairing potential of Codiliprane® varies with age. 
Codiliprane did not impair driving performance when administered to young, healthy volunteers, even 
at high doses. But Codiliprane® produced driving impairment when administered to elderly healthy 
volunteers even al low doses. 
Single doses (10 and 20mg) of Dronabinol (Marinol®) impaired road tracking performance of 
occasional cannabis users (representing acute effects of Dronabinol) during on-the-road driving tests 
in a dose related manner. Those impairments were bigger than the impairment caused by BAC of 
0.5g/L. The effects of Dronabinol on driving performance of heavy cannabis users (representing 
chronic use of Dronabinol) were less pronounced or even absent. This suggests that tolerance to the 
impairing effects develops.  
Driving performance of a sample of patients suffering from chronic non-cancer pain under long-term 
treatments with opioid analgesics (transdermal Fentanyl, transdermal Buprenorphine, slow-
release Oxycodone (sometimes in combination with naloxone), slow-release Hydromorphone 
or slow-release Morphine) was not impaired compared to a sample of healthy controls.  
Some performance measures in driving tests of schizophrenic patients with a history of psychotic 
episodes treated with Risperidone or Paliperidone were impaired (D1.2.2).  
 
Within D1.1.2c studies dealing with application of a single dose of opioids, narcoanalgesics and 
hallucinogens have been summarized. For all substances at least impairment in certain groups of 
tasks has been found, although this does not necessarily mean that this would increase the accident 
risk in real traffic. In an overview the impairing doses and concentrations are related to the half-life of 
the drugs, which gives an idea how long the impairment can be assumed for the respective substance.  
Patients treated chronically with morphine showed no impairment compared to untreated patients 
(although in comparison to healthy volunteers impairment in psychomotor (and probably in cognitive) 
abilities was found. Pain by itself reduces psychomotor functions.  
Substances used in maintenance treatment (methadone, buprenorphine) cause impairment even at 
low dosages when given as a single dose to healthy subjects. There is no clear evidence if patients 
treated chronically are able to drive, as there are huge interindividual differences. Many of 
maintenance patients use other substances additionally, so it is recommended that a screening for 
other substances should always be done if a maintenance patient should be allowed to drive 
(D1.1.2c). 
 
Meta-analysis on experimental studies showed that there are many factors influencing the degree of 
impairment caused by the intake of a medicinal drug, e.g. active agent, galenics, route of 
administration, dose, time of administration (in the day, in the night), time period between 
administration and performance requirement, compliance and disposition of the patient as well as 
concomitant use of additional drugs. Generally speaking the start of a therapy is the most crucial 
phase with respect to performance impairment. Derived from published studies D 1.1.2b provides in a 
meta-analytic approach detailed information for major medicinal drugs (psycholeptics, anxiolytics, 
hypnotics and sedatives, psychoanaleptics, antidepressants and antihistamines) on the kind of 
performance impairments (see figure 38 as an example), the duration of the impairment and the 
degree of impairment caused by a certain dosage of a given active agent. 
It is, at most, more the dose than the agent itself that determines the degree of performance 
impairment. In addition the available information of a specific active agent is summarized and 
information on the dosage causing an impairment equivalent to 0.5g/L BAC is given (see table 27 as 
example).  
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Figure 38: Oxazepam 15 mg, time-dependent 
impairment (D 1.1.2 B, p. 57). 
 
Table 27: Oxazepam, summary of results.  
 
 
Blood specimens are often drawn several hours after the actions. Pharmacokinetic data makes it 
possible to calculate the concentration of a given active agent at action time and to explain the effects 
at the time of the incident. Based on a comprehensive meta-analysis of pharmacokinetic studies time 
courses of plasma-concentration and other pharmacokinetic parameters (see figure 39 as example) 
are given for a huge number of major psychoactive medicines in this deliverable. 
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Figure 39: Plasma concentration-time curve of zolpidem after oral 
administration. (D 1.1.2 B, p. 469).  
 
Further information on the effect of medicines on driving performance based on the literature have 
been evaluated and categorized in WP4 (classification, see according chapter and deliverables). 
3.3.5 Overview box – psychoactive medicines 
Box 3: Summary of main DRUID results – PYCHOACTIVE MEDICINES 
Prevalence of psychoactive medicines in relation to road safety: 
• DRUID studies indicate that some selected psychoactive medicines (benzodiazepines, 
medicinal opiates and opioids and Z-drugs) are less prevalent in the driving population 
(estimated EU mean 1.4%) (D2.2.3) as well as is in seriously injured drivers (D2.2.5) 
compared to alcohol (estimated EU mean 3.48%) and illicit drugs (estimated EU mean 
1.90%). Among the killed drivers the presence of benzodiazepines was the second most 
frequent toxicological finding after alcohol (D2.2.5). Psychoactive medicines, such as 
(frequently used) antidepressants, anti-epileptics and antipsychotics, were not included 
in the DRUID studies. Therefore an underestimation of prevalence should be 
considered. 
• In most countries benzodiazepines were the most common psychoactive medicines in 
traffic but as for illicit drugs the prevalence of the different psychoactive medicines 
show high national variability (D2.2.3, D2.2.5).  
• Epidemiological studies indicate a major increase in the consumption of 
antidepressants and drugs used in addictive disorders in the general population in 
Europe within the last years (D2.1.1).  
• General driving population (D2.2.3): 
o Psychoactive medicine s: estimated EU mean for one or more psychoactive medicine 
1.36% (range 0.17-2.99%); main EU region: no specific region; 
o Benzodiazepines alone:  estimated EU mean 0.90% (range 0.14-2.73%); prevalence 
ranking from all investigated substances #4; main EU region: Southern Europe; not 
often used in combination with other psychoactive substances (proportion around 
15% in most countries); 
o Medicinal opiates and opioids alone: estimated EU mean 0.35% (range 0.00-0.79%); 
prevalence ranking from all investigated substances #9; relatively often used in 
combination with other psychoactive substances; in CZ, ES and PL only single use 
was detected; 
o Z-drugs alone:  estimated EU mean 0.09% (range 0-0.69%); prevalence ranking from 
all investigated substances #10; relatively often combined with other psychoactive 
substances. 
• Seriously injured and killed drivers (D2.2.5; D2.2.4; D2.3.4): 
o Hospital study: no clear picture of the distribution of psychoactive medicines among 
injured and killed drivers could be identified, as the prevalence of different substances 
showed great national variability. Seriously injured drivers: benzodiazepines (range 
0.0-10.2%) were third most frequent finding after alcohol and THC. Killed drivers: 
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benzodiazepines (range 1.8-13.3%), were the second most found substance group 
after alcohol, followed by amphetamine (D2.2.5).  
o Responsibility study in DE, LT, HU, SK (D2.3.4): about 6% of all tested drivers were 
under the influence of psychoactive medicines (mainly benzodiazepines).   
Characteristics of drivers tested positive for psychoactive medicines:  
• Psychoactive medicines were in general mainly detected among older female drivers 
during daytime hours (D2.2.3).  
• General driving population (D2.2.3): 
o Benzodiazepines in drivers in traffic (D2.2.3): 
 Most prevalent among middle aged and older drivers (35+);  
 More prevalent in female than in male drivers;  
 Most commonly detected in daytime hours. 
o Medicinal opiates in drivers in traffic (D2.2.3): 
• Most prevalent among middle aged and older drivers (35+); 
• More prevalent in female than in male drivers; 
• Most commonly detected in daytime hours. 
• Seriously injured and killed drivers (D2.2.5): 
o Most prevalent in middle aged and older drivers (35+); 
o More prevalent in male than in female drivers; 
o The majority of psychoactive substances appeared to be used in combination with 
other psychoactive substances (mainly alcohol and benzodiazepines).  
Accident risk for driving with psychoactive medicines:  
• Alcohol impaired driving is the main problem in traffic safety, but also psychoactive 
medicines can constitute a problem in traffic safety. Therefore, both health care 
providers and patients should be properly informed and aware of the potential risks 
associated with the use of psychoactive medicines (link WP4/7). Based on case-control 
studies, the relative risk of serious injury or fatality for benzodiazepines + Z-drugs and 
medicinal opioids) is estimated to be about 2-10 times (medicinal opioids in the upper 
part of the interval; benzodiazepines + Z-drugs in the lower part of the interval) as high 
as that of drivers below the DRUID cut-off for any substance (D2.3.5). 
• DRUID accident risk studies: 
o NL study (D2.3.1): The risk of being involved in an accident is highest for users of 
modern antidepressants (1.76, CI: 1.38-2.24), followed by patients who use 
combinations of psychoactive medicines (1.55, CI: 1.20-2.02), and patients using at 
least one psychoactive medication (1.28, CI: 1.12-1.46).  
o Case control study (D2.3.5): The medium increase of the relative risk of serious injury 
or fatality for a driver when positive for benzodiazepines + Z-drugs and medicinal 
opioids) is estimated to be about 2-10 times (higher risk for medicinal opiods; lower 
risk for benzodiazepines + Z-drugs) (D2.3.5). 
Results from experimental studies on the effect of psychoactive medicines on driving performance  
• Psychoactive medicines can impair driving performance (e.g. D1.2.2, D1.1.2b, D1.1.2c). 
Besides the agent itself there are many factors influencing the degree of impairment 
(e.g. galenics, route of administration, dose, time period between administration and 
driving, concomitant use of other (medicinal) drugs, habituation).  
• Zopiclone (7.5mg) and alprazolam (0.5mg) produced significant driving impairment in 
patients as well as in healthy controls during morning driving 10-11 hrs after drug 
intake (D1.2.2). 
• The impairing potential of Codiliprane® varies with age (D1.2.2). 
• Single doses (10 and 20mg) of Dronabinol (Marinol®) impaired road tracking 
performance of occasional cannabis users (representing acute effects of Dronabinol) 
during on-the-road driving tests in a dose related manner. Those impairments were 
bigger than the impairment caused by BAC of 0.5g/L (D1.2.2). 
• After habituation transdermal application of opioid analgesics as well as oral 
administration of slow release formulations of opioid analgesics caused no impairment 
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in patients suffering from chronic pain (D1.2.2). 
• Even at low dosages methadone and buprenorphine caused impairment when given as 
a single dose to healthy subjects. No clear evidence exists if patients under 
maintenance treatment are able to drive safely. Many maintenance patients use other 
substances in addition, so it is recommended that a screening for other substances is 
done if a maintenance patient should be allowed to drive (D1.1.2c). 
3.4 Summary of the problem situation  
The DRUID investigations show that alcohol impaired driving is the biggest problem (prevalence and 
risk estimation) in all EU MS. Therefore, main focus of countermeasures on European- as well as 
on national levels should always lie on preventing alcohol impaired driving. The prevalence 
distribution of other psychoactive substances than alcohol (illicit drugs, psychoactive medicines) 
shows more national variability. “In terms of preventive measures and legislative considerations 
alcohol should be emphasized as a key substance which presents a permanent threat to road safety 
in Europe” (D2.3.4 p. 4). 
 
Estimated EU prevalence means and risk estimate data can form the basis for defining common 
thresholds within the community. The gathered national prevalence data on alcohol and other 
psychoactive substances provides the basis for specifying national countermeasures in more details 
(e.g. D2.2.3, D2.2.5). “National roadside surveys on the prevalence of substance use in traffic on a 
regular, say, annual or bi-annual base would be a helpful tool to monitor the trend of drink and drug 
driving” (D2.2.3 PART I p. 10). 
 
The following estimations of EU mean prevalence of psychoactive substances based on the DRUID 
road side survey (D2.2.3) have been presented within this review (figure 40). A more detailed 
overview of the estimated European prevalence of psychoactive substances and killed can be found in 
D2.2.3 PART I p. 9 (annex 4). 
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Figure 40:  Estimated EU mean prevalence of use of psychoactive substances in traffic based 
on D2.2.3 
 
Table 28 shows the percentage of driver positive for one or more substances (mutually exclusive 
groups) within the DRUID hospital studies (D2.2.5).  
  
Table 28: Percentage of drivers positive for one or more substances (mutually exclusive 
groups) (D2.2.5 p. 4)  
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Table 29 gives an overview of the presented adjusted OR for getting seriously injured and killed based 
on aggregated data (D2.3.5). Note that some of the risk estimates for illicit drugs vary to a large 
degree among the single countries; others are based on few positive cases and/or controls which 
result in wide confidence intervals. Therefore these estimates are uncertain. 
 
Table 29: Overview of OR for getting seriously injured and killed drivers based on aggregated 
data (D2.3.5) 
 Substance Included 
country 
OR for getting 
seriously injured Included 
country 
OR for getting killed Risk of 
injury Adjusted 
OR 95% CI 
Adjusted 
OR 95% CI 
Alcohol 
(BAC) 
alone 
0.1-0.5g/L BE, DK, LT, NL 1.18* 0.81-1.73 NO, PT 8.01 5.22-12.29 
slightly 
increased 
0.5 - 0.8g/L BE, DK, LT, NL 3.64 2.31-5.72 NO, PT 45.93 23.02-91.66 
medium 
increased 
0.8 - 1.2g/L BE, DK, LT, NL 13.35 8.15-21.88 NO, PT 35.69 15.68-81.22 
highly 
increased 
≥1.2g/L BE, DK, LT, NL 62.79 44.51-88.58 NO, PT 500.04 238.07-inf. 
extremely 
increased 
Illicit 
drugs 
alone 
Amphetamine
s 
BE, DK, FI, 
IT, LT, NL 8.35 3.91-17.83 
FI, NO, 
PT, SE 24.09 9.72-59.71 
highly 
increased 
Benzoylecgoni
ne 
BE, DK, FI, 
IT, LT, NL 3.70 1.60-8.57  n.a. n.a. 
medium 
increased 
Cocaine** BE, DK, FI, IT, LT, NL 3.30 1.40-7.79  n.a. n.a. 
medium 
increased 
THC*** BE, DK, FI, IT, LT, NL 1.38* 0.88-2.17 
FI, NO, 
PT, SE 1.33* 0.48-3.67 
slightly 
increased 
Illicit opiates BE, DK, FI, IT, LT, NL 2.47* 0.50-12.10  n.a. n.a. 
medium 
increased 
Medicines 
Alone 
Benzodiazepi
nes + Z-drugs 
BE, DK, FI, 
IT, LT, NL 1.99 1.36-2.91 
FI, NO, 
PT, SE 5.40 3.90-7.46 
medium 
increased 
Medicinal 
opioids 
BE, DK, FI, 
IT, LT, NL 9.06 6.40-12.83 
FI, NO, 
PT, SE 4.82 2.60-8.93 
medium 
increased 
Combined 
use 
Alcohol-
drug**** 
BE, DK, LT, 
NL 28.82 18.41-45.11 NO, PT 31.52 16.83-59.05 
extremely 
increased 
Drug-drug BE, DK, FI, IT, LT, NL 8.01 5.34-12.01 
FI, NO, 
SE, PT 18.51 10.84-31.63 
highly 
increased 
* not significant **Cocaine or cocaine + benzoylecgonine; ***THC or THC + THCCOOH; ****Alcohol ≥0.1g/L; more precise 
substance definitions can be found in Annex 3: Substance classes, groups and the analytical findings within DRUID hospital 
studies 
 
Table 30 shows the estimated increase of relative risk of serious injury or fatality based on case 
control studies. Note that some of the risk estimates for illicit drugs vary to a large degree among the 
single countries; others are based on few positive cases and/or controls which result in wide 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
83 
confidence intervals. Therefore these estimates are uncertain. Furthermore, an overview of the main 
results of all investigated substances in the DRUID road side survey (D2.2.3) and case-control study 
(D2.3.5) can be found in the annex 5.  
 
Table 30: Overview of estimated increase of relative risk of serious injury or fatality based on 
case control studies (D2.3.5).  
 Substance 
Estimated relative risk of serious 
injury or fatality based on case 
control studies 
Risk of injury 
Alcohol 
(BAC) 
Alone 
0.1-0.5g/L 1-3x slightly increased 
0.5 - 0.8g/L 2-10x medium increased 
0.8 - 1.2g/L 5-30x highly increased 
≥1.2g/L 20-200x extremely increased 
Illicit 
drugs 
Alone 
Amphetamines 5-30x highly increased 
Benzoylecgonine 2-10x medium increased 
Cocaine* 2-10x medium increased 
THC** 1-3x slightly increased 
Illicit opiates 2-10x medium increased 
Medicines 
Alone 
Benzodiazepines + Z-drugs 2-10x medium increased 
Medicinal opioids 2-10x medium increased 
Combined 
use 
Alcohol-drug*** 20-200x extremely increased 
Drug-drug 5-30x highly increased 
*Cocaine or cocaine + benzoylecgonine; **THC or THC + THCCOOH; ***Alcohol ≥0.1g/L; more precise substance definitions 
can be found in Annex 3: Substance classes, groups and the analytical findings within DRUID hospital studies 
4 Countermeasures 
4.1 Enforcement (WP3) 
DRUID WP3 conducted a large scale scientific and practical evaluation of on-site screening for 
impairing psychoactive substances other than alcohol in drivers. The main focus was on illegal drugs. 
A number of on-site drug screening devices were first practically evaluated, followed by an analytical 
evaluation of devices that were deemed promising, followed by a cost-benefit analysis of the use of 
such devices (D3.3.1). Furthermore, current selection criteria, based on signs of impairment, before 
using on-site screening devices were also part of the evaluation. Selection criteria should allow the 
police to check for suspicious signs leading to a conclusion of possible drug usage. WP3 aim was to 
describe a good police practice and to formulate an advice on effective legislation for an effective drug 
driving enforcement. The results should improve the possibilities of detecting drug-driving in Europe, 
providing a good grounding for harmonising the European police requirements for on-site drug 
screening.  
 
Both, the practical experiences of police officers as well as scientific evidence should be bared in mind 
while evaluating and implementing standards for drug-driving enforcement. Out of police perspective 
the following recommendations for drugs and driving legislation have been formulated within the 
DRUID project:  
• Illicit substances: zero tolerance for known illicit substances, impairment limits for 
psychoactive substances not yet mentioned in Traffic Acts (zero tolerance does NOT mean 
analytical zero values; see D1.4.2);  
• Medicines: driving with medicines on prescription is allowed. Police should be able to require 
prescription as evidence. The advice of labels of medicines should be respected (conform 
classification DRUID WP4). Illegal use is considered as illicit drug use;  
• Police enforcement: random selection should be possible, but applied in a prudent way due to 
high cost and required time of screening;  
• Screening: operational acceptable oral fluid screening device is desirable. If its screening 
result is negative, but clinical signs of impairment are present, the subject can still be under 
suspicion (e.g. GHB). An extensive Drug Recognition Evaluation (DRE) is not believed to have 
an added value besides drug testing, as it is very time-consuming and therefore not practical  
• Evidence: confirmation analysis of an oral fluid sample by an appointed forensic laboratory is 
preferred. Blood is the alternative;  
• Driving license: in case of suspicion of addiction, drivers can be tested for their suitability or 
capability to drive a motor vehicle. Based on a medical, psychological or other examination the 
driving license could be withdrawn (see also D5.1.1, D6.2). 
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Very often control strategies and detection methods are not standardised and very time consuming. 
Essential elements to optimise this enforcement practice are seen in (1) the training of police officers 
in drug recognition, (2) the development of sensitive and specific detection devices and (3) the 
deliberate use of control strategies.   
4.1.1 Training for police officers in drug recognition 
DRUID WP3 developed and evaluated a checklist for clinical signs of impairment (CSI) in order to 
see if visible signs of impairment can be used as preceding selection criteria for performing an on-site 
test. The checklist was based on several existing checklists, e.g. one developed for the German police 
and previously used in the European IMMORTAL (Impaired Motorists, Methods Of Roadside Testing 
and Assessment for Licensing) project.  
The results of the evaluations of the current CSI checklist were so far not very promising. The 
checklist scored a low sensitivity value (Dutch study, sensitivity: 32% if self-reported drug use was 
included, and a meagre 13% if only signs and symptoms were considered), low correlation of 
symptoms and actual presence of drugs (Belgian study) or there were difficulties in correlating the 
symptoms to actual drug use due to the insufficient data collection (Finnish study). Training of police 
officers will probably improve the results of the CSI checklists.  
4.1.2 Development of on-site drug screening devices 
The quality of an oral on-site screening device depends on both scientific as well as practical needs; 
both should be taken into account while developing and implementing screening devices into police 
practice. The following police user requirements and specifications (PURS) for oral fluid screening 
devices have been formulated: 
 
Requirements for training of police officers on the use of oral fluid screening devices: 
• Police officers trained by police instructors (0,5 – 1 hour); 
• Police instructors trained by manufacturer (1 – 2 hours); 
• Learning by demonstrating; 
• Learning by doing; 
• Information about do's and don’ts; 
• Clear hygienic and safety measures; 
• Instruction card for each officer during training; 
• Material available through police intranet; 
• All materials in native language. 
 
Requirements for operational use of these devices: 
• 75% of tests qualified as simple to operate; 
• Hygienic use of device; 
• Sufficient amount of collected oral fluid; 
• Detectable substances at least Cannabis, Cocaine, Opiates, Amphetamines(analogues); 
• At least 75% of the tests should be correct for at least one of the substances; 
• Indication lines should remain visible for at least 3 minutes. 
 
Requirements for documentation: 
• Device user manual in native language; 
• Device instruction card for each trained officer; 
• CD ROM or DVD available for each force/unit; 
• (User manual for electronic reader). 
 
The classic scientific test performance indicators are sensitivity, specificity and accuracy, but also 
positive predictive values and negative predictive values, calculated with drug prevalence for the 
population for which the screening is intended, should be considered as factors when selecting which 
on-site device to use. Within the DRUID evaluation studies test performance was assessed based on 
both DRUID and manufacturer cut-offs. Sensitivity, specificity and accuracy performance values of 
80% or more were set as a desirable target value. 
 
The tested substance classes within the DRUID evaluation were amphetamine, metamphetamines 
(including ecstasy (MDMA)), cannabis, cocaine, opiates, benzodiazepines and phencyclidine (PCP). 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
85 
Eight out of 13 devices were selected as promising based on practical police on-site test requirements 
(i.e. Mavand RapidSTAT, Securetec Drugwipe 5+, Branan Oratect XP, Varian Oralab 6 , Innovacon 
OrALert, Cozart DDS, Dräger Drug Test 5000 and Biosensor BIOSENS12) and 3 out of 8 devices were 
evaluated positive within the scientific evaluation (Dräger Drug Test 5000, Mavand RapidSTAT and 
Securetec Drugwipe 5+). None of the tests reached the target value of >80% for sensitivity, specificity 
and accuracy for all the separate tests they comprised (see table 31).   
 
Table 31: Overall test performance of the different drug screening devices within the DRUID 
investigation (WP3) 
Substance Sensitivity Specificity Accuracy 
Cannabis 11-59% 90-100% 84-98% 
Amphetamines 0-87% 90-100% 84-98% 
Cocaine 13-50% 99-100% 86-100% 
Opiates 69-90% 81-100% 75-99% 
Benzodiazepines 48-67% 94-100% 77-100% 
 
However, there were tests that performed already on a promising level for one or more substance 
classes. Within the DRUID investigation the DrugTest 5000 had the best overall results followed by 
the Rapid STAT, which performed at a similar level, except for the cocaine test which was somewhat 
less sensitive. Best performing device in terms of sensitivity for amphetamines was within the DRUID 
study the DrugWipe 5+. None of the 8 tested on-site screening devices in the scientific evaluation 
attained 80% sensitivity for cannabis which is the most commonly used illegal drug and for cocaine. 
Further testing of the cocaine tests is desirable due to the low prevalence and the low concentrations 
encountered in this study. There are several countries in Central and Southern Europe for which these 
two substance classes are of special interest (e.g. ES).  
 
The results of the DRUID evaluation of each drug screening device “need to be viewed in the context 
of the study population on which they were tested (e.g. test in clinics, coffee shops, at the roadside). 
For some of the devices, a full performance evaluation was not possible for all of the test strips on the 
panel due to low prevalence of the substance(s) in question. Sensitivity is usually enhanced to some 
extent if the study population has a high prevalence for the screened drug and if the concentrations of 
the drugs contained in the samples from the study population are high because of recent 
consumption. Conversely, when interpreting specificity values it should be noted that when a 
population with a low prevalence of the desired substance is tested, specificity can be expected to be 
high. Such a population can also be expected to result in higher accuracy results in a similar manner. 
Also, it should be borne in mind that sensitivity, specificity and accuracy are specific for this study and 
the study populations investigated in this study. Positive predictive values and negative predictive 
values, calculated with drug prevalence for the population for which the screening is intended, should 
be considered as factors too when selecting which on-site device to use” (D3.2.2 p. 95).  
 
Since the finalisation of the EU projects ROSITA II, which also evaluated screening devices (2005), no 
significant improvements concerning the quality of oral fluid screening devices were achieved. 
Consequently, there seems to be a strong need for improving the quality of oral on-site screening 
devices, particular for detecting cannabis. Further research is needed on the test performance of on-
site oral screening devices for cocaine.  
4.1.3 Deliberate use of control strategies   
The choice of control strategy depends on the specific characteristics of the problem situation 
(prevalence and risk estimates WP1-2). Main outlines of a common standard enforcement 
procedure should be formulated on EU level. The implementation of specific enforcement activities 
should be based on the specific characteristics of the problem situation on national level.  
One of the advantages of a common standard would be that it would also stimulate the competition 
within the respective industries to develop valid and reliable detection devices. 
 
The DRUID cost-benefit-analysis (CBA13; an assessment to what degree (increased) enforcement of 
driving under the influence of drugs is profitable in economic terms for society, together with an 
                                                 
12
 During specific enforcement activities where a great number of persons should be tested in a limited period of time. 
 
13
 The CBA will be updated in 2011, based on final DRUID results regarding the prevalence and risk of drug driving (WP1-2). 
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assessment of which devices for such enforcement are more profitable) which was based on good 
practice and scientific research has shown that an increased drug-driving enforcement is potentially 
cost-beneficial, especially for countries that currently have a low enforcement level. It will NOT 
be beneficial if this increase is financed (time and money) at the cost of drink-driving 
enforcement. Thus, also within an economic perspective alcohol impaired driving is the biggest 
problem.  
The quality of an on-site screening device seems to have a strong influence on the cost-benefit 
outcome. Screening devices that performed better than average showed a cost-benefit ratio which 
was almost twice as high as the ratio of devices that performed less than average (although higher 
sensitivity in detecting drug-driving will increase the safety benefits, the enforcement costs, particularly 
following a positive test, dominate to such an extent that high specificity is relatively more important 
than high sensitivity).  
 
An increasing number of countries are planning to introduce on-site saliva screening as a legal 
method to detect drugged drivers (e.g. BE and NL). Two major benefits of saliva screening for drugs 
are that saliva collection is much less invasive than urine collection and that it better detects recent 
drug use (than in urine, sweat or hair), especially in the case of cannabis.  
 
“Theoretically, the largest general deterrence effects on drug-driving may be expected from large-
scale random drug testing, as is the case with random breath testing for alcohol (Homel, 199814). 
However, the time-consuming process of on-site oral fluid screening, in combination with the quite 
high cost of the devices and the relatively low sensitivity for cannabis, which in many countries is the 
most frequently used illegal drug, will probably prevent large-scale random drug testing in practice. 
 
For cost-benefit purposes, a working method to preselect suspected drivers for on-site drug screening 
would be desirable. Unfortunately, the evaluation of the CSI (clinical signs of impairment) checklist in 
this project did not give very encouraging results. Apparently, at least for persons with little 
observational training for clinical signs of impairment, or only relatively short-term experience of this, 
symptoms of drug use remain easily undetected. Also, correlation between signs of impairment and 
findings in oral fluid was not very good. However, proper training and long-term experience of 
observing clinical signs of impairment could reasonably be expected to yield better results. 
 
The effectiveness of drug-driving enforcement can be further enhanced by preselecting times and 
places with a likelihood of elevated numbers of drug positive drivers and by targeting alcohol 
positive drivers. This is not only because alcohol positive drivers are likely to have a higher exposure 
to drugs than alcohol negative drivers, but also due to the fact that the risk of combined alcohol and 
drug use is extremely high (D3.3.1 p. 28f)”.  
4.1.4 Overview box – Enforcement 
Box 4: Summary of main DRUID results – ENFORCEMENT 
• DRUID provides guidelines for everyday drug-driving police enforcement and installs scientific 
demands for on-site screening for impairing psychoactive substances other than alcohol in 
drivers (e.g. legal frame, basic standards of procedure and devices) (D3.1.1, D3.2.1, D3.2.2). 
• First enforcement priority should always lie on alcohol, other drugs are second priority 
(D3.3.1).  
• Characteristics of the problem situation on national level determine the focus (and devices) of 
drug enforcement (D3.3.1).  
• Increase of drug enforcement is potentially cost-beneficial, especially for countries that 
currently have a low enforcement level. It will NOT be beneficial if this increase is financed 
(time and money) at the cost of drink-driving enforcement (D3.3.1). 
• The effectiveness of drug-driving enforcement can be enhanced by e.g. (D3.3.1):  
o Using on-site screening devices which fulfil practical as well as scientific requirements 
(two major benefits of saliva screening for drugs are that saliva collection is much less 
invasive than urine and blood collection and that it better detects recent drug use than 
in urine, sweat or hair; Cost-Benefit Analysis (CBA): emphasis on high specificity). 
o Ideally large-scale random drug testing (largest general deterrence effects) is done, 
                                                 
14
 Homel R. Policing and Punishing the Drinking Driver: A Study of General and Specific Deterrence. Research in Criminology. 
Springer Verlag; 1998. 
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but this is not feasible in practice since the devices are too expensive and take too 
much time for sample collection and analysis. The effectiveness can also be 
enhanced by: pre-selection of time, place and target group (e.g. alcohol impaired 
drivers), based on specific characteristics of the problems (national and regional 
level).  
o Clinical Signs Inventory (CSI) checklist as working method to preselect suspected 
drivers for on-site drug screening, did not give very encouraging results; more 
experience and better training of police may improve the results. 
4.2 Classification (of diving impairing medicines) (WP4) 
The establishment of criteria for a European categorization will have to serve most of the needs of all 
parties involved: health professionals, drug regulatory agencies, drug manufacturers and patients. For 
patients to make the best (and safest) use of their medicines, clear warnings and symbols are needed. 
 
(1) For health professionals  
 
DRUID as produced a categorization/labelling for existing medicines, as well as producing specific 
information for health professionals (physicians and pharmacists) to be delivered to the driver patient. 
For each category information for developing directions for health care professionals and warning 
levels and warning symbols has been presented. The categorization system could be seen as a tool to 
improve prescribing and dispensing procedures both at a national and European level, and, therefore, 
as a instrument to better inform and involve HCPs (Health Care Professionals) [Talbot & Stephens, 
2004]. With this respect, it is important that HCPs know the fundamentals of the categorization 
system, and, consequently, use it properly in order to fully inform their patients about the risks of 
driving under the influence of impairing medicines. Furthermore, HCPs should be able to distinguish 
between the four levels of impairment, and, therefore, if possible, choose the least impairing 
medication within the same therapeutic group. Moreover, this system should encourage HCPs to 
update their knowledge on medicines and driving in order to be prepared to answer questions that 
patients might have on this topic (de Gier et al., 2009; AFSSAPS, 2009).  
The DRUID categorization system should also be used as a tool to motivate health care professionals 
to provide patients with clear information, communicate to patients the risk associated with driving 
under the influence of medicines, and start HCP-patient discussion leading to both safer prescriptions 
and the patient’s conscious decision whether to drive or not (Talbot & Stephens, 2004; de Gier et al., 
2009).  
Finally it is recommended, that the development of supplementary information for health care 
professionals. A guideline (e.g. prescribing and dispensing guidelines) should be developed to explain 
the use of the categorization system to HCPs and to serve as a support in the decision making 
process. 
 
(2) For drug regulatory agencies 
 
Recently has been approved SmPC guidelines, in September 2009 (which applies as from 1st of May 
2010),by EMA, based on the DRUID WP$ proposal categories a) no or negligible influence, b) minor, 
c) moderate influence, and d) major influence on driving fitness are specified with some important 
guidance in special circumstances. 
This consensus on the wording in the Patient Information Leaflet is another and important step to 
harmonize information to patients on a medicine’s impairing effects on fitness to drive. However, it is 
acknowledged by the Pharmaco-vigilance Working Party and WP4 partners that at the Member 
States’ level more activities are needed in order to reinforce the awareness of patients on the effects 
of medicines on fitness to drive, e.g. by the use of an alerting pictogram on the product packaging or 
further stratification of the number of categories of risk with a maximum of four.   
Several meetings have taken place in collaboration with national agencies. For instance, in AFSSAPS 
(Agence Francaise de Sécurité Sanitaire des Produits de Santé) on February 28th 2008, where 
DRUID partners attended a “regular” meeting of the French Medicinal Agency regarding medicines 
and driving. The criteria used and the experience on labelling medicines regarding to driving in France 
was shown.  
The attendance at the Pharmacovigilance Working Party (PhVWP) at EMA (European Medicinal 
Agency) has also been of great value for the development of WP4 tasks. 
However, the DRUID categorization system is, although it may have benefitted from many other early 
experiences, a new categorization. 
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However, the DRUID classification system is, although it may have benefited from many other early 
experiences, is a new categorization that can help at drugs regulatory agencies to harmonize their 
contents about the categorization / labeling of medicines. 
 
(3) Drug manufacturers and patients 
 
DRUID WP4 partners have produced patient-oriented information for each one of the medicines 
categorized.  
The aim of producing this patient-oriented information is to help physicians and pharmacists (and 
other health professionals) in providing appropriate information to their patients. It is true that Patient 
Information Leaflets contain some sort of information regarding driving. However, DRUID WP4 
partners considered that it is also quite important that health professionals provide further information 
for medicines and driving to their patients 
Clear warnings and symbols are needed so patients use their medicines in the most optimal (and 
safest) way possible. Since the patient package leaflet is the most accessible source of information for 
patients, it would also be advisable to develop an effective strategy to communicate the risk related to 
the use of medicines and driving. For instances, a straightforward grading system could be included in 
the patient package leaflet and the use of pictograms (warning labels) could be printed on the 
medication box to provide clear directions for patients. 
4.2.1 DRUID methodology on categorization/labelling on medicines and 
driving  
The development of the DRUID categorization/labelling system was based on the criteria that were 
established by the DRUID WP4 partners, and based on their consensus. 
 
The DRUID WP4 expert group established and agreed that, according to its influence on the ability to 
drive, a medicine could be categorized as follows regarding driving (see table 32):  
• category 0 (no or negligible influence on fitness to drive); 
• category I (minor  influence on fitness to drive); 
• category II (moderate influence on fitness to drive);  
• category III (severe influence on fitness to drive). 
 
This was in line with the recent approved SmPC guidelines adopted in September 2009 (which applies 
as from 1st of May 2010) by EMA, based on the DRUID WP4 proposal submitted for consideration by 
the CMD(h), as a response during the consultation phase of the revision of the SmPC guidelines in 
February/March 2008, proposing that in section 4.7 ”Effects on ability to drive and use machines”....., 
specify whether the medicinal product has a) no or negligible influence b) minor; c) moderate influence 
or d) major influence on these abilities....(see also:  
http://ec.europa.eu/health/documents/eudralex/vol-2/index_en.htm 
http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf) 
 
Table 32: DRUID categorization/labelling system for medicines and driving (version February 
2010). 
Information for physicians and pharmacists 
 
Warning for patients (with 
warning symbols and standard 
descriptions per country) 
Description of categories with levels 
of impairment (compared with 
alcohol) 
Information on how to advise their patients  
Category 0 
Presumed to be safe or unlikely to 
produce an effect on fitness to drive. 
Confirm that the medicine will be safe for 
driving, provided that combinations with alcohol 
and other psychotropic medicines are excluded. 
[no warning needed] 
Category 1 
Likely to produce minor adverse effects 
on fitness to drive.  
 
Inform the patient that impairing side effects 
may occur especially during the first days and 
that they have a negative influence on his/her 
driving ability. Give the patient the advice not to 
drive if these side effects occur. 
Warning level 1 
Do not drive without having read 
the relevant section on driving 
impairment in the package insert. 
 
Category 2 
Likely to produce moderate adverse 
effect on fitness to drive.  
 
Inform the patient about the possible impairing 
side effects and the negative influence on 
his/her driving ability. Advise the patient not to 
drive during the first few days of the treatment. If 
possible prescribe a safer medicine, if effective 
and acceptable by the patient. 
Warning level 2 
Do not drive without advice of a 
health care professional. Read the 
relevant sections on driving 
impairment in the package insert 
before consulting the physician or 
pharmacist. 
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Category 3 
Likely to produce severe effects on 
fitness to drive or presumed to be 
potentially dangerous.  
Inform the patient about the possible impairing 
side effects and the negative influence on 
his/her driving ability. Urgently advise the patient 
not to drive.  Consider prescribing a safer 
medicine, if acceptable by the patient. 
Warning level 3 
Do not drive. Seek medical advice 
after a period of treatment about 
the conditions to restart driving 
again. 
 
In summary, categorization of a medicine on driving includes several steps of evaluation (table 33): 
1. Pharmacodynamic and pharmacokinetic data; 
2. Pharmacovigilance data (including prevalence of unwanted effects reported in the SmPC); 
3. Experimental and epidemiological data; 
4. Additional data derived from the Patient Information Leaflet (PIL) and existing categorization 
systems; 
5. Synthesis.  
 
Table 33: Methodology of DRUID categorization/labelling system for medicines and driving 
Categorization 
based on SmPC  
section 4.7  
Data to be used for assigning the category  
 Pharmaco-
dynamic 
& -kinetic data 
Pharmaco-
vigilance 
Data 
 
Experimental & 
epidemiology 
data 
Additional 
data 
Synthesis 
 
a) No or negligible 
influence 
No influence 
expected 
No demonstration of 
CNS side effects or 
other unwanted 
effects on driving 
No demonstration of 
impairment 
No further data 
on impairment 
No or negligible 
influence 
b) Minor influence No influence 
expected 
Some demonstration 
of CNS side effects 
or unwanted effects 
that impair driving 
Some impairment in 
some experimental 
studies. Slight 
increased risk 
demonstrated in 
epidemiological 
studies 
Some data on 
possible 
impairment 
Minor influence 
c) Moderate 
influence 
Moderate 
influence 
expected 
Demonstration of 
CNS side effects 
(not severe) or 
unwanted effects 
that impair driving 
Impairment of driving 
performance is seen 
in various 
experimental studies. 
In epidemiological 
studies a significant 
increased risk is 
demonstrated 
Various data on 
impairment (not 
severe) 
Moderate 
influence 
d) Major influence Severe influence 
expected 
Demonstration of 
CNS side effects 
(severe) or 
unwanted effects 
that impair driving 
Gross impairment of 
driving performance 
or performance 
related to driving is 
repeatedly seen. In 
epidemiological 
studies a significant 
and meaningful 
increased risk is 
demonstrated  
Data on severe 
impairment 
Major influence 
 
Specific sections of the SmPC and PIL were used to retrieve details on the active substance 
presentation, indications, posology, administration, pharmacodynamic and pharmacokinetic profile, 
section 4.7 on effects on the ability to drive and use machines, and section 4.8 undesirable effects 
related to driving and operating machines.  
 
During the activities in Task 4.3 on categorization of the existing medicines, the occurrence of 
undesirable effects was considered as key information for categorising some medicines, in 
circumstances that information on experimental studies for assessing a medicine’s effect on driving or 
skills related to driving or epidemiological data were lacking or limited. For that reason, section 4.8 of 
the SmPC was used (as well as specific literature search), if necessary. Recently, EMA has started to 
use the following categorization on frequency of undesirable effects, side effects or adverse reactions: 
 very common (>1/10); 
 common (>1/100, <1/10);  
 uncommon (>1/1,000, <1/100);  
 rare (>1/10,000, <1/1,000);  
 very rare (<1/10,000); 
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 not known (cannot be estimated from the available data, since no valid estimate can be derived 
from clinical trials or epidemiological studies). 
 
DRUID Partners have taken into account this categorization of undesirable effects, side effects or 
adverse reactions in their categorization framework for medicines and driving. Firstly by considering 
those effects categorized as very common (>1/10) and common (>1/100, <1/10), and secondly, those 
undesirable effects that can potentially impair the fitness to drive safely. In case rare or very rare 
unwanted effects or certain severely impairing effects occur, for example sudden sleep attacks, 
DRUID Partners recommend that this should be mentioned in the patient information leaflet. 
 
The following criteria were used for assigning a medicine to a specific category, in case experimental 
or epidemiological data are lacking (table 34). 
 
Table 34: Relationship of “undesirable effects category” in SmPC to DRUID category 
Declaration of undesirable effects that can potentially 
impair the fitness to drive safely 
DRUID category 
Very common (> 1/10) (Medications with very common side 
effects affecting the ability to drive) 
Category  2 or higher 
Common (>1/100, <1/10) (Medications that have only 
common side effects that affect the ability to drive) 
Category 1 
Rare (>1/10,000, <1/1,000)  
or very rare (<1/10,000) (Medications that have not very 
common or  common side effects that affect the ability to 
drive, only rare o very rare side effects) 
Category 0 
 
 
In the following table all relevant potentially undesirable effects to be considered when categorising 
the effects of medicines on driving are listed (table 35). 
 
Table 35: Undesirable effects that can impair fitness to drive grouped by system organ class  
System organ class Selection of undesirable effects that can impair the fitness to drive safely  
 
Nervous system 
disorders 
 Somnolence, dizziness, drowsiness 
 Confusion - cognitive disorder- disorientation – co-ordination disturbances 
 Involuntary movement disorders: ataxia, tremor, Parkinsonism, acute dystonic (dyskinesia) and 
dyskinetic reactions (dystonia) 
 Convulsions – seizures 
 Muscle weakness 
Psychiatric disorders  Perception disturbances (hallucination, visual hallucination, auditory hallucination, illusion) 
 Psychotic reactions and psychotic disorder (including paranoia psychosis) 
 [Other: Emotional lability, mood swings, aggression, nervousness, irritability, personality 
disorders, thinking abnormal, abnormal behaviour, euphoric mood, restlessness (emotional state 
of excitement), depersonalisation]  
Eye disorders  Diplopia or double vision  
 Blurred vision  
 Accommodation disorders 
 Visual acuity reduced 
 Photophobia 
 [Other: visual field defect, peripheral vision loss, altered visual depth perception, oculogyric 
crisis]. 
Ear and Labyrinth 
disorders 
 Vertigo 
 Hearing loss 
 [Other: buzzing, tinnitus] 
Metabolism and 
nutrition disorders 
 Hypoglycaemia 
 
Vascular disorders   Hypotension 
4.2.2 Categorization, labelling and patient oriented information for 
relevant therapeutic groups of medicines available on EU market 
The aim of WP4 was to provide a categorization for the relevant therapeutic groups of medicines 
available on the European Union Market.  
 
In this way, DRUID task 4.3 was able to provide categorization, labelling and patient-oriented 
information for the following ATC groups (The Anatomical Therapeutic Chemical –ATC- classification 
system; http://www.whocc.no/). 
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Individual medicines were categorized according to the DRUID classification system:   
 
A - ALIMENTARY TRACT AND METABOLISM 
B - BLOOD AND BLOOD FORMING ORGANS 
C - CARDIOVASCULAR SYSTEM 
D - DERMATOLOGICALS 
M - MUSCULO-SKELETAL SYSTEM 
N - NERVOUS SYSTEM 
N01 ANESTHETICS 
N02 ANALGESICS 
N03 ANTIEPILEPTICS 
N04 ANTIPAKINSON 
N05 PSYCHOLEPTICS 
N05A Antipsychotics 
N05B Anxiolytics 
N05C Hypnotics and sedatives 
N06 PSYCHOANALEPTICS 
N06A Antidepressant 
N06B Psychostimulants, agents used for ADHD and Nootropics 
N06C Psycholeptics and psychonaleptics in combination 
N06D Anti-dementia drugs 
N07 OTHER NERVIOUS SYSTEM  DRUGS 
R - RESPIRATORY SYSTEM 
S - SENSORY ORGANS 
 
Furthermore, Fact Sheets were produced for the N01-N07 (nervous system) and R06 (respiratory 
system) ATC groups of medicines. Each fact sheet contains information on: source of information, 
presentations, indications, posology and method of administration, pharmacodynamic and 
pharmacokinetic properties, possible side-effects related to driving, Summary of Product 
Characteristics (SmPC) section 4.7 effects on effects on ability to drive and use machines, leaflet 
section on driving and using machines, studies on psychomotor performance and risk studies, current 
categorization in some EU countries, proposed  DRUID based categorization, information for the 
patient, and place and date of agreement by the DRUID WP4 members. 
 
Table 36 shows the DRUID categorization of the medicines in the ATC groups (the Anatomical 
Therapeutic Chemical –ATC- classification system; http://www.whocc.no/), A, B, C, D, M, N, R and S 
evaluated in DRUID WP4, while table 37 shown the DRUID categorization of the medicines from N01 
to N07. 
 
The DRUID project has proposed for analysis and categorization a total of 3,037 medicines from these 
ATC groups. Of these 3,037 medicines, 1,495 have not been categorized, because they are not 
available on the European Union market (not available on DRUID WP4 countries Belgium, France, 
Greece, Germany, Netherlands, and Spain, as well as in the UK and Ireland), as there is no sense in 
categorizing/labelling medicines which are not available (see table 36-37). 
 
Table 36: DRUID categorization on medicines and driving: number of medicines categorized by 
ATC group 
ATC GROUP 
 
Not evaluated.  
Not available at  
EU market 
DRUID Categorization TOTAL 
0 I II III MC DC 
         
A - ALIMENTARY TRACT AND METABOLISM 243 234 69 8 1 4 4 563 
B - BLOOD AND BLOOD FORMING ORGANS 86 135 1 1   2 225 
C - CARDIOVASCULAR SYSTEM 246 90 200 11  1  548 
D – DERMATOLOGICALS 156 192 1   4  353 
M - MUSCULO-SKELETAL SYSTEM 88 22 44 28 15   197 
N - NERVOUS SYSTEM 346 9 30 86 53 36  560 
R - RESPIRATORY SYSTEM 195 62 24 32 10 5 14 342 
S - SENSORY ORGANS 153 31 31 6 11 18 16 266 
TOTAL 1513 775 400 172 90 68 36 3054 
MC = Multiple categories; D= Depending on the medicine in combination 
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Table 37: Number of medicines from the ATC group, N-nervous system medicines, categorized 
in each DRUID category 
ATC GROUP 
 
N-NERVOUS SYSTEM 
 
Not evaluated. 
Not available 
at 
EU market 
DRUID Categorization TOTAL 
0 I II III MC DC 
         
N01 ANESTHETICS 31 3 3 1 12 10  60 
N01A  Anesthetics, general 20    11 1  32 
N01B Anesthetics, local 11 3 3 1 1 9  28 
N02 ANALGESICS 93 2 7 10 3 7  122 
N02A Opioids 31    2 7  40 
N02B Other analgesics and antipyretics 52 2 6 1 1   62 
N02C Antimigraine preparations 10  1 9    20 
N03 ANTIEPILEPTICS 23   14 4 2  43 
N03A Antiepileptics 23   14 4 2  43 
N04 ANTIPAKINSON 16  3 16  1  36 
N04A  Anticholinergic agents 10   4  1  15 
N04B Dopaminergic agents 6  3 12    21 
N05 PSYCHOLEPTICS 107  4 16 26 12  165 
N05A Antipsychotics 31   13 8 9  65 
N05B Anxiolytics 23  1 3 7 1  35 
N05C Hypnotics and sedatives 53  3  11 2  69 
N06 PSYCHOANALEPTICS 62 2 10 20 7 1  102 
N06A Antidepressant 37 1 7 12 7 1  65 
N06B Psychostimulants, agents used for ADHD and 
Nootropics 
22  3 4    29 
N06C Psycholeptics and psychonaleptics in combination 2       2 
N06D Anti-dementia drugs 1 1  4    6 
N07  OTHER NERVIOUS SYSTEM  DRUGS 14 2 3 9 1 3  32 
N07A Parasympathomimetics 6   2  1  9 
N07B Drugs used in addictive disorders 2 2 1 4 1 2  12 
N07C Antivertigo preparations  2  1 2    5 
N07X Other nervous system drugs 4  1 1    6 
TOTAL 346 9 30 86 53 36  560 
MC = Multiple categories; D= Depending on the medicine in combination 
 
As can be seen in the following figure 41, the distribution of the 1,541 categorized medicines was as 
follows: Category 0 – 50,3%, Category I – 26%, Category II – 11,2%, Category III – 5,8%, Multiple 
category – 4,4% and the Depending on the medicine in combination 2,3%. 
 
 
Figure 41: Percentage of medicines categorized within each DRUID category 
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4.2.3 Establishment of criteria for a European Categorization System for 
Medicines and Driving: proposals for harmonising criteria towards 
an European system  
After the development of the input for establishing criteria for a European categorization system, 
progress and steps forward have been achieved in discussing these proposals with the 
Pharmacovigilance Working Party (PhVWP) of the Committee for Medicinal Products for Human Use 
(CHPM), whose meetings are held monthly at the European Medicines Agency (EMA).  
 
The PhVWP came to a consensus based on a compromise, that a common approach should be 
developed which: 
• Takes into account scientific evidence. 
• Recognises different national approaches and experiences. 
• Acknowledges the difficulty of having a consistent classification for all medicines based on 
current scientific evidence. 
• Ensures that any information on the influence of medicines on fitness to drive should be 
simple and patient-centred, and therefore should be reflected in the Patient Leaflet, although 
information directly provided to the patient by prescribers and/or pharmacists is very relevant. 
• Recognises that in addition to the legal, social, medical, and pharmacological aspects of the 
issue, individual responsibility of the patients plays an important role that should be 
considered and reflected in the appropriate way in the product information of any medicine. 
 
Currently national approaches differ substantially: from France at one end of the extreme,  where 
labelling with pictograms on the medicine box at three levels according to impairing properties of the 
medicine was enforced in 2005, to Sweden at the other end where labelling with the red triangle was 
removed from medicines in 2007. Sweden amended their labelling in response to patient surveys 
which revealed that the red triangle pictogram was misunderstood, and therefore replaced the 
pictogram with a generic warning in the patient leaflet. 
 
A consensus within the PhVWP was reached that a basic 2 tier framework would be developed as a 
basis for warnings to be presented to the patient through the Patient Leaflet. This differentiates 
between medicines with a relevant potential influence on driving and those which do not.  
4.2.4 Policy implications 
During the development of task 4.2, the following agreements were reached with the PhVWP: 
 
“Conclusions and recommendations 
Input for the further development of criteria for a European categorization system is based on the 
following conclusions derived from the activities in Work Package 4. 
 
General conclusions 
1. The overview of perspectives in classification systems shows the evolution in the development 
of the classification systems, from an effort to achieve consensus about the various categories 
and descriptions from a scientific perspective to efforts  for informing health care professionals 
(e.g. Belgium, the Netherlands, Spain) to efforts for introducing warning symbols and 
directions for patients, as end users, in a legal framework (e.g. in France, Spain and 
Slovenia).  
2. It has been made clear by the developments and experiences in various countries that 
categorization of medicines is possible, needed and well accepted by all parties that have an 
interest in the safe use of medicines. 
 
Conclusions at the level of developing criteria 
1. At the level of categorising medicines it was agreed that several factors (e.g. 
pharmacodynamics, pharmacokinetics, pharmacovigilance data, experimental and 
epidemiological data, individual sensitivity, conditions of use) need to be considered for 
evaluating the medicines’ overall potential to impair fitness to drive. 
2. In circumstances where information on experimental studies or epidemiological data are 
lacking, the occurrence of pharmacodynamic effects resulting in undesirable effects that have 
the potential to impair the fitness to drive based on information in section 4.8 of the SmPC, 
was considered as key information for categorising some medicines. 
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3. The revised SmPC Guidelines (adopted in September 2009 and to be applied as from 1st of 
May 2010) show four descriptions of potential levels of influence on fitness to drive (a-d in 
section 4.7.). DRUID and the PhVWP concluded, however, that an evidence based approach 
supported a two tier system of warnings which may be supported by symbols or pictograms. 
4. Warning levels, symbols and pictograms (in combination with a short explanation in writing) to 
inform patients can be developed.  
 
Recommendations 
It is clear that the establishment of criteria for a European categorization system for medicines and 
driving should be based on the involvement of all relevant stakeholders. Their input is needed for 
developing legislation, guidelines and procedures for assigning driving impairing medicines to the 
appropriate category and for developing information to support health care professionals in prescribing 
and dispensing driving impairing medicines and patients for safely using these medicines. The 
following recommendations will guide further activities after the completion of the DRUID project: 
1. There is a need to improve information related to effects on driving in the PIL. Information to 
patients who are advised to use medicines that may impair driving fitness needs to be 
improved by simple and patient-centered directions based on a clear categorization system 
and reflected in the PIL. 
2. A basic 2-tier risk categorization system with standard wordings for the PIL is recommended 
for medicines without a potential influence on driving fitness (Level 1, reflective of SmPC 
descriptions; a) no or negligible influence or b) minor influence) and for medicines with a 
potential relevant influence on driving fitness (Level 2, reflective of SmPC descriptions; c) 
moderate influence and d) major influence).  
3. Clarification of criteria for the evidence in forming the categorizations, as described as  a)-d) in 
the SmPC (section 4.7) into the 2 levels, should be derived in a collaborative effort of DRUID 
experts and the members of the PhVWP of CHMP, among other partners, preferably with 
support of EU bodies, such as DG Sanco and DG Move.  
4. The development of supplementary information for patients (e.g. warning levels, pictograms) 
and health care professionals (prescribing and dispensing guidelines) , in support of the 
categorization system, could be guided with input provided by the DRUID project (D 4.2.1., D 
4.3.1. , D 7.3.2. and D 7.4.2.) as well as by experiences in EU Member States” (D4.2 p. 55ff). 
More information can be found in D4.2 p. 47-54 and D4.3 p. 13-35.      
4.2.5 Overview box – Classification  
Box 5: Summary of main DRUID results – CLASSIFICATION 
DRUID WP4 proposed four level classification and a labelling system regarding the influence of 
medicines on driving performance (D4.2.1, D4.3.1):  
• category 0: no or negligible influence on fitness to drive (no warning needed); 
• category 1: minor influence on fitness to drive  (warning level 1); 
• category 2: moderate influence on fitness to drive (warning level 2);  
• category 3: major influence on fitness to drive (warning level 3). 
DRUID WP4 developed a methodology to categorize the influence of medicines on driving 
performance. The categorization is based on an evaluation of the following issues/steps (D4.3.1): 
• conditions of use of the medicine at the European Union market;  
• pharmacodynamic and pharmacokinetic data; 
• pharmacovigilance data (including prevalence of unwanted effects reported in the SmPC); 
• experimental and epidemiological data ; 
• additional data derived from the Patient Information Leaflet (PIL) and existing categorization 
systems, and information from other sources; 
• synthesis of the available information;  
• DRUID categorization and labelling of the psychoactive medicine. 
Over 3000 medicines were reviewed and over 1500 of them were categorized in regard to their 
influence on driving performance (D4.3.1, D4.4.1): 
• Medicines in the relevant therapeutic groups that are currently on the market have been 
categorized according to the DRUID classification system (ATC groups: A, B, C, D, N01-N07, 
M01-M03, R01-R06, S). 
• The DRUID project has proposed for analysis and categorization a total of 3,054 medicines 
from these ATC groups. Of these 3,054 medicines, 1,513 have not been categorized (49,5%), 
because they are not available on the European Union market. 
• The distribution of the 1,541 categorized medicines was as follows: Category 0 – 50,3%, 
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Category I – 26%, Category II – 11,2%, Category III – 5,8%, Multiple category – 4,4% and the 
Depending on the medicine in combination 2,3%. 
• Detailed Fact Sheets were elaborated for the N01-N07 (nervous system) and R06 (respiratory 
system) therapeutic groups of medicines, including information on possible side-effects related 
to driving, reference studies on psychomotor performance and risk studies, the proposed 
DRUID categorization level, and relevant information for the patient. 
Within DRUID WP4 partners have produced patient-oriented information for each one of the medicines 
categorized (D4.3.1, D4.4.1).  
• The aim of producing this patient-oriented information is to help physicians and pharmacists 
(and other health professionals) in providing appropriate information to their patients. Although 
Patient Information Leaflets contain some sort of information regarding driving, DRUID WP4 
partners considered that it is also quite important that health professionals provide further 
information for medicines and driving to their patients. 
DRUID WP4 categorization and labelling should be integrated in existing computerized prescribing 
and dispensing systems for physicians/pharmacists (D7.4.2, D4.3.1). 
Policy implications (D4.2.1, D4.3.1): 
• The DRUID WP4 categorization was in line with the recent approved SmPC guidelines 
adopted in September 2009 (which applies as from 1st of May 2010) by EMA, based on the 
DRUID WP4 proposal submitted for consideration by the CMD(h), as a response during the 
consultation phase of the revision of the SmPC guidelines in February/March 2008, proposing 
that in section 4.7 ”Effects on ability to drive and use machines”....., specify whether the 
medicinal product has a) no or negligible influence b) minor; c) moderate influence or d) major 
influence on these abilities.... 
• DRUID results are compatible with any existing national classification system (e.g. FR, ES) 
and could be integrated in them.  
• The following agreements were reached with the PhVWP (recommendations): 
• There is a need to improve information related to effects on driving in the PIL. Information 
to patients who are advised to use medicines that may impair driving fitness needs to be 
improved by simple and patient-centred directions based on a clear categorisation system 
and reflected in the PIL. 
• A basic 2-tier risk categorisation system with standard wordings for the PIL is 
recommended for medicines without a potential influence on driving fitness (Level 1, 
reflective of SmPC descriptions; a) no or negligible influence or b) minor influence) and for 
medicines with a potential relevant influence on driving fitness (Level 2, reflective of 
SmPC descriptions; c) moderate influence and d) major influence).  
• Clarification of criteria for the evidence in forming the categorisations, as described as  a)-
d) in the SmPC (section 4.7) into the 2 levels, should be derived in a collaborative effort of 
DRUID experts and the members of the PhVWP of CHMP, among other partners, 
preferably with support of EU bodies, such as DG Sanco and DG Move.  
• The development of supplementary information for patients (e.g. warning levels, 
pictograms) and health care professionals (prescribing and dispensing guidelines), in 
support of the categorisation system, could be guided with input provided by the DRUID 
project (D 4.2.1, D 4.3.1, D 7.3.2 and D 7.4.2) as well as by experiences in EU Member 
States.      
4.3 Rehabilitation (WP5) 
Sanctions are necessary, but are only the ultima ratio. The driving population must be informed about 
the problem (risk / danger) and must be convinced in a way that opens self-responsible behaviour. In 
case of contraveners, individually tailored rehabilitation measures should be offered aiming at 
regaining the driving ability.  
 
Driver rehabilitation (DR) was defined in DRUID WP5 as “a collective term for specific secondary 
interpersonal prevention measures that focus on attitudinal and behavioural changes of drink- (DUI) 
and drug-driving (DUID) offenders”; structural interventions like alcohol ignition interlock systems were 
no primary focus of the investigation. The primary aim of DR is to avoid new traffic offences and/or to 
re-integrate the individual into the traffic system without imposing a risk on other traffic participants. 
Alcohol ignition interlock programmes can be an additional option for DUI offenders but they can not 
substitute treatment, as they are only effective as long as they are installed. 
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DRUID WP5 aimed at providing updated comprehensive knowledge (incl. scientific evidence, previous 
projects (e.g. ANDREA), experiences in- and outside Europe) on DR for intoxicated drivers, in order to 
file recommendations on good/best DR practices for DUI/DUID offenders, and to propose adequate 
DR schemes for different groups of DUI/DUID offenders. With focus on the European situation, actual 
in-depth information from DR providers was specially considered via an EU-wide survey.  
The DRUID WP5 investigation has shown that DUI/DUID rehabilitation helps to prevent people 
from impaired driving and restores their mobility in a safe way. European standard group 
intervention programmes for DUI offenders show an average recidivism reduction rate of 45.5% 
but with a variation of 15 - 71%.  
At the time of the DRUID WP5 investigation, at least 47 providers in 12 European countries were 
carrying out DR services on a regular base. The provider survey gathered information on 87 
programmes (53 for DUI offenders, 21 for DUID offenders, 13 for mixed groups). It is clear that the 
majority of current DR measures focus on DUI offenders, which corresponds to the higher prevalence 
of alcohol-impaired, as compared to drug-impaired, driving. Although the DR implementation in the 
national contexts varies to a great extent, the approaches for non-dependent DUI/DUID offenders are 
rather similar. Furthermore, DR courses are generally very positively evaluated by participants across 
Member States and also similar change effects are obtained. 
4.3.1 Recommendations on good DUI/DUID rehabilitation practices 
The within DRUID WP5 developed Driver Rehabilitation Evaluation Tool (DRET) consolidates the 
different WP5 investigations and includes the main Europe-wide standards and recommendations of 
good/best practices on national system level (legal implementation, assignment, quality management) 
as well as on single programme level (prior assessment; programme operation, content and 
evaluation) for DUI/DUID rehabilitation measures. This user-friendly tool is aimed as support for 
implementation, assessment or evaluation of existing or new DR systems or programmes, and could 
be the starting point of a European networking and documentation process of DR measures.  
 
Main elements of effective DR are seen in (1) the assignment procedure (2) the matching of different 
rehabilitation options according to the needs of different offenders and (3) a quality management 
system (D5.2.4): 
 
(1) Recommendation on assignment to DR  
• Legal regulation of DR participation should be established in order to systematically bring 
offenders to intervention.  
• A linkage of participation in DR and licensing procedure is considered as important, e.g. 
participation in DR as a precondition for the reduction of the suspension period or for license 
re-instatement.  
• In general regulations on DR participation should care for an early access of the offender to 
specific measures in order to minimize the risk of problem escalation and secondary 
delinquency. 
• In case of suspicion of addiction a (fitness to drive) driver assessment prior to DR should 
be carried out in order to match offenders to appropriate treatment. In all other cases formal 
criteria (such as high BAC-level, re-offending within five years, refusal of test) might be 
sufficient to directly assign DUI/DUID offenders to DR or at least to counselling in order to 
initiate problem awareness and screen for a severe alcohol or drug problem. DR participation 
should be mandatory for high-risk offenders, repeat offenders and young (novice) 
drivers.  
 
(2) Rehabilitation options according to needs of different offenders 
• Different types of DUI/DUID offenders have different needs and require different types of 
rehabilitation.  
• The intensity of intervention should increase with the severity of the problem behaviour. 
Addicted DUI/DUID offenders should be at least separated from non-addicted offenders. If 
possible DUI and DUID offenders (excluding combined use of alcohol and drugs) should not 
be mixed within these groups as both groups do not only differ regarding the drug and its 
legality/illegality but also in relevant socio-demographic and offence related aspects. Scientific 
evidence regarding the latter group still has to be improved. 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
97 
• European standard group DR interventions (6-12 participants; psychological-therapeutic 
approach with educative elements; lead by specially qualified course leader or psychologist 
respectively) can be recommended as a good practice example for non-addicted DUI/DUID 
offenders.  
• Information exchange between experts from DR interventions and addiction treatment should 
be encouraged. 
 
(3) Quality management system for DR 
• QM systems in DR schemes are necessary to create transparency of procedures by fixing 
rules and instructions (standards) for carrying out DR services. The compliance with the 
standards is a medium to create confidence and a necessary condition for the trust of all 
sides: legislators, authorities, individuals and the public. WP5 developed a decision-tree which 
may serve as an evaluation tool for already established resp. newly introducing QM systems, 
focussing on the essential criteria (on European, country, provider and programme level)  to 
be met in order to implement a comprehensive QM system. Optimally (to enhance EU 
harmonisation), these standards are defined on European level. A (national) quality 
management body should be installed which has an independent, authoritative position to 
execute the operative quality management tasks in driver rehabilitation. 
• Applied programmes should be evaluated on a regular basis regarding their effectiveness for 
traffic safety. 
 
 (4) European initiative 
 
DRUID WP5 strongly supports a preventive DR concept which is compatible with the overall 
objective of mobility of European citizens without endangering traffic safety. Therefore, the following 
initiatives are recommended on European level:  
1. A basic statement on DR should be included in the EU Road Safety Act, stating that driver 
rehabilitation for non-dependent DUI/DUID offenders should be an integrated part of a 
comprehensive countermeasure system in Europe. Participation should be legally 
regulated in order to systematically bring offenders to intervention.   
2. In a next working step, European guidelines for legally regulated DR systems and 
procedures should be established taking the WP5 results (DRET) into account. 
 
This European initiative would support the application of adequate, effective, uniform and high quality 
DR measures for DUI/DUID offenders in the Member States, above all in countries, which newly 
implement this measure on national level.  
4.3.2 Overview box – Rehabilitation 
Box 6: Summary of main DRUID results – REHABILITATION 
• DUI/DUID rehabilitation helps to prevent people from impaired driving and restores their 
mobility in a safe way (D5.1.1, D5.2.4).  
• DR should be an integrated part of a comprehensive countermeasure system. This should be 
stated on EU level (D5.1.1, D5.2.4).  
• Main outlines of rehabilitation procedures should be formulated on EU level (guidelines for 
legal regulations and standardised procedure). DRUID WP5 developed Europe-wide 
standards and recommendations of good practice for DUI/DUID rehabilitation measures, 
which were couched into the form of a user friendly tool (Development of Driver Rehabilitation 
Evaluation Tool, DRET) for implementation, assessment or evaluation of existing or new DR 
systems or programmes. It can be the starting point of a European networking and 
documentation process of DR measures (D5.2.4).  
• Recommendation on assignment to DR (D5.1.1, D5.2.4): 
o Legal regulation of DR participation should be established in order to systematically 
bring offenders to intervention. 
o A linkage of participation in DR and licensing procedure is considered as important, 
e.g. participation in DR as a precondition for the reduction of the suspension period or 
for license re-instatement.  
o Formal criteria for directly assigning DUI/DUID offenders to DR (or at least to 
counselling) should be established in order to initiate problem awareness and screen 
for a severe alcohol or drug problem. WP5 proposes to use high BAC-level (above 
1.6g/L), re-offending within five years, and refusal of test as assignment criteria.  
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o Driver assessment prior to DR should be obligatory in case of suspicion of addiction in 
order to match offenders to appropriate treatment. 
o DR participation should be mandatory for high-risk offenders, repeat offenders and 
young (novice) drivers. 
• Rehabilitation options according to needs of different offenders (D5.1.1, D5.2.1, D5.2.4): 
o Different types of DUI/DUID offenders have different needs and require different types 
of rehabilitation. The intensity of intervention should increase with the severity of the 
problem behaviour. Addicted DUI/DUID offenders should be at least separated from 
non-addicted offenders. If possible DUI and DUID offenders should not be mixed 
within these groups. 
o European standard group DR interventions (6-12 participants; psychological-
therapeutic approach with educative elements; led by specially qualified course leader 
or psychologist respectively) can be recommended as a good practice example for 
non-addicted DUI/DUID offenders.  
o Information exchange between experts from DR interventions and addiction treatment 
should be encouraged. 
• Quality related requirements of DR (D5.2.3, D5.2.4): 
o The importance of implementation of quality management systems on European, 
national and driver rehabilitation provider level is stressed.  
o Quality management requirements should be established on a legal base in order to 
achieve uniform quality management standards. Optimally, these standards are 
defined on European level.  
o A (national) quality management body should be installed which has an independent, 
authoritative position to execute the operative quality management tasks in driver 
rehabilitation. 
• Alcohol ignition interlock programmes can be effective for DUI offenders in combination with 
rehabilitation (D5.1.1, D5.2.4). 
4.4 Withdrawal (of driving license) (WP6) 
The European Road Safety Action Programme as well as many of the national safety programmes 
within the European states is stressing the importance and effectiveness of the different enforcement 
measures to improve road safety. Enforcement is one of the most cost effective measures and needs 
no investment like changes in road infrastructure and vehicles do. In order to support this European 
Transport Policy and to be able to implement European Traffic Enforcement Recommendations 
DRUID WP6 investigated different attempts made in Europe (27 EU countries, Switzerland, Norway 
and Croatia) to combat DUI/DUID and discussed their experience with countermeasures and 
prevention. Aim was to bring together those different solutions and to come closer to a "best practice" 
procedure to be recommended to the Member States.  
 
The DRUID WP6 recommendations are based on the national practices in Europe, the empirical 
evidence of withdrawal effectiveness and expert opinions.  
4.4.1 Overview of national strategies  
DRUID WP6 set up a comprehensive overview of legal systems as well as practices in European 
countries (27 EU countries, Switzerland, Norway and Croatia) with respect to withdrawal of a driving 
licence due to impaired driving, i.e., driving under the influence of alcohol, illicit drugs or medicine. The 
results reveal that the strategies are very heterogeneous, hence, a clustering of strategies or countries 
is difficult. Considering the fact that the national legal regulations in case of withdrawal differ 
considerably, the overall valid recommendation can be made that regulations in European 
countries regarding withdrawal and accompanying measures should be harmonized. The 
following recommendations, which are mainly based on empirical primary results and expert opinions, 
can be elements of such a uniform withdrawal system.  
 
These recommendations have been summarized in D6.2 as follows (D6.2 p. 49ff):  
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4.4.2 General recommendations on withdrawal and conditional 
withdrawal   
DRUID WP6 derived “the following recommendations which are valid for substance impaired driving in 
general, including all problem groups (DUI, DUID, substitution treatment and chronic medical 
treatment). 
 
The analysis has shown that withdrawal is a considerable effective general and special deterrent 
factor, if sanction certainty and celerity are provided (above all immediate withdrawal/suspension of 
driving licence and a high level of perceived detection risk). Sanction severity is less important. In all 
investigated countries the combination of licence withdrawal and treatment/rehabilitation shows more 
deterrent effects (higher level of general and special deterrence) than licence withdrawal as stand-
alone measure. Especially in case of addiction or misuse, punitive sanctions alone are not able to 
serve as a considerable deterrent factor, because these sanctions are not able to combat the 
underlying drinking problem. The distinction between withdrawal and driving ban is in general not able 
to serve as a considerably additional deterrent element, as the re-granting procedure (e.g. a check 
of fitness to drive/medical-psychological examination) is a more important deterrent factor than the 
revocation procedure. The imposition of driving licence measures shows a higher correlation with 
the level of deterrence than other sanctions (e.g. imprisonment or fines). 
 
The withdrawal duration should be between 3 and 12 months. Shorter withdrawal periods, 
especially short-term driving bans (12 – 24 hours), are commonly not effective. Longer withdrawal 
periods lead to an increase of driving without a driving licence. 
 
The DRUID WP5 analysis has shown that DUI/DUID rehabilitation helps to prevent people from 
impaired driving and restores their mobility in a safe way. The measure of driver rehabilitation is in 
itself an effective special deterrent factor but cannot substitute driving licence measures. Driver 
rehabilitation should be an integrated part of a comprehensive countermeasure system in 
Europe. Participation in driver rehabilitation should also be legally regulated and obligatory in order 
to bring high-risk offenders systematically to an intervention or treatment. 
 
A conditional withdrawal (including a conditional re-instatement of the licence) supports a re-
integration process and respectively minimizes the social segregation effects, but has to be combined 
with rehabilitative measures and close monitoring in order to achieve measurable effects. Possible 
conditions are for example: driving is allowed for important activities (e.g. for work and 
treatment/rehabilitation), installation of an alcohol ignition interlock or regular medical checks. 
 
DRUID WP6 was not able to conclude on a final recommendation on either administrative or criminal 
procedure: advantages of an administrative procedure are seen in the sanction celerity and sanction 
certainty (especially in case of per se legislation); disadvantages of a criminal procedure are related to 
huge differences in the severity of the imposed sanctions” (D6.2 p. 49f; see also D1.4.1). 
4.4.3 Further recommendations for specific problem groups  
(1) DUI 
 
In regard to DUI DRUID WP6 recommends “per se laws with a graduated system of withdrawal 
and additional measures depending on the BAC level. 
In cases of high levels of alcohol intoxication, re-offending within five years, and refusals of alcohol 
tests, a medical-psychological assessment is necessary for the decision on fitness to drive and 
further intervention. Medical follow-up controls should be imposed in individual cases in the frame of 
fitness to drive; whereby frequency and intensity should depend on the individual case. 
 
In regard to DUI rehabilitation DRUID recommends to provide at least two levels of intervention: (1) 
less intense rehabilitative measures for non-dependent offenders (European standard group 
intervention as good practice) and (2) an intense treatment for dependent offenders (established 
addiction therapy in the health sector). The assignment procedure should be defined and formal 
criteria should be fixed which lead directly to participation. 
 
Participation in an alcohol ignition interlock programme should not substitute a minimum period of 
full licence withdrawal, but should be offered as an option in exchange for a reduced length of 
licence suspension. The duration of the programme should be criterion-based, i.e. the offender 
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should not be released from the programme before he/she proved to drive sober in a stable way (= at 
least 6 months without starting failure for first offenders, 12 months without starting failure for repeat 
offenders). An interlock programme should always include at least strict medical counselling or 
even psychological support. 
 
Interlock legislation must include supplementary provisions that prohibit a driver from asking 
someone else to provide a breath sample in an attempt to start the vehicle and driving a vehicle not 
equipped with an interlock device. The interlock restriction must be clearly marked on the driver’s 
licence in order to assure enforcement in case of programme violations” (D6.2 p. 50; see also 
D1.4.1). 
 
(2) DUID 
 
In general, “the system of withdrawal and additional measures for DUID should be in line with the 
system regarding alcohol.  
 
In case of DUID, including refusal of drug test, a driver assessment should always be carried out for 
the decision on fitness to drive and further intervention, unless threshold values for DUID are 
defined. As in the case of DUI, medical follow-up controls have to be imposed in individual cases in 
the frame of fitness to drive. The frequency and intensity should depend on the individual case. 
 
Rehabilitative interventions for non-dependent and dependent offenders have to be provided 
(European standard group intervention as good practice and established addiction therapy in the 
health sector)” (D6.2. p. 51, see also D1.4.1). 
 
(3) Patients in substitution treatment 
 
“There should be no basic difference made between patients in substitution treatment and 
patients in other medicinal treatments. 
Each patient in substitution therapy has to be assessed individually regarding fitness to drive. 
Thereby, the assessment and evaluation model should be adaptable to the specific case: addictions to 
others substances (e.g. alcohol, benzodiazepines) are exclusion criteria, patients treated with 
diamorphine (pharmacological heroine) are not fit to drive, substitution substance (Methadone vs. 
Buprenorphine vs. Morphine) and the height of the daily dosage in milligrams are no criteria for the 
(decision about the) fitness to drive. The adequacy of the substance and dosage for each client is a 
crucial issue; in cases of intake of other disease-related prescribed medicines, tests of cognitive 
performance are recommended, especially for older long-term using patients. 
 
Based on the fitness to drive examination, a conditional licence with regular follow-up controls 
is recommendable. Thereby, follow-up controls are related to alcohol-driving abstinence 
(separation of drinking and driving) as well as abstinence of relevant parallel consumption of other 
drugs, a follow-up period after tapering the dose (treatment end) should be defined individually” (D6.2 
p. 51; see also D1.4.1). 
 
(4) Patients in long-term treatment with psychoactive medicines 
 
“Patients should be adequately informed on possible impairing effects and how to recognize them (link 
to WP4). 
The usage compliance with prescription and misuse has to be distinguished. In the latter case, the 
legal procedure and consequences should be in line with DUID. Legal measures should only be taken 
after an incident in traffic, whereby impairment is the key for sanctioning.  
 
Based on a medical expertise / assessment, an individual solution can be developed. Thus, no 
approach solely on substance classes is needed. A model of conditional licensing (after a full 
withdrawal) is recommendable” (D6.2 p. 50f, see also D1.4.1). 
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4.4.4 Overview box – Withdrawal 
Box 7: Summary of main DRUID results – WITHDRAWAL 
• Regulations in European countries regarding withdrawal and accompanying measures should 
be unified as far as possible and as far as they do not intervene with other national strategies 
against DUI/DUID. So far, national strategies are very heterogeneous, hence a clustering of 
strategies or countries is difficult (D6.2). 
General recommendations on withdrawal and conditional withdrawal (D6.2.): 
• Sanction certainty and celerity are crucial for the general and special deterrent impact of 
sanctions, above all immediate withdrawal/suspension of driving licence and a high level of 
perceived detection risk. 
• The imposition of driving licence measures shows a higher correlation with the level of 
deterrence than other sanctions (e.g. imprisonment or fines). 
• Withdrawal duration should be set between 3 and 12 months. The deterrent impact of shorter 
and longer durations has not been proven by empirical primary research; a longer withdrawal 
period leads in general to an increase in driving without a licence.  
• Generally, the combination of withdrawal and rehabilitation/treatment is connected with higher 
levels of deterrence than the sole imposition of each measure. 
• A conditional withdrawal (including a conditional re-instatement of the licence) supports a re-
integration process and can be applied if certain requirements are met. Possible conditions 
are, above all rehabilitative/treatment measures, but also installation of an alcohol ignition 
interlock and/or regular medical checks. 
• DRUID WP6 was not able to conclude on a final recommendation on either administrative or 
criminal procedure: advantages of an administrative procedure are seen in the sanction 
celerity and sanction certainty (especially in case of per se legislation); disadvantages of a 
criminal procedure are related to huge differences in the severity of the imposed sanctions. 
Further recommendations for specific problem groups (D6.2):  
• DUI drivers: 
o A graduated system of withdrawal and additional measures - depending on the BAC 
level - should be introduced. 
o Driver assessment and rehabilitation should be legally regulated and based on 
defined criteria (see WP5) 
o An alcohol ignition interlock could be offered as an option in exchange for a reduced 
length of licence suspension and should include at least strict medical counselling or 
even psychological support.  
• DUID drivers: 
o General DUI deterrent principles are also valid for DUID. 
o As long as no threshold values for DUID are defined, driver assessment should 
always be carried out to assess the fitness to drive and to decide on further 
rehabilitation/treatment. 
• Patients in substitution treatment: 
o Each patient in substitution therapy has to be assessed individually regarding fitness 
to drive. 
o A conditional licence, based on the fitness to drive examination, is recommendable 
combined with follow-up controls, above all focussing on abstinence of parallel 
consumption of other drugs. 
• Patients in long-term treatment with psychoactive medicines: 
o Legal measures should be taken only after an incident in traffic; impairment is the key 
indicator for sanctioning. 
o A model of conditional licensing, based on the fitness to drive examination, is 
recommendable. 
4.5 Guidelines and risk communication (WP7) 
Health care professionals need to be informed about the potential road safety risk associated with the 
use of medicines. The availability of clear information with respect to the medicinal categorisation 
system (WP4) will contribute to more driver-patient safety and better use of medicines. Physicians and 
pharmacists are key actors to forward this information to patients. Practice guidelines and protocols to 
make physicians and pharmacists aware of their role and to provide them with relevant information 
needed to be developed. The emphasis should lay on using relatively safer medicines if available, and 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
102 
on improving warnings and advices to patients how to act responsibly if using medicines that have the 
potential to impair driving. These measures should be supported by adequate training activities and 
supporting tools (e.g. integrated in software package of daily practice).  
 
DRUID WP7 generally aims at providing guidelines and tools that will increase the general awareness 
of accident risks involved with the use of psychoactive substances (alcohol, illicit drugs and 
medicines). The main focus lays on improving the risk communication between health care 
professional and patients, but also other target groups (general public, young drivers, policy makers 
on EU and national level) were addressed within this work package.  
 
The specific objectives of DRUID WP7 were: (1) to review the state-of-the-art of existing campaigns 
regarding psychoactive substances by using different media, focussed on the general public and 
health care professionals, as well as the documented effectiveness of those campaigns and 
knowledge translation;  (2) to development of prescribing and dispensing guidelines for 
physicians and pharmacists to select the least impairing medicine within a therapeutic class and to 
provide patient information that will meet the patient’s needs;  (3) to develop recommendations for 
improving the procedures for assessing fitness to drive within the framework of Council Directive 
91/439/EEC (on driving licences), allowing doctors to exert a responsibility in this process without 
incurring possible penal proceedings in the event of an accident occurring after a positive decision 
from their side; (4) to develop information materials aimed at the general public, young drivers, drivers 
as patients, physicians and pharmacists and policy makers on EU and national level and health care 
professionals; and (5) to evaluate practice guidelines and protocols in every day medical and 
pharmaceutical practice by focussing on different practice models, with and without the application of 
Information and Communication Technologies (ICT), as well as the evaluation of risk communication 
to patients and to young drugs consuming drivers (DRUID Technical Annex p. 105). 
4.5.1 Recommendations and guidelines for communication   
In order to develop guidelines on informing different target groups regarding driving under the 
influence of alcohol, drugs and medicines, different investigations were conducted  in WP7:  
• state-of-the-art review of existing DUI/DUID information campaigns (75 campaigns from 13 
different countries) (D7.1.1 p. 81f); 
• state-of-the-art review of theoretical background for information campaigns  (EU CAST 
project) (D7.3.1); 
• experts’ on-line survey on the criteria for the design of prototype documents for information 
regarding psychoactive substances and driving (D7.3.1). 
 
This input together with the more general literature review on risk communication theories (D7.3.2 Part 
I) are presented as framework for extracting  target group specific information (D7.3.2 Part III) from the 
gathered main DRUID results (D7.3.2 Part II).  
 
The main results of the campaigns’ review can be summarized as follows (D7.1.1 p. 81f): 
• The focus of campaigns (content, target group, media etc.) should be selected according to 
the specific characteristic of problem situation and risk group.  
• Most of the retrieved DUI/DUID information campaigns were conducted through mass media. 
The type of medium used the most is brochures, followed by posters, written press, websites, 
booklets, TV commercials, radio spots, leaflets, tutorials or another type of medium. 
• Most campaigns are organized by governmental agencies and road safety organisations. 
• Evaluation studies of the campaigns are often lacking. Information on the impact of the 
campaign was only found in 7 cases. As the evaluations were performed in many different 
ways, it was not possible to draw conclusions concerning the association between the design 
of the campaigns and their effectiveness (D7.1.1).  
 
The EU project Campaigns and Awareness-raising Strategies in Traffic Safety (CAST: www.cast-
eu.org) emphasized the following key points for developing and evaluating campaigns:  
•  “Target audience: A key factor of success of road safety communication strategies is the 
identification of the target audience since this enables defining the best way to reach the 
targeted individuals. Furthermore, segmenting the target audience enhances the likelihood of 
success of the message and strategy in reaching and involving the intended audience. Once 
the target audience is defined, it is very important to find out and to know what the audience 
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wants and what their needs are, as well as what will have the greatest effect on changing their 
behaviour. 
• Analysing the situation: The background of a campaign refers to results from the: in-depth 
analysis of the problematic behaviour and possible solutions; identification of the target group 
at risk and how to reach and influence them; translation of the overall campaign goal into 
specific objectives. 
• Message: An effective message strategy, based on the communication objectives, is essential 
for the success of a campaign. It can be subdivided into content strategy (what will be said) 
and execution strategy (how and by whom it will be said). 
• Means and features (media): Target segments’ factors as well as media-related factors should 
be taken into account when choosing the type(s) of communication and media. Target 
audience factors include aperture (or opening), which is the audience’s general habits, general 
interests and media habits. Media-related factors include the ability of media vehicles and 
combined actions to reach the target audience, and the communication capacity of media 
vehicles and combined actions. 
• Communication objectives: This refers to the translation of the general goal of the campaign 
(based on the problem analysis) into the expected effects (objectives). It should be defined 
which behaviour (= primary objectives) is to be adapted by the target group to realise the 
general goal of the campaign. Furthermore, the factors that can contribute (i.e. knowledge, 
beliefs, attitudes … = secondary objectives) to reaching the primary objectives can be defined. 
The specific campaign objectives are used during the evaluation of a campaign. Therefore, 
objectives should be clearly defined with their levels of accomplishment (e.g. % increase of 
knowledge) in order to evaluate the success (effectiveness)” (D7.3.2 p. 10f). 
 
Experts’ opinions ( D 7.3.1.) on information documents on DUI/DUID were:  
• Medicines and illicit drugs should be addressed separately.  
• Much more attention should be paid to the elderly, either in campaigns addressed to the public 
in general as well as to the aged patients who drive.   
• Illicit drugs and medicines should be dealt with by substance group. 
• With regard to illicit drugs, most emphasis should be given to risks caused by use of cannabis 
followed by illicit use of benzodiazepines and stimulants such as ecstasy, amphetamines and 
cocaine.  
• With regard to medicines, priority should be given to medicines used in anaesthesia (general 
anaesthetics) followed by analgesics, hypnotics and sedatives, ophthalmologic medicines and 
anti-epileptics and anti-psychotics, anxiolytics, drugs used in addictive disorders and psycho-
stimulants. 
• With regard to the content, the main focus should lie on the risks and effects of the substances 
on driving. For “general public”, “driver as patients” and the “younger public”, also information 
on sanctions should be included. For the “general public”, also information on the size of the 
phenomenon (data on epidemiology) is considered important. For “physicians/pharmacists” 
and “policy makers”, information should be included on the size of the phenomenon and 
current legislation. 
4.5.2 Guidelines and professional standards 
Based on existing guidelines and a survey among driving licensing authorities and experts 
(feedback from 18 EU countries; response rate 62%), DRUID WP7 concluded that guidelines and 
standards for health care professionals pertaining to medicines and driving are generally lacking in 
most European MS although decision support for example at the start of a treatment is needed for 
selecting the least impairing medicines. “Strict and binding regulations concerning prescribing and 
dispensing of psychoactive medicines, which might have an impact on the driving performance, are 
the exception rather than the rule. The compiled guidelines are typically recommendations not 
regulations. The role, responsibilities and tasks of physicians and pharmacists are “not defined 
uniformly” and, “in most cases, physicians and pharmacists will not be made legally responsible” when 
one of their patients [taking a driving impairing medicine(s)] is made responsible for a traffic accident” 
(D7.2.1 p. 4).  
 
Recommendations on improving the Council Directive 91/439/EEC 
 
DRUID WP7 derived eight recommendations on improving the procedures for assessing fitness to 
drive within the framework of Council Directive 91/439/EEC (on driving licences). The 
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recommendations aim at allowing medical doctors to exert a responsibility in this process without 
incurring possible penal proceedings in the event of an accident occurring after a positive decision 
from their side.  
•  “Some of the recommendations point at the vague terms that are used in Article 15 (such as 
substance abuse, regular use, both for medicines and illicit drugs, etc.), whereas more 
internationally accepted terms exist”.  
• It is also recommended “to include the underlying cause or reason for taking medicines, as 
well as all co-morbidity factors, while assessing fitness to drive.  
• Another recommendation points at the term combinations of medicines with central nervous 
system activity. (…) This is especially of interest for drivers with co-morbidities and in case of 
polypharmacy.  
• It is also recommended to apply the DRUID (WP4) categorisation system for medicines 
affecting driving performance in developing national requirements for fitness to drive.  
• Finally it is recommended that in situations where physicians will advise a patient to start 
driving again after a period in which the advice was given not to drive while using the 
medicine, specific procedures are needed to structure the consultation and to manage the risk 
of litigation in case an accident could occur.  
 
(for more details see D7.2.1 p. 55-59)” (D7.2.1 p. 5; D7.2.2 p. 64)”. The WP7 team stress that these 
suggestions should be discussed in working groups/expert rounds with physicians, pharmacists, 
driving licensing authorities and policy makers in order to reach a consensus at European level.  
 
Prescribing and dispensing guidelines for physicians and pharmacist 
 
Reference is made to the developed guidelines in ICADTS and a stepwise approach for prescribing 
and dispensing safe medicinal treatment to drivers (see table 38).  
 
The emphasis should be given to shared decision making between health care professionals and 
patients and on documentation of patient consultations (to avoid liability issues).  
 
Table 38: Prescribing and Dispensing guidelines form ICADTS, 200115 
Prescribing Guidelines Dispensing Guidelines 
1. Realize that the use of some psychoactive medicines has 
been associated with an increased risk of causing an 
injurious accident and that patients should receive this 
information. 
1. Discuss with prescribing physicians what patient 
information (written and oral) should be provided  at the 
first delivery of a particular impairing medicine  
2. Consider an alternative in the light of experimental 
research showing large differences between the effects 
on driving performance of various medicines within the 
same therapeutic class. 
2. Inform the prescribing physician that alternative drugs exist 
in case a medicine in class II or III has been prescribed, 
and inform the patient. 
3. Start with the lowest doses of psychoactive medical 
medicines and whenever possible avoid multiple dosing 
over the day. 
3. Advise the physician to prescribe the lowest effective dose 
of a particular psychoactive medicine and to avoid multiple 
dosing over the day. Inform the patient. 
4. Do not reflexively "double the dose" if patients fail to 
respond to psychoactive medication. 
4. Advise the physician to try another medicine if the patient 
reports a lack of efficacy after beginning of treatment and 
inform the patient. If higher doses are needed advise the 
patient to use the largest part before sleep (if compatible 
with the therapeutic regimen). 
5. Avoid prescribing different psychoactive medicines in 
combination. 
5. Explain to the patient that poly-therapy with psychoactive 
medicines is always an experiment with the patient's safety 
and avoid to driving if treatment can not be adjusted. 
6. Do not rely solely upon the manufacturers' advice for 
counselling patients about the effects of medicine upon 
driving. 
6. Explain to the patient why warnings provided by the 
manufacturer about their medicine's effects on driving are 
vague, illogical and sometimes misleading. 
7. Advise patients concerning the ways they can minimize 
the risk of causing a traffic accident if it is impossible to 
avoid prescribing an obviously impairing medicine or one 
with unknown impairing potential (see next table). 
7. Advise the patient the ways they can minimize the risk of 
causing a traffic accident if they have to use a drug with an 
impairing potential (see next table). 
8. Monitor the patient's driving experience with the drug. 8. Monitor the patient's driving experience with the drug (e.g. 
at the first refill) and report back to the physician or ask the 
patient to inform the physician. 
                                                 
15
 International Council on Alcohol Drugs and Traffic Safety (ICADTS) Working Group Report on Prescribing 
and Dispensing Guidelines for Medicinal Drugs that Affect Driving Performance, 2001. http://www.icadts.org/ 
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Source: International Council on Alcohol Drugs and Traffic Safety (ICADTS) Working Group Report on Prescribing and 
Dispensing Guidelines for Medicinal Drugs that Affect Driving Performance, 2001. http://www.icadts.org/  
 
Figure 42: Prescription of medicines to patients who drive a vehicle (Álvarez, 2006). 
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Checklist with issues for documenting the decision-making process to avoid liability issues (D7.4.1 p. 
28): 
 
Actions to be checked during the consultation: 
• Advise not to combine psychoactive medication. 
• Check whether the patient is willing and able to follow the treatment plan. 
• Advise the patient to be aware of possible side-effects. 
• Advise the patient to report on these side-effects during a follow up visit. 
 
Documentation of the following items: 
• tests done and / or information gathered in assessing fitness to drive; 
• assessment of patient’s decision-making competence based on advices given; 
• patient’s understanding of impairing properties of the medication; 
• specific actions to achieve fitness to drive (changes in medication or instructions for use); 
• follow up visit for evaluation of interventions (advices given, self-assessment of patient). 
 
In order to easy access protocols and guidelines should be integrated in existing computer software 
used by health care professionals in daily practice. DRUID WP7 developed or adjusted information to 
be used in existing software packages (see D7.2.2) which have been evaluated in BE, ES and NL 
(see D. 7.4.2.).  
4.5.3 ICT and paper tools for physicians and pharmacists  
DRUID WP7 developed several tools which can be used to aid the prescribing and dispensing process 
in considering possible driving impairing effects: a training paper tool aiming to inform and sensitise 
health care professionals on this issue, as well as supportive software including the relevant medicinal 
risk information and categorisation (WP4) which can either be installed in existing daily used software 
packages (integrated) or be used as a stand-alone tool (USB). Furthermore, a paper tool 
(compendium) including the individual medicinal risk categorisation and (WP4) Fact Sheets was 
developed. (see also DRUID CD-rom demonstration D7.2.2). These tools have been evaluated in BE, 
ES and NL and preliminary results are presented in the following part.   
4.5.4 Evaluation of risk communication 
Pictograms for showing risk  
 
Two studies on the risk communication to patients have been carried out in ES and NL and one on the 
risk communication to young drugs consuming drivers in DE. The results of these studies can be 
found in Part I of this deliverable (D7.3.2 Part I).   
The primary aims of the studies were  
• to evaluate the effectiveness of the rating model pictogram (showing four possible categories 
or risk of impairment levels in different colours, presented in a bar, and a black triangle in the 
assigned category; with or without side-text explaining how to act)  in communicating risk 
associated with driving impairing medicines to patients, and  
• to assess patients’ level of understanding and intention to change driving behaviour by looking 
at various pictograms.  
A comparison with a similar and already existing (in France) pictogram with or without side-text how to 
act was conducted (triangle model pictogram; a single black triangle on the box with a specific colour 
for a assigned risk of impairment level) 
 
Patients visiting a community pharmacy and actively participating in traffic (in NL) and patients visiting 
health services, such as pharmacies, primary care physicians and hospitals, with or without a driving 
license (in ES) were interviewed. The results show that: 
 
• All pictograms (different categories presented in the two models) were found to be clear, 
informative, easy, understandable, not complex, and not ambiguous.  
• Respondents’ opinions of  categories II and III of the rating model were those associated with 
more dangerous situations compared to respective categories as shown with the triangle 
model. 
• Respondents’ likelihood to change driving behaviour is significantly higher with the rating 
model pictogram than with the triangle model. 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
107 
• Respondents stated that they would be likely to change their driving behaviour by driving less 
frequently. No statistically significant differences were found between both types of models.  
• About 40% of the respondents would change their driving behaviour by not driving anymore, if 
refrain from driving is advised whenever a category III medicine is prescribed. 60% of the 
respondents who first saw category III pictograms from the rating model would not drive 
anymore, against 43.3% of those who saw the homologue triangle model.  
• Respondents’ preference in understanding the pictogram for explaining a side-text warning 
and for showing the level of impairment was significantly higher for the rating model. A 
negative correlation between age and pictogram model of preference was found: older 
participants were more in favour of the triangle model than younger participants. 
 
Prescribing/dispensing guidelines and supporting tools   
 
The above mentioned practice guidelines and protocols as well as supporting tools have been 
evaluated in everyday medical and pharmaceutical practice in BE, ES and NL (D7.4.2).  
 
The results of these studies will be available at the end of the DRUID Project (October 2011), but 
preliminary findings could already be included in this deliverable. 
 
Preliminary evaluation results based on the consolidated database (including common NL, ES and BE 
results) indicate a positive effect of training on and implementation of the DRUID guidelines (as 
intervention):  
• After training on and implementation of the DRUID dispensing guidelines, pharmacists had 
significant positive changes in reported behaviour (increased consideration in informing 
patients about medicines’ impairing effects regarding driving), attitudes and awareness about 
medicines’ dispensing and driving and actual knowledge about categories of medicines and 
their effect on driving behaviour.  
• With regard to physicians, significant differences (in the expected direction) were observed 
between the control and intervention groups for attitudes and reported behaviour after the 
training and implementation phase of the DRUID prescribing guidelines.  
• Overall, health care professionals are very satisfied with and strongly prefer ICT supporting 
tools which are integrated in their prescribing/dispensing software systems over other 
supporting tools. The participating ICT software providers expressed high interest to continue 
offering these additional tools (which had to be stopped after the study period since update of 
the information was no longer guaranteed). 
 
Risk communication towards young consumers of alcohol and drugs 
 
During a DRUID-workshop on risk communication media- and communication-experts recommended 
putting a strong emphasis on the risks of drink driving. They favoured the idea to include into the 
target group even younger people just reaching the phase of getting a driving license, thus extending 
the target group to adolescents and young adults of 15-24 years. The effectiveness of adequate, 
general preventive approaches should be investigated, as well as special focussed preventive 
measures for certain smaller subgroups (lifestyle types). It was suggested, to check for efficient 
approaches via social networks (internet) or personal contacts (peers). 
 
To gain a closer look on the target group a formative evaluation was started in form of a representative 
sampling with 800 young people. The sampling focused on: 
• status of information and need for information on alcohol/drugs and driving; 
• personal involvement; 
• relevant attitudes and behavioural aspects; 
• subjective norms; 
• subjective risk perception; 
• acceptance and credibility of certain media and mediators. 
 
The results of the workshop and the formative evaluation are part of DRUID Deliverable 7.4.3. 
4.5.5 Overview box – Guidelines and risk communication 
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Box 8: Summary of main DRUID results – GUIDELINES/RISK COMMUNICATION 
Reviewing DUI/DUID information and education campaigns (D7.1.1; D7.3.1; D7.3.2 at hand): 
• The focus of campaigns (content, target group, media etc.) should be selected according to 
the specific characteristic of problem situation and risk group. The majority of the retrieved 
campaigns concerned driving under the influence of drugs, aimed at young people (this is not 
reflecting the actual problem situation) (D7.1.1, D7.3.1). 
• Campaigns are more successful if they are targeted (specific issues, groups, etc.). Therefore, 
large campaigns should be designed as sets of a larger number of activities on a smaller scale 
(D7.1.1, D7.3.1). 
• Campaigns should be evaluated (D7.1.1, D7.3.1). 
• Key points for developing and evaluating campaigns have been formulated in the EU project 
CAST (www.cast-eu.org) (target audience, analysing the situation, message, means and 
features (media) and communication objectives) (D7.3.1). 
• The report at hand is aiming at extracting main DRUID information per target group (general 
public, young drivers, drivers as patients, physicians and pharmacists and policy makers on 
EU and national level) based on the theoretic frame of CAST (campaigns) and a more general 
literature review on risk communication (D7.3.2 at hand). 
Guidelines and professional standards (D7.2.1, D7.4.1): 
• Guidelines and standards for health care professionals pertaining to medicines and driving are 
generally lacking in most European MS (D7.2.1). 
• Decision support at the start of a treatment is needed for selecting the least impairing 
medicines (D7.2.1). 
• Eight recommendations on improving the procedures for assessing fitness to drive within the 
framework of Council Directive 91/439/EEC (on driving licences) have been formulated within 
DRUID WP7. They aim at allowing doctors to exert a responsibility in this process without 
incurring possible penal proceedings in the event of an accident occurring after a positive 
decision from their side. These suggestions should be discussed in working groups/expert 
rounds with physicians, pharmacists, driving licensing authorities and policy makers in order to 
reach a consensus at European level (D7.2.1). 
• Emphasis in prescribing and dispensing guidelines for physicians and pharmacist should be 
given to shared decision making (health care professional together with the patient) and 
documentation of patient consultation (to avoid liability issues). Recommendations on the 
content of prescribing and dispensing guidelines for physicians and pharmacists have been 
formulated within DRUID WP7. Protocols and guidelines should be integrated in existing 
computer software used by health care professionals in daily practice (7.4.1). 
ICT and paper tools for prescribing and dispensing medicines (D7.2.2): 
• DRUID WP7 developed materials to be used in existing software packages for supporting 
integrated application in prescribing and dispensing practices as well as in stand-alone 
software packages and paper tools in which risk categorisation and Fact Sheets provided in 
WP4 are made accessible for physicians and pharmacists (see also DRUID CD-rom 
demonstration) (D7.2.2). 
Evaluation on risk communication (D7.4.2Draft; D7.4.3Draft): 
• The use of pictograms on medicine boxes for risk communication to patients is effective in 
explaining a risk of impairment level after using a driving impairing medicine. Patients’ 
likelihood to drive less frequently under the influence of a medicine is higher if the pictogram 
shows reference to all possible risk levels, and identifies the selected risk level from a rating 
bar model as compared to a single triangle model without explanation of possible risk levels. 
Younger patients (more in favour) and older patients (less in favour) differ in their preference 
for more complex presentations of risk of impairment levels in a pictogram.  
• Preliminary evaluation results based on the consolidated database (including common NL, ES 
and BE results) indicate a positive effect of the DRUID guidelines. Overall, health care 
professionals are very satisfied with and strongly prefer ICT supporting tools which are 
integrated in their dispensing/prescribing tools over other supporting tools (D7.4.2Draft). 
• Preliminary results of D7.4.3 show that the emphasis should be given to drink driving 
prevention, targeting the age group 15-24 year. Preventive measures should be differentiated 
into general preventive approaches (e.g. campaigns) and special focussed preventive 
measures for certain smaller subgroups (lifestyle types e.g. personal communication). The 
effectiveness of approaches should be analyzed in-depth based on representative samples 
(according results for e.g. DE will be available at the end of the DRUID project) (D7.4.3Draft). 
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Part III. Extraction per target group  
Authors: Uta Meesmann, Sofie Boets (IBSR-BIVV, Belgium), Han de Gier, Susana Monteiro, 
(RUGPha, University of Groningen, the Netherlands), F. Javier Alvarez (UVa, University of Valladolid, 
Spain), Kristin Thorsteinsdottir, Wolfram Hell, (LMU, Ludwig-Maximilians-Universität München, 
Institute for Forensic Medicine, Germany) 
 
Within this chapter key elements of risk communication (Part I) and main DRUID results (Part II) for 
and about specific target groups are extracted. The organisation of this Chapter is structured in a way 
that information addressed to a specific target group is presented in a complete manner. As a result 
content repetition in the text for each target group is possible.  For their own convenience readers 
interested in the content for and about one specific target group are not guided to different sections of 
the Chapter.  
1 General public 
1.1 Key elements of risk communication  
The aim of risk communication addressed to the general public is to (i) make them aware that the use 
of psychoactive substances (including some medicines) is not always compatible with car driving, (ii) 
support them to make their own problem definition, according to personal beliefs and expectations of 
risk, with or without the help of a (healthcare) professional, (iii) allow them to decide how to manage 
the risk in their daily life activities.  
 
For addressing risk communication messages to the general public, the following issues need to be 
considered: 
1. Factors that play a role in perceiving and accepting risk (see Part I. 3.2. Risk acceptability) For 
driving under the influence of psychoactive substances it seems obvious to address these 
factors carefully in defining messages of risk communication to the general public. A trusted 
organization, credible and with an eye on values and interests that people feel important can 
do a proper job in convincing them that, although DUI is a voluntary risk, it will not be 
completely controlled by the person due to the effects of psychoactive substances.   
2. Groups with higher socioeconomic status are more likely to benefit from an increasing flow of 
information on many issues, including drugs and driving issues. However, there are many 
contributory factors that could reduce the knowledge gap. First of all a content domain related 
factor, people might feel that health issues are more relevant to them than other issues, also 
certain groups could experience a greater impact of information due to the channel that was 
chosen, and used more frequently by them (e.g. internet applications, newsgroups), and 
individual motivational factors. It is expected that users of ICT technologies will use the 
information “on demand”, allowing them to control the media technologies and attempts to 
change their behaviour. This, however, is also a risk for widening the knowledge gap, 
because access could be determined by socioeconomic status and necessary skills.    
3. The “power” of any single channel of communication (being mass media or interpersonal) may 
depend on the complexity of the behaviour change being sought. If the change is less 
complex, a single channel of communication may lead to development of the promoted 
behaviour. If, however, the behaviour change is more complex an individual will need the use 
of multiple sources of information and the application of multiple channels of communication. 
1.2 Extraction of main DRUID results  
Problem situations 
 
Alcohol 
• Prevalence: Alcohol (≥0.1g/L) is the most frequently detected psychoactive substance in the 
driving population (estimated EU mean 3.48%) (D2.2.3) as well as in the seriously injured 
(range 17.7-42.5%) and in killed drivers (range 19.0-44.9%) in Europe (D2.2.5; D2.2.4; 
D2.3.4).  
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• Alcohol was in the general driving population mainly detected among older male drivers, with 
lower BAC levels (D2.2.3).  
• Within the accident involved drivers alcohol was mainly detected among younger male drivers 
with a high BAC level (D2.2.5). Alcohol appeared most often alone compared to other 
substances. When alcohol was combined with other psychoactive substances, 
benzodiazepines and cannabis (THC and/or THCCOOH) were the most common associated 
findings (D2.2.5; D2.3.4). 
 
• Risk: Alcohol has a negative impact on driving performance and highly increases accident risk 
(e.g. D1.1.2a, D2.3.2; D2.3.3; D2.3.4; D2.3.5 DRAFT).  
• Based on case- control studies, the relative risk of serious injury or fatality for alcohol (≥0.5 
g/L) is estimated to be significantly increased compared to that of drivers below the DRUID 
cut-off for any substance (D2.3.5) The risk increases dramatically with the alcohol 
concentration. 
• An increased risk was associated with high BAC level, young age and speed (D2.3.3). 
• The risk multiplies with combined use (e.g. cannabis) (D2.3.2). 
• The general finding is that alcohol use in traffic is already risky at low BAC levels, especially 
for younger drivers who have less driving experience than older drivers. Alcohol affects the 
driving behaviour by increasing the reaction time and decreasing concentration, coordination 
and tracking. Furthermore, alcohol leads to more risk-taking behaviour and affects decision 
making and planning, since drivers overestimate their skills and underestimate the risk due to 
the effects of alcohol (Kelly et al., 2004; Steyvers & Brookhuis, 1996) (D2.2.3). 
 
• Motives behind DUI: Drivers do not think that alcohol impairs their performance; Drivers 
whose drinking and driving was related to problems with alcohol argue that losing the licence 
or even to be imprisoned would not have helped them to stop re-offending; instead, it they 
argue that the treatment programme had helped them by providing a greater insight into their 
own problems; factors influencing the decision to DUI/DUID: risk perceptions (e.g. beliefs in 
the objective danger/effect of the substance on driving ability, perceived chance to be involved 
in an accident / fear of injuring others, perceived chances to get caught / to lose DL), 
knowledge (effects of alcohol, safe alcohol consumption levels for driving), subjective 
norm/social norms and expectations/peer pressure (D2.2.1). 
 
• Clear information about sanctions (certainty/celerity) of DUI is required (D6.2, D1.4.1). 
 
• For more details see overview box 1.  
 
Illicit drugs 
• Prevalence: All DRUID investigations (e.g. D2.2.3, D2.2.5, D2.3.4) show that the prevalence 
of illicit drugs in the driver population (estimated EU mean 1.90%) is lower than the alcohol 
prevalence (estimated EU mean 3.48%) (D2.2.3).  
• Within the accident involved drivers, the majority of drugs appeared to be used in combination 
with other psychoactive substances (mainly alcohol) (D2.2.5). 
• THC is generally the most frequently detected illicit drug, followed by cocaine, but the 
prevalence of the different illicit substances show high national variability (e.g. D2.2.3, D2.2.5, 
D2.3.4). 
• Illicit drugs were in general mainly detected among young male drivers, during all times of the 
day but mainly at the weekend (D2.2.3).  
• Combined use of alcohol and drugs (illicit drugs and/or psychoactive medicine) is in general 
often prevalent among young (<35 years) male drivers during night time hours (D2.2.3).  
• Multiple drugs (illicit drugs and/or psychoactive medicines) use is in general most common in 
males (D2.2.3).  
• Age groups and time periods vary considerably by country (D2.2.3).  
 
• Risk: Based on case-control studies, the relative risk of serious injury or fatality for different 
illicit substances varies between the substances. For: THC about 1-3 times; benzoylecgonine, 
cocaine and illicit opiates about 2-10 times; amphetamines about 5-30 times as high as that of 
drivers below the DRUID cut-off for any substance (D2.3.5 DRAFT; see also D1.1.2b, D1.2.1, 
D2.3.2). Some of the risk estimates for illicit drugs vary to a high degree among the single 
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countries; others are based on few positive cases and/or controls which result in very wide 
confidence intervals. Therefore the estimates are uncertain.  
• Experimental studies have shown that the dose equivalent for BAC 0.5g/L-3.7ng/mL THC 
(range 3.1-4.5ng/mL) for oral administration and 3.8 ng/mL (range 3.3-4.5ng/mL) for smoked 
administration (D1.1.2b, see also D1.4.2 for more information on cut-offs equivalent to BAC 
0.5g/L). 
• The risk multiplies with combined use (e.g. alcohol) (e.g. D2.3.2, D2.3.5).  
• Experimental studies evaluating the effect of stimulants on driving (MDMA and 
dexamphetamine) did not reveal impairing effects on driving performance. However, the 
stimulant effects of MDMA and dexamphetamine are not sufficient to overcome or 
compensate driving impairments produced by concomitant of alcohol use or sleep deprivation 
(D1.1.2b, D1.2.1).  
 
• Motives behind DUID: Addicted drivers did not believe that they would be stopped by the 
police. They did not believe that alcohol or drugs would impair their driving and therefore they 
did not perceive any real risks of driving (D2.2.1). Findings indicate that especially moderate 
substance users can realistically judge their intoxication and are responsible-minded 
concerning drugs in traffic (D2.2.2).  
 
• Clear information about sanctions (certainty/celerity) of DUID is required (D6.2, D1.4.1). 
 
• For more details see overview box 2.  
 
Medicines 
• Prevalence: DRUID studies indicate that some selected psychoactive medicines 
(benzodiazepines, medicinal opiates and opioids and Z-drugs) are less prevalent in the driving 
population (estimated EU mean 1.4%) (D2.2.3) as well as is in seriously injured drivers 
(D2.2.5) compared to alcohol (estimated EU mean 3.48%) and illicit drugs (estimated EU 
mean 1.90%). Among the killed drivers the presence of benzodiazepines was the second 
most frequent toxicological finding after alcohol (D2.2.5). Psychoactive medicines, such as 
(frequently used) antidepressants, anti-epileptics and antipsychotics, were not included in the 
DRUID studies. Therefore an underestimation of prevalence should be considered. 
• In most countries benzodiazepines were the most common psychoactive medicines in traffic 
but as for illicit drugs the prevalence of the different psychoactive medicines show high 
national variability (D2.2.3, D2.2.5).  
• Epidemiological studies indicate a major increase in the consumption of antidepressants and 
drugs used in addictive disorders in the general population in Europe within the last years 
(D2.1.1).  
• Psychoactive medicines were in general mainly detected among older female drivers during 
daytime hours (D2.2.3).  
 
• Risk: Alcohol impaired driving is the main problem in traffic safety, but also psychoactive 
medicines can constitute a problem in traffic safety. Therefore, both health care providers and 
patients should be properly informed and aware of the potential risks associated with the use 
of psychoactive medicines (link WP4/7). 
• Based on case-control studies, the relative risk of serious injury or fatality for benzodiazepines 
+ Z-drugs and medicinal opioids is estimated to be about 2-10 times (medicinal opiods in the 
upper part of the interval; benzodiazepines + Z-drugs in the lower part of the interval) as high 
as that of drivers below the DRUID cut-off for any substance (D2.3.5). 
• The risk of being involved in an accident for medicine users compared to non-users is highest 
for users of modern antidepressants (1.76, CI: 1.38-2.24), followed by patients who use 
combinations of psychoactive medicines (1.55, CI: 1.20-2.02), and patients using at least one 
psychoactive medication (1.28, CI: 1.12-1.46) (D2.3.1).  
 
• Awareness: Medicines (in contract to illicit drugs) must be used to cure or alleviate 
indispositions or diseases, with regulated dose and under (effects’) control of a physician, it is 
important that (both health care workers and) patients are aware of the possible driving 
impairing effects. 
• General information that medicines, including over-the-counter medication, can have an 
influence on driving performance.  
• Always read the package leaflet (3 warning levels), pictogram. 
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• Ask your physician/pharmacists for additional information on impairing effects of a medicine 
• Awareness for clinical signs of impairment; signs to look out (e.g. blurred or double vision, 
difficulty concentrating or remaining alert, surprise at normal occurrences while driving, 
difficulty in remembering how the destination was reached, difficulty in driving straight, 
frequently driving in the wrong line or in the middle of the road…). 
• Medication and alcohol together can greatly increase adverse effects.  
• Take especially care during the first few days of the treatment, especially several hours after 
taking the medication. 
• Always follow the instructions of the physician/pharmacist on how to use the medicine: at the 
time and with the dosage indicated. 
• Never use medicines prescribed for others.  
• If you have to drive frequently, tell your physician. He/she will try to find the medication which 
interferes least with your fitness to drive. 
• Clear information about fitness to drive assessment and sanctions (certainty/celerity) of driving 
under the influence of medicines are required (D6.2, D1.4.1). 
 
• For more details see overview box 3.  
2 Drivers as patients 
2.1 Key elements of risk communication  
The aim of risk communication addressed to the patients is to (i) make the patient aware that the use 
of psychoactive medication is not always compatible with car driving, (ii) support them to make their 
own problem definition, according to personal beliefs, opportunities to use alternative transportation 
and expectations of risk, due to individual circumstances of disease and treatment, with or without the 
help of a healthcare professional, (iii) allow them to decide how to manage the risk in their daily life 
activities.  
 
For addressing risk communication messages to the drivers as patients, the following issues need to 
be considered: 
1. Factors that play a role in perceiving and accepting risk (see Part I. 3.2. Risk acceptability) For 
driving under the influence of psychoactive substances it seems obvious to address these 
factors carefully in defining messages of risk communication to the drivers as patients. A 
trusted organization, credible and with an eye on values and interests that people feel 
important can do a proper job in convincing them that, although DUI is a voluntary risk, it will 
not be completely controlled by the person due to the effects of psychoactive substances.   
2. Focus on messages that respect patient involvement in shared decision-making and 
information allowing the patient to decide on certainty about the best option. 
3. Groups with higher socioeconomic status are more likely to benefit from an increasing flow of 
information on many issues, including drugs and driving issues. However, there are many 
contributory factors that could reduce the knowledge gap. First of all a content domain related 
factor, people might feel that health issues are more relevant to them than other issues, also 
certain groups could experience a greater impact of information due to the channel that was 
chosen, and used more frequently by them (e.g. internet applications, newsgroups), and 
individual motivational factors. It is expected that users of ICT technologies will use the 
information “on demand”, allowing them to control the media technologies and attempts to 
change their behaviour. This, however, is also a risk for widening the knowledge gap, 
because access could be determined by socioeconomic status and necessary skills.    
4. The “power” of any single channel of communication (being mass media or interpersonal) may 
depend on the complexity of the behaviour change being sought. If the change is less 
complex, a single channel of communication may lead to development of the promoted 
behaviour. If, however, the behaviour change is more complex an individual will need the use 
of multiple sources of information and the application of multiple channels of communication. 
5. Informing the drivers as patients about issues that they can discuss with a trusted person, e.g. 
health care professional in the case of impairing medicines, implies that those trusted 
person’s need to be informed about the risk problems and possible solutions for solving 
these. It is crucial that information campaigns to the patients as drivers  should be preceeded 
by information activities towards the trusted parties. 
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2.2 Extraction of main DRUID results  
Problem situation 
 
Medicines 
• Prevalence: DRUID studies indicate that some selected psychoactive medicines 
(benzodiazepines, medicinal opiates and opioids and Z-drugs) are less prevalent in the driving 
population (estimated EU mean 1.4%) (D2.2.3) as well as is in seriously injured drivers 
(D2.2.5) compared to alcohol (estimated EU mean 3.48%) and illicit drugs (estimated EU 
mean 1.90%). Among the killed drivers the presence of benzodiazepines was the second 
most frequent toxicological finding after alcohol (D2.2.5). Psychoactive medicines, such as 
(frequently used) antidepressants, anti-epileptics and antipsychotics, were not included in the 
DRUID studies. Therefore an underestimation of prevalence should be considered. 
• In most countries benzodiazepines were the most common psychoactive medicines in traffic 
but as for illicit drugs the prevalence of the different psychoactive medicines show high 
national variability (D2.2.3, D2.2.5).  
• Epidemiological studies indicate a major increase in the consumption of antidepressants and 
drugs used in addictive disorders in the general population in Europe within the last years 
(D2.1.1).  
• Psychoactive medicines were in general mainly detected among older female drivers during 
daytime hours (D2.2.3).  
 
• Risk: Alcohol impaired driving is the main problem in traffic safety, but also psychoactive 
medicines can constitute a problem in traffic safety. Therefore, both health care providers and 
patients should be properly informed and aware of the potential risks associated with the use 
of psychoactive medicines (link WP4/7). 
• Based on case-control studies, the relative risk of serious injury or fatality for benzodiazepines 
+ Z-drugs and medicinal opioids is estimated to be about 2-10 times (medicinal opiods in the 
upper part of the interval; benzodiazepines + Z-drugs in the lower part of the interval) as high 
as that of drivers below the DRUID cut-off for any substance (D2.3.5). 
• The risk of being involved in an accident for medicine users compared to non-users is highest 
for users of modern antidepressants (1.76, CI: 1.38-2.24), followed by patients who use 
combinations of psychoactive medicines (1.55, CI: 1.20-2.02), and patients using at least one 
psychoactive medication (1.28, CI: 1.12-1.46) (D2.3.1).  
 
• For more details see overview box 3.  
 
Countermeasures 
 
General information 
• Patients need to be informed about the potential effect of their disease (fitness to drive) and 
their medication on driving performance.  
• Relevant therapeutic classes (DRUID classification system): alimentary tract and metabolism, 
blood and blood forming organs, cardiovascular system, dermatologicals, nervous system 
(anesthetics, analgesics, anti-epileptics, anti-parkinson drugs, psycholeptics, 
psychoanaleptics, other nervous system drugs), musculo-skeletal system, respiratory system 
(antihistamines for systemic use), sensory organs.   
• For patients receiving psychoactive medicines for chronic or long term treatment it is important 
to check their fitness to drive regarding the pathology (e.g. diabetes, epilepsy, or substitution 
treatments in addiction); for some pathologies a medical examination is required.  
• Patients need be informed about the possibility of criminal sanction in case of accident after 
being advised by physician not to drive: legal aspects. 
• Key actors to provide this information to the patient are prescribing physicians and dispensing 
pharmacists. 
• Patients should always check the risk information in the package insert (multi-level 
classification + risk communication pictogram is recommended). 
• Patients should be advised about the ways they can recognize signs of impaired driving 
performance (such as drowsiness, dizziness or sleepiness in particular during the first period 
of treatment (1-2 weeks), if these side effects occur the patient should not drive). 
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• Patients should be advised to report to their prescribing doctor or dispensing pharmacist on 
side effects during a follow up visit after the first 2 weeks of treatment. Based on the outcomes 
of the assessment, after this visit or any follow-up visit, driving might be possible taking into 
account some personalised advice (e.g. on adjusting lifestyle, not changing dosages, or take 
most of the daily dose at night).  
• Patients should be advised not to combine psychoactive medication with the use of alcohol or 
other medicines that might affect the central nervous system, because this may increase the 
impairing effect on the patient’s fitness to drive. 
• Clear information about fitness to drive assessment and sanctions (certainty/celerity) of driving 
under the influence of medicines is required. DRUID recommends that legal measures 
(withdrawal) should be taken only after an incident in traffic; impairment is the key indicator for 
sanctioning. A model of conditional licensing, based on the fitness to drive examination, is 
recommendable (D6.2, D1.4.1). 
 
Further information in case of addictive disorder  
• Alcohol and drug dependent drivers are, by EU legislation, not considered fit to drive (Directive 
91/439/EEC) (D5.1.1, D5.2.4). 
• Driver assessment prior to DR should be obligatory in case of suspicion of addiction in order 
to match offenders to appropriate treatment. The intensity of intervention should increase with 
the severity of the problem behaviour (D5.1.1, D5.2.4). 
• Within DR addicted DUI/DUID offenders should be at least separated from non-addicted 
offenders. If possible DUI and DUID offenders should not be mixed within these groups 
(D5.1.1, D5.2.4). 
• Information exchange between experts from DR interventions and addiction treatment should 
be encouraged (D5.1.1, D5.2.4).  
• Clear information about fitness to drive assessment and sanctions (certainty/celerity) of driving 
under the influence of medicines are required. DRUID recommends that: each patient in 
substitution therapy has to be assessed individually regarding fitness to drive; for patients in 
substitution treatment, a conditional licence, based on the fitness to drive examination, is 
recommendable combined with follow-up controls, above all abstinence of parallel 
consumption of other drugs (D6.2, D1.4.1). 
• Alcohol ignition interlock programmes can be an additional option for DUI offenders but they 
can not substitute treatment, as they are only effective as long as they are installed (D5.1.1, 
D5.2.4, D6.2). 
 
• For more details see overview box 5-8. 
3 Young drivers 
The DRUID consortium decided to put an extra emphasis on the risk communication with young 
drivers. Therefore, an extra task was dedicated to analyse in-depth the risk communication about 
impaired driving with young people (T7.4.3). Preliminary results of D7.4.3 show that the emphasis 
should be given to drink driving prevention, targeting the age group 15-24 year. Preventive measures 
should be differentiated into general preventive approaches (e.g. campaigns) and special focussed 
preventive measures for certain smaller subgroups (lifestyle types e.g. personal communication). The 
effectiveness of approaches should be analyzed in-depth based on representative samples (according 
results for e.g. DE will be available at the end of the DRUID project) (D7.4.3Draft). 
3.1 Key elements risk communication  
The aim of risk communication addressed to young drivers is to (i) make them aware that the use of 
psychoactive substances (including some medicines) is not always compatible with car driving, (ii) 
support them to make their own problem definition, according to personal beliefs, opportunities to use 
alternative transportation and expectations of risk, due to individual circumstances of substance use, 
with or without the help of a (healthcare) professional, (iii) allow them to decide how to manage the 
risk in their daily life activities.  
 
For addressing risk communication messages to the young drivers, the following issues need to be 
considered: 
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1. Factors that play a role in perceiving and accepting risk (see Part I. 3.2. Risk acceptability). 
For driving under the influence of psychoactive substances it seems obvious to address these 
factors carefully in defining messages of risk communication to young drivers. A trusted 
organization, credible and with an eye on values and interests that young people feel 
important can do a proper job in convincing them that, although DUI is a voluntary risk, it will 
not be completely controlled by the person due to the effects of psychoactive substances.   
2. Groups with higher socioeconomic status are more likely to benefit from an increasing flow of 
information on many issues, including drugs and driving issues. However, there are many 
contributory factors that could reduce the knowledge gap. First of all a content domain related 
factor, people might feel that health issues are more relevant to them than other issues, also 
certain groups could experience a greater impact of information due to the channel that was 
chosen, and used more frequently by them (e.g. internet applications, newsgroups), and 
individual motivational factors. It is expected that users of ICT technologies will use the 
information “on demand”, allowing them to control the media technologies and attempts to 
change their behaviour. This, however, is also a risk for widening the knowledge gap, 
because access could be determined by socioeconomic status and necessary skills.    
3. The “power” of any single channel of communication (being mass media or interpersonal) may 
depend on the complexity of the behaviour change being sought. If the change is less 
complex, a single channel of communication may lead to development of the promoted 
behaviour. If, however, the behaviour change is more complex an individual will need the use 
of multiple sources of information and the application of multiple channels of communication. 
3.2 Extraction of main DRUID results  
This chapter summarizes extracted DRUID information for and about the target group (young drivers) 
on general level, more in-depth information will be available within D7.4.3 at the end of the DRUID 
project). 
 
Alcohol 
• Prevalence: Alcohol (≥0.1g/L) is the most frequently detected psychoactive substance in the 
driving population (estimated EU mean 3.48%) (D2.2.3) as well as in the seriously injured 
(range 17.7-42.5%) and in killed drivers (range 19.0-44.9%) in Europe (D2.2.5; D2.2.4; 
D2.3.4).  
• Alcohol was in the general driving population mainly detected among older male drivers, with 
lower BAC levels (D2.2.3).  
• Within the accident involved drivers alcohol was mainly detected among younger male drivers 
with a high BAC level (D2.2.5). Alcohol appeared most often alone compared to other 
substances. When alcohol was combined with other psychoactive substances, 
benzodiazepines and cannabis (THC and/or THCCOOH) were the most common associated 
findings (D2.2.5; D2.3.4). 
 
• Risk: Alcohol has a negative impact on driving performance and highly increases accident risk 
(e.g. D1.1.2a, D2.3.2; D2.3.3; D2.3.4; D2.3.5 DRAFT).  
• Based on case- control studies, the relative risk of serious injury or fatality for alcohol (≥0.5 
g/L) is estimated to be significantly increased compared to that of drivers below the DRUID 
cut-off for any substance (D2.3.5). The risk increases dramatically with the alcohol 
concentration. 
• An increased risk was associated with high BAC level, young age and speed (D2.3.3). 
• The risk multiplies with combined use (e.g. cannabis) (D2.3.2). 
• The general finding is that alcohol use in traffic is already risky at low BAC levels, especially 
for younger drivers who have less driving experience than older drivers. Alcohol affects the 
driving behaviour by increasing the reaction time and decreasing concentration, coordination 
and tracking. Furthermore, alcohol leads to more risk-taking behaviour and affects decision 
making and planning, since drivers overestimate their skills and underestimate the risk due to 
the effects of alcohol (Kelly et al., 2004; Steyvers & Brookhuis, 1996) (D2.2.3). 
 
• Motives behind DUI: Drivers do not think that alcohol impairs their performance; Drivers 
whose drinking and driving was related to problems with alcohol argue that losing the licence 
or even to be imprisoned would not have helped them to stop re-offending; instead, it they 
argue that the treatment programme had helped them by providing a greater insight into their 
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own problems; factors influencing the decision to DUI/DUID: risk perceptions (e.g. beliefs in 
the objective danger/effect of the substance on driving ability, perceived chance to be involved 
in an accident / fear of injuring others, perceived chances to get caught / to lose DL), 
knowledge (effects of alcohol, safe alcohol consumption levels for driving), subjective 
norm/social norms and expectations/peer pressure (D2.2.1). 
 
• Clear information about sanctions (certainty/celerity) of DUI is required (D6.2, D1.4.1). 
• The important role of alcohol in social activities and the high susceptibility to peer pressure is 
specifically stressed among young persons. The combination of some specific young (novice) 
drivers’ constellations of lifestyle and drinking/drug taking habits with the lack of driving 
experience is considered to bring this group at higher risk for and when DUI/DUID. Schulze 
(1999) investigated the lifestyle of young drivers. He classified the data of his German sample 
(18 to 24 years) into five categories. Two types were of special interest: “Action type” – drivers 
who were found to consume alcohol several times a week, drinking high amounts and also 
consumed marihuana several times or regularly; and “Looking for a kick” type – drivers who 
drive less often, but have more frequent driving accidents as they often tend to violate norms 
and rules. This group had the highest percentage of marihuana consumers and highest 
amount of alcohol consumption of 18 to 24 years olds. Drug and alcohol re-offenders 
(recidivists) tend to be significantly younger at the first offence than those who do not re-
offend. Driver rehabilitation participation should be mandatory for high-risk offenders, repeat 
offenders and young (novice) – to grab the problem in an early stage – drivers (D5.1.1).  
• Lower BAC thresholds are current practice for young drivers in three countries (Germany, 
Luxemburg and Croatia) and for novice drivers in nine countries (Austria, Germany, Greece, 
Latvia, Lithuania , Luxembourg, the Netherlands, Slovenia and Spain). Furthermore, some 
countries have more severe sanctions for young drivers driving under the influence of alcohol 
(Germany, Bulgaria and Cyprus), illicit drugs (Bulgaria and Cyprus) and medicines (Cyprus). 
Novice drivers are often also young drivers, which mean that in countries with more severe 
sanctions for novice drivers, young drivers will also receive more severe sanctions (D6.1 p. 
23ff). 
 
• For more details see overview box 1.  
 
Illicit drugs 
• Prevalence: All DRUID investigations (e.g. D2.2.3, D2.2.5, D2.3.4) show that the prevalence 
of illicit drugs in the driver population (estimated EU mean 1.90%) is lower than the alcohol 
prevalence (estimated EU mean 3.48%) (D2.2.3).  
• Within the accident involved drivers, the majority of drugs appeared to be used in combination 
with other psychoactive substances (mainly alcohol) (D2.2.5). 
• THC is generally the most frequently detected illicit drug, followed by cocaine, but the 
prevalence of the different illicit substances show high national variability (e.g. D2.2.3, D2.2.5, 
D2.3.4). 
• Illicit drugs were in general mainly detected among young male drivers, during all times of the 
day but mainly at the weekend (D2.2.3).  
• Combined use of alcohol and drugs (illicit drugs and/or psychoactive medicine) is in general 
often prevalent among young (<35 years) male drivers during night time hours (D2.2.3).  
• Multiple drugs (illicit drugs and/or psychoactive medicines) use is in general most common in 
males (D2.2.3).  
• Age groups and time periods vary considerably by country (D2.2.3).  
 
• Risk: Based on case-control studies, the relative risk of serious injury or fatality for different 
illicit substances varies between the substances. For: THC about 1-3 times; benzoylecgonine, 
cocaine and illicit opiates about 2-10 times; amphetamines about 5-30 times as high as that of 
drivers below the DRUID cut-off for any substance (D2.3.5 DRAFT; see also D1.1.2b, D1.2.1, 
D2.3.2). Some of the risk estimates for illicit drugs vary to a high degree among the single 
countries; others are based on few positive cases and/or controls which result in very wide 
confidence intervals. Therefore the estimates are uncertain.  
• The risk multiplies with combined use (e.g. alcohol) (e.g. D2.3.2, D2.3.5).  
 
• Illicit drug effects: Experimental studies have shown that the dose equivalent for BAC 
0.5g/L-3.7ng/mL THC (range 3.1-4.5ng/mL) for oral administration and 3.8 ng/mL (range 3.3-
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4.5ng/mL) for smoked administration (D1.1.2b, see also D1.4.2 for more information on cut-
offs equivalent to BAC 0.5g/L). 
• Experimental studies evaluating the effect of stimulants on driving (MDMA and 
dexamphetamine) did not reveal impairing effects on driving performance. However, the 
stimulant effects of MDMA and dexamphetamine are not sufficient to overcome or 
compensate driving impairments produced by concomitant alcohol use (increased risk taking 
behaviour) or sleep deprivation (sleep deprivation generates same degree of impairing effects 
as under the influence of BAC 0.8g/L); Users of stimulating drugs need to be educated about 
this effect and its possible dangers. The pharmacological effects of stimulants and the effects 
of drug use setting (e.g. poly-drug use, concomitant alcohol use and sleep deprivation) are 
intertwined and significantly contribute to driver impairment (D1.1.2b, D1.2.1).  
 
• Motives behind DUID: Addicted drivers did not believe that they would be stopped by the 
police. They did not believe that alcohol or drugs would impair their driving and therefore they 
did not perceive any real risks of driving (D2.2.1). Findings indicate that especially moderate 
substance users can realistically judge their intoxication and are responsible-minded 
concerning drugs in traffic (D2.2.2). 
 
• Clear information about sanctions (certainty/celerity) of DUID is required (D6.2, D1.4.1).  
 
• For more details see overview box 2.  
4 Physicians and pharmacists 
4.1 Key elements risk communication  
The aim of risk communication addressed to physicians and pharmacists is to (i) make them aware 
that the use of psychoactive medication is sometimes not compatible with car driving, depending upon 
the patient’s treatment, lifestyle and disease conditions, provided that good information has been 
provided to the patient, (ii) support them to develop their own strategy of selecting the least impairing 
medicine (iii) allow them to decide how to guide the patient in the best way to manage the risk in their 
daily life activities.  
 
For addressing risk communication messages to physicians and pharmacists, the following issues 
need to be considered: 
1. A trusted organization, credible and with an eye on values and interests that physicians and 
pharmacists feel important, need to be involved in preparing risk communication messages to 
physicians and pharmacists.   
2. Physicians and pharmacists should be made aware that in patient information activities the 
focus needs to be on messages that respect patient involvement in shared decision-making 
and information allowing the patient to decide on certainty about the best option (not to drive x 
days after the start of treatment, or refrain from driving till medical conditions have been 
tested to be improved). 
3. Physicians and pharmacists should be informed that in giving risk communication messages 
to patients, certain groups could experience a greater impact of information due to the 
channel that was chosen, and used more frequently by them (e.g. internet applications, 
newsgroups), and individual motivational factors. It is expected that patients who use ICT 
frequently will use the information “on demand”, allowing them to control the media 
technologies and attempts to change their behaviour. Knowledge about the content of these 
sources is required in order to be prepared for discussions with their patients.  
4. Physicians and pharmacists should be aware that campaigns aiming at informing the general 
public about issues that they can discuss with a trusted person, e.g. health care professional 
in the case of impairing medicines, implies that those trusted persons need to be informed 
about the risk problems and possible solutions for solving these. It is crucial that physicians 
and pharmacists should be informed about these issues before public campaigns will be 
launched.   
5. Physicians and pharmacists should be supported by practical information on how to prescribe 
or dispense impairing medicines to their patients, presented in clear instructions during their 
daily work routines using ICT supported tools.  
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4.2 Extraction of main DRUID results  
Problem Situation 
 
Medicines 
• Prevalence: DRUID studies indicate that some selected psychoactive medicines 
(benzodiazepines, medicinal opiates and opioids and Z-drugs) are less prevalent in the driving 
population (estimated EU mean 1.4%) (D2.2.3) as well as is in seriously injured drivers 
(D2.2.5) compared to alcohol (estimated EU mean 3.48%) and illicit drugs (estimated EU 
mean 1.90%). Among the killed drivers the presence of benzodiazepines was the second 
most frequent toxicological finding after alcohol (D2.2.5). Psychoactive medicines, such as 
(frequently used) antidepressants, anti-epileptics and antipsychotics, were not included in the 
DRUID studies. Therefore an underestimation of prevalence should be considered. 
• In most countries benzodiazepines were the most common psychoactive medicines in traffic 
but as for illicit drugs the prevalence of the different psychoactive medicines show high 
national variability (D2.2.3, D2.2.5).  
• Epidemiological studies indicate a major increase in the consumption of antidepressants and 
drugs used in addictive disorders in the general population in Europe within the last years 
(D2.1.1).  
• Psychoactive medicines were in general mainly detected among older female drivers during 
daytime hours (D2.2.3).  
 
• Risk: Alcohol impaired driving is the main problem in traffic safety, but also psychoactive 
medicines can constitute a problem in traffic safety. Therefore, both health care providers and 
patients should be properly informed and aware of the potential risks associated with the use 
of psychoactive medicines (link WP4/7). 
• Based on case-control studies, the relative risk of serious injury or fatality for benzodiazepines 
+ Z-drugs and medicinal opioids is estimated to be about 2-10 times (medicinal opiods in the 
upper part of the interval; benzodiazepines + Z-drugs in the lower part of the interval) as high 
as that of drivers below the DRUID cut-off for any substance (D2.3.5). 
• The risk of being involved in an accident for medicine users compared to non-users is highest 
for users of modern antidepressants (1.76, CI: 1.38-2.24), followed by patients who use 
combinations of psychoactive medicines (1.55, CI: 1.20-2.02), and patients using at least one 
psychoactive medication (1.28, CI: 1.12-1.46) (D2.3.1).  
 
• For more details see overview box 3.  
 
Countermeasures 
 
General information 
• Patients need to be informed about the potential effect of their disease and their medication on 
driving performance (for more information see also information provided for patients in D7.3.2 
Part II chapter 2.2).  
• Key actors to provide this information to the patient are prescribing physicians and dispensing 
pharmacists.  
• Physicians/pharmacists need to be informed about their responsibilities and possible penal 
proceedings in the event of accidents occurring after a positive decision from their side that 
driving is possible in a responsible manner.  
Information about counselling the patient-driver regarding medication and driving  
• Guidelines for prescribing and dispensing medicines: decision supporting tools to select the 
least impairing medicines at the start of a treatment; emphasis on shared decision making 
(health care professional together with the patient) and documentation of patient consultation 
(to avoid liability issues); checklist with issues for documenting the decision-making process to 
avoid liability issues (D7.4.1 p. 28): (1) Actions to be checked during the consultation: advise 
not to combine psychoactive medication; check whether the patient is willing and able to follow 
the treatment plan; advise the patient to be aware of possible side-effects; advise the patient 
to report on these side-effects during a follow up visit (2) Documentation of the following items: 
tests done and / or information gathered in assessing fitness to drive; assessment of patient’s 
decision-making competence based on advices given; patient’s understanding of impairing 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
119 
properties of the medication; specific actions to achieve fitness to drive (changes in 
medication or instructions for use); follow up visit for evaluation of interventions (advices 
given, self-assessment of patient); protocols and guidelines should be integrated in existing 
computer software used by health care professionals in daily practice). DRUID developed 
such supporting tools which have been evaluated in BE, ES and NL. Preliminary evaluation 
results based on the consolidated database of the three countries indicate a positive effect of 
the DRUID guidelines: After training on and implementation of the DRUID dispensing 
guidelines, pharmacists had significant positive changes in reported behaviour (increased 
consideration in informing patients about medicines’ impairing effects regarding driving), 
attitudes and awareness about medicines’ dispensing and driving and actual knowledge about 
categories of medicines and their effect on driving behaviour. With regard to physicians, 
significant differences (in the expected direction) were observed between the control and 
intervention groups for attitudes and reported behaviour after the training and implementation 
phase of the DRUID prescribing guidelines. Overall, health care professionals are very 
satisfied with and strongly prefer ICT supporting tools which are integrated in their 
dispensing/prescribing tools over other supporting tools (D7.4.2Draft). 
• DRUID WP4 proposed four level classification and a labelling system regarding the influence 
of medicines on driving performance, from category 0 (no or negligible influence on fitness to 
drive) to category 3 (major influence on fitness to drive).  The DRUID WP4 categorization was 
in line with the recent approved SmPC guidelines adopted in September 2009 (which applies 
as from 1st of May 2010) by EMA (D4.3.1, D4.4.1).  
• Medicines in the relevant therapeutic groups that are currently on the market have been 
categorized according to the DRUID classification system (ATC groups: A, B, C, D, N01-N07, 
M01-M03, R01-R06, S) (D4.3.1, D4.4.1). 
• Most of them were Category 0: 50.3%, while 5.8% were Category III (Major influence in fitness 
to drive). DRUID results are compatible with any existing national classification system (e.g. 
FR, ES) and could be integrated in them (D4.3.1, D4.4.1). 
• Detailed Fact Sheets were elaborated for the N01-N07 (nervous system) and R06 (respiratory 
system) therapeutic groups of medicines, including information on possible side-effects related 
to driving, reference studies on psychomotor performance and risk studies, the proposed 
DRUID categorization level, and relevant information for the patient (D4.3.1, D4.4.1). 
• Risk communication pictogram (rating model, bar form): Evaluation studies in ES and NL have 
indicated that the use of pictograms on medicine boxes for risk communication to patients is 
effective in explaining a risk of impairment level after using a driving impairing medicine. 
Patients’ likelihood to drive less frequently under the influence of a medicine is higher if the 
pictogram shows reference to all possible risk levels, and identifies the selected risk level from 
a rating bar model as compared to a single triangle model without explanation of possible risk 
levels. Younger patients (more in favour) and older patients (less in favour) differ in their 
preference for more complex presentations of risk of impairment levels in a pictogram. 
Fitness to drive assessment and licensing withdrawal 
• Clear information about fitness to drive assessment and sanctions (certainty/celerity) of driving 
under the influence of medicines are required (D6.2, D1.4.1).  
• DRUID recommends that legal measures (withdrawal) should be taken only after an incident 
in traffic; impairment is the key indicator for sanctioning. A model of conditional licensing, 
based on the fitness to drive examination, is recommendable (D6.2).  
• Each patient in substitution therapy has to be assessed individually regarding fitness to drive. 
A conditional licence, based on the fitness to drive examination, is recommendable combined 
with follow-up controls, above all focussing on abstinence of parallel consumption of other 
drugs. 
• DRUID recommendations for patients in long-term treatment with psychoactive medicines: 
Legal measures should be taken only after an incident in traffic; impairment is the key 
indicator for sanctioning. A model of conditional licensing, based on the fitness to drive 
examination, is recommendable. 
Further information in case of addictive disorder 
• Alcohol and drug dependent drivers are, by EU legislation, not considered fit to drive (Directive 
91/439/EEC) (D5.1.1, D5.2.4). 
• Driver assessment prior to DR should be obligatory in case of suspicion of addiction in order 
to match offenders to appropriate treatment. The intensity of intervention should increase with 
the severity of the problem behaviour (D5.1.1, D5.2.4). 
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• Within DR addicted DUI/DUID offenders should be at least separated from non-addicted 
offenders. If possible DUI and DUID offenders should not be mixed within these groups 
(D5.1.1, D5.2.4). 
• Information exchange between experts from DR interventions and addiction treatment should 
be encouraged (D5.1.1, D5.2.4).  
• Alcohol ignition interlock programmes can be an additional option for DUI offenders but they 
can not substitute treatment, as they are only effective as long as they are installed (D5.1.1, 
D5.2.4, D6.2). 
 
• For more details see overview box 5-8. 
5 Policy makers at EU level  
5.1 Key elements risk communication 
The aim of risk communication addressed to European policy makers is to (i) make them aware that 
the use of psychoactive substances (including some medicines) is not always compatible with car 
driving, (ii) support them to make their own problem definition, according to personal beliefs and 
professional responsibilities within the European context, (iii) provide them opportunities to use risk 
management tools (such as the risk management framework) in discussing risk control with relevant 
European stakeholders, (iii) allow them to decide how to contribute to the management of the risk in 
European society.  
 
For addressing risk communication messages to policy makers on an EU level, the following issues 
need to be considered: 
3. Policy makers need to be addressed with information on risk communication using the risk 
management framework (see table 1, p. 17). This will allow them to understand that DRUID 
outcomes describing the risk of driving under the influence of alcohol, illicit drugs or psychoactive 
medicines, can serve the purpose of discussing EU policy measures, e.g. EU risk control 
measures. 
4. European stakeholders need to be involved in the development of a risk management framework 
for risk communication aiming at European bodies, such as: 
• Directorate General for Health and Consumer Affairs of the EC (DG SANCO); 
• Directorate-General for Mobility and Transport of the EC (DG MOVE); 
• Trans-European Transport Network Executive Agency of the EC (TEN-T EA); 
• European Transport Safety Council (ETSC); 
• European Parliament; 
• European Commission; 
• European Medicines Agency (EMA); 
• European professional organisation of pharmacists. physicians, psychologists and other 
health professionals; 
• International Alliance of Patients’ Organisations (IAPO); 
• European Association of Pharmaceutical Manufacturers; 
• other bodies… 
5.2 Extraction of main DRUID results 
Alcohol is the most serious problem compared to illicit drugs and psychoactive medicines in traffic in 
all investigated EU Member States (e.g. prevalence, risk estimates and cost-benefit-analysis of 
enforcement measures). Consequently, the first priority of countermeasures should always lie on 
alcohol; other psychoactive substances are second priority.  
 
The results of the DRUID studies in regard to the problem situation can generally be used in selecting 
overall activities and target groups in the policy field of psychoactive substance use in traffic across 
Europe. However, the results indicate, that the prevalence of psychoactive substances by gender, age 
and time period varies largely per country. “Therefore, recommendations for national activities 
regarding, e.g., policy issues, enforcement, education or campaigns, should primarily be based on the 
results of the country reports, rather than on the general report” (D2.2.3 PART I p. 10). 
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Problem Situation (WP1/2) 
 
Alcohol  
• Alcohol (≥0.1g/L) is the most frequently detected psychoactive substance in the driving 
population (estimated EU mean 3.48%) (D2.2.3) as well as in the seriously injured (range 
17.7-42.5%) and in killed drivers (range 19.0-44.9%) in Europe (D2.2.5; D2.2.4; D2.3.4).  
• Alcohol was in the general driving population mainly detected among older male drivers, with 
lower BAC levels (D2.2.3).  
• Within the accident involved drivers alcohol was mainly detected among younger male drivers 
with a high BAC level (D2.2.5). 
• Alcohol has a negative impact on driving performance and highly increases accident risk (e.g. 
D1.1.2a, D2.3.2; D2.3.3; D2.3.4; D2.3.5 DRAFT).  
• Based on case- control studies, the relative risk of serious injury or fatality for alcohol (≥0.5 
g/L) is estimated to be significantly increased compared to that of drivers below the DRUID 
cut-off for any substance (D2.3.5) The risk increases dramatically with the alcohol 
concentration. 
• An increased risk was associated with high BAC level, young age and speed (D2.3.3). 
• The risk multiplies with combined use (e.g. cannabis) (D2.3.2). 
• For more details see overview box 1.  
 
Illicit drugs 
• All DRUID investigations (e.g. D2.2.3, D2.2.5, D2.3.4) show that the prevalence of illicit drugs 
in the driver population (estimated EU mean 1.90%) is lower than the alcohol prevalence 
(estimated EU mean 3.48%) (D2.2.3).  
• Within the accident involved drivers, the majority of drugs appeared to be used in combination 
with other psychoactive substances (mainly alcohol) (D2.2.5). 
• THC is generally the most frequently detected illicit drug, followed by cocaine, but the 
prevalence of the different illicit substances show high national variability (e.g. D2.2.3, D2.2.5, 
D2.3.4). 
• Illicit drugs were in general mainly detected among young male drivers, during all times of the 
day but mainly at the weekend (D2.2.3).  
• Combined use of alcohol and drugs (illicit drugs and/or psychoactive medicine) is in general 
often prevalent among young (<35 years) male drivers during night time hours (D2.2.3).  
• Multiple drugs (illicit drugs and/or psychoactive medicines) use is in general most common in 
males (D2.2.3).  
• Age groups and time periods vary considerably by country (D2.2.3).  
• Based on case-control studies, the relative risk of serious injury or fatality for different illicit 
substances varies between the substances. For: THC about 1-3 times; benzoylecgonine, 
cocaine and illicit opiates about 2-10 times; amphetamines about 5-30 times as high as that of 
drivers below the DRUID cut-off for any substance (D2.3.5 DRAFT; see also D1.1.2b, D1.2.1, 
D2.3.2). Some of the risk estimates for illicit drugs vary to a high degree among the single 
countries; others are based on few positive cases and/or controls which result in very wide 
confidence intervals. Therefore the estimates are uncertain.  
• Experimental studies have shown that the dose equivalent for BAC 0.5g/L-3.7ng/mL THC 
(range 3.1-4.5ng/mL) for oral administration and 3.8 ng/mL (range 3.3-4.5ng/mL) for smoked 
administration (D1.1.2b, see also D1.4.2 for more information on cut-offs equivalent to BAC 
0.5g/L). 
• The risk multiplies with combined use (e.g. alcohol) (e.g. D2.3.2, D2.3.5).  
• Experimental studies evaluating the effect of stimulants on driving (MDMA and 
dexamphetamine) did not reveal impairing effects on driving performance. However, the 
stimulant effects of MDMA and dexamphetamine are not sufficient to overcome or 
compensate driving impairments produced by concomitant of alcohol use or sleep deprivation 
(D1.1.2b, D1.2.1).  
• For more details see overview box 2.  
 
Medicines 
• DRUID studies indicate that some selected psychoactive medicines (benzodiazepines, 
medicinal opiates and opioids and Z-drugs) are less prevalent in the driving population 
(estimated EU mean 1.4%) (D2.2.3) as well as is in seriously injured drivers (D2.2.5) 
compared to alcohol (estimated EU mean 3.48%) and illicit drugs (estimated EU mean 
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1.90%). Among the killed drivers the presence of benzodiazepines was the second most 
frequent toxicological finding after alcohol (D2.2.5). Psychoactive medicines, such as 
(frequently used) antidepressants, anti-epileptics and antipsychotics, were not included in the 
DRUID studies. Therefore an underestimation of prevalence should be considered. 
• In most countries benzodiazepines were the most common psychoactive medicines in traffic 
but as for illicit drugs the prevalence of the different psychoactive medicines show high 
national variability (D2.2.3, D2.2.5).  
• Epidemiological studies indicate a major increase in the consumption of antidepressants and 
drugs used in addictive disorders in the general population in Europe within the last years 
(D2.1.1).  
• Psychoactive medicines were in general mainly detected among older female drivers during 
daytime hours (D2.2.3).  
• Alcohol impaired driving is the main problem in traffic safety, but also psychoactive medicines 
can constitute a problem in traffic safety. Therefore, both health care providers and patients 
should be properly informed and aware of the potential risks associated with the use of 
psychoactive medicines (link WP4/7). 
• Based on case-control studies, the relative risk of serious injury or fatality for benzodiazepines 
+ Z-drugs and medicinal opioids is estimated to be about 2-10 times (medicinal opiods in the 
upper part of the interval; benzodiazepines + Z-drugs in the lower part of the interval) as high 
as that of drivers below the DRUID cut-off for any substance (D2.3.5). 
• The risk of being involved in an accident for medicine users compared to non-users is highest 
for users of modern antidepressants (1.76, CI: 1.38-2.24), followed by patients who use 
combinations of psychoactive medicines (1.55, CI: 1.20-2.02), and patients using at least one 
psychoactive medication (1.28, CI: 1.12-1.46) (D2.3.1).  
• For more details see overview box 3.  
 
Countermeasures (WP3-7) 
 
Countermeasures always have to be seen as a comprehensive countermeasure system. 
 
Enforcement (WP3) 
• DRUID provides guidelines for everyday policy enforcement and installs scientific demands for 
on-side drug screening (e.g. legal frame; basic standards of on-site screening procedure; 
basic standards for on-site screening detection devices).  
• Cost benefit analyses have shown that first enforcement priority should lie on alcohol; other 
psychoactive substances are second priority. 
• For more details see overview box 4. Furthermore, a detailed evaluation of legal 
countermeasures from the perspective of criminology can be found in D1.4.1  
 
Classification (of diving impairing medicines) (WP4) 
• DRUID WP4 proposed four level classification and a labelling system regarding the influence 
of medicines on driving performance, from category 0 (no or negligible influence on fitness to 
drive) to category 3 (major influence on fitness to drive). The DRUID WP4 categorization was 
in line with the recent approved SmPC guidelines adopted in September 2009 (which applies 
as from 1st of May 2010) by EMA.  
• DRUID WP4 reviewed over 3000 medicines and over 1500 of them were categorized in 
regard to their influence on fitness to drive: Most of them were Category 0: 50.7%, while 6% 
were Category III (Major influence in fitness to drive). DRUID results are compatible with any 
existing national classification system (e.g. FR, ES) and could be integrated in them. 
• Politicians should promote that the DRUID WP4 categorization and labelling be integrated in 
existing computerized prescribing and dispensing systems for physicians/pharmacists at the 
various EU member states. 
• There is a need to improve information related to effects on driving, particularly in the Patient 
Information Leaflet (PIL). Information to patients who are advised to use medicines that may 
impair driving fitness needs to be improved by simple and patient-centred directions based on 
a clear categorisation system and reflected in the PIL.  
• For more details see overview box 5.   
 
Rehabilitation (WP5) 
• It should be stated on EU level that Driver Rehabilitation should be an integrated part of a 
comprehensive countermeasure system.  
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• Main outlines of rehabilitation procedures should be formulated on EU level (guidelines for 
legal regulations and standardised procedure). DRUID WP5 developed Europe-wide 
standards and recommendations of good practice for DUI/DUID rehabilitation measures, 
which were couched into the form of a user friendly tool (Development of Driver Rehabilitation 
Evaluation Tool, DRET) for implementation, assessment or evaluation of existing or new DR 
systems or programmes. It can be the starting point of a European networking and 
documentation process of DR measures.  
• For more details see overview box 6. 
 
Withdrawal (of driving license) (WP6) 
• Regulations in European countries regarding withdrawal and accompanying measures should 
be unified. So far, national strategies are very heterogeneous. Hence a clustering of strategies 
or countries is difficult.  
• DRUID WP6 developed Europe-wide recommendations on withdrawal and conditional 
withdrawal for the general driving population and specific problem groups such as DUI/DUID 
drivers, patients in substitution or other long-term treatment with psychoactive medicines (see 
also D1.4.1). 
• For more details see overview box 7.  
 
Guidelines for health care professionals (WP7) 
• Decision support at the start of a treatment is needed for selecting the least impairing 
medicines. Therefore, guidelines and standards for health care professionals pertaining to 
medicines and driving could be initiated on EU level (D7.2.1).  
• Eight recommendations on improving the procedures for assessing fitness to drive within the 
framework of Council Directive 91/439/EEC (on driving licences) have been formulated within 
DRUID WP7. These suggestions should be discussed in working groups/expert rounds with 
physicians, pharmacists, driving licensing authorities and policy makers in order to reach a 
consensus at European level (D7.2.1). 
• The implementation of existing protocols and guidelines into existing computer software used 
by health care professionals could be stimulated by e.g. incentives for organisations for 
maintaining databases and software companies.  
• For more details see overview box 8. 
 
Risk communication (WP7) 
• The focus of campaigns (content, target group, media etc.) should be selected according to 
the specific characteristic of problem situation and risk group (D7.1.1, D7.3.1). 
• Campaigns are more successful if they are targeted (specific issues, groups, etc.). Therefore, 
large campaigns should be designed as sets of a larger number of activities on a smaller scale 
(D7.1.1, D7.3.1). 
• Campaigns should be evaluated (D7.1.1, D7.3.1). The EU project CAST provides guidelines in 
designing and evaluating campaigns (D7.1.1; D7.3.1). 
• Risk communication pictograms on medicine boxes are effective in communicating risk to the 
patient (rating models are preferred over no rating indications) (study: ES NL) (D7.3.2).  
• Prescribing and dispensing guidelines show a positive effect (e.g. reported behaviour, attitude) 
after training and implementation phase (study: BE, ES, NL). Health care professionals 
strongly prefer ICT supporting tools which are integrated in their daily dispensing/prescribing 
software packages (D7.4.2).  
• The emphasis of risk communication towards young people should be given to drink driving 
prevention, targeting the age group 15-24 year. Preventive measures should be differentiated 
into general preventive approaches (e.g. campaigns) and special focussed preventive 
measures for certain smaller subgroups (lifestyle types e.g. personal communication). The 
effectiveness of approaches should be analyzed in-depth based on representative samples 
(according results for e.g. DE will be available at the end of the DRUID project) (D7.4.3Draft).  
• For more details see overview box 8.  
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6 Policy makers at national level  
6.1 Key elements risk communication 
The aim of risk communication addressed to national policy makers to (i) make them aware that the 
use of psychoactive substances (including some medicines) is not always compatible with car driving, 
(ii) support them to make their own problem definition, according to personal beliefs and professional 
responsibilities within the national context, (iii) provide them opportunities to use risk management 
tools (such as the risk management framework) in discussing risk control with relevant national 
stakeholders, (iii) allow them to decide how to contribute to the management of the risk in their own 
society.  
 
For addressing risk communication messages to policy makers on a national level, the following 
issues need to be considered: 
1. National policy makers need to be addressed with information on risk communication using 
the risk management framework (see also table 1, p.17). This will allow them to understand 
that DRUID outcomes describing the risk of driving under the influence of alcohol, illicit drugs 
or psychoactive medicines, can serve the purpose of discussing national policy measures, e.g. 
national risk control measures. 
2. National stakeholders need to be involved in the development of a risk management 
framework for risk communication aiming at national bodies, such as: 
• Ministry of (Public) Health; 
• Ministry of Transport; 
• National Medicines Agency; 
• National professional organisation of pharmacists. physicians, psychologists 
and other health professionals; 
• National Alliance of Patients’ Organisations; 
• National Association of Pharmaceutical Manufacturers; 
• National Association Traffic Safety Institutes; 
• other bodies… 
6.2 Extraction of main DRUID results 
Problem Situation (national level) 
 
• Alcohol is also on national level the most frequent problem compared to illicit drugs and 
medicines in traffic in all EU Member States (prevalence, risk estimates, CBA enforcement) 
(e.g. D2.2.3; D2.2.4; D2.2.5). Consequently, the main focus of countermeasures should lie on 
alcohol followed by illicit drugs and medicines.  
• Recommendations for national activities regarding, e.g. enforcement, education or campaigns, 
should primarily be based on country specific characteristics of the problem situation (not on 
EU means) (see country specific reports e.g. D2.2.3, D2.2.5).  
• For more details see overview box 1-3. 
 
Countermeasures (national level) 
 
In general countermeasures always have to be seen as comprehensive countermeasure system. 
 
Enforcement (WP3) 
• Characteristics of the problem situation on national level determine the focus (and devices) of 
drug enforcement.  
• Increase of drug enforcement is potentially cost-beneficial, especially for countries that 
currently have a low enforcement level. It will NOT be beneficial if this increase is financed at 
the cost of drink-driving enforcement. 
• DRUID provides guidelines for everyday policy enforcement and installs scientific demands 
(e.g. legal frame; basic standards of on-site screening procedure; basic standards for on-site 
screening detection devices).  
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• “National roadside surveys on the prevalence of substance use in traffic on a regular, say, 
annual or bi-annual base would be a helpful tool to monitor the trend of drink and drug driving” 
(D2.2.3 PART I p. 10).  
• For more details see overview box 4, D1.4.1 and D1.4.2. 
 
Classification (of diving impairing medicines) (WP4) 
• National specific risk communication strategies would help to implement a Europe-wide 
classification and labelling system regarding the influence of medicines on driving 
performance (including the suggested common pictogram (rating model, bar form)). 
• For more details see overview box 5.  
 
Rehabilitation (WP5) 
• The quality standards of DR rehabilitation which should be defined on EU level should be 
controlled by a (national) quality management body which has an independent, authoritative 
position to execute the operative quality management tasks in driver rehabilitation.  
• Applied programmes should to be evaluated on a regular basis regarding their effectiveness 
for traffic safety 
• DRUID WP5 developed Europe-wide standards and recommendations of good practice for 
DUI/DUID rehabilitation measures, which were couched into the form of a user friendly tool 
(Development of Driver Rehabilitation Evaluation Tool, DRET) for implementation, 
assessment or evaluation of existing or new DR systems or programmes. It can be the starting 
point of a European networking and documentation process of DR measures. 
• For more details see overview box 6.  
 
Withdrawal (of driving licence) (WP6) 
• Regulations in European countries regarding withdrawal and accompanying measures should 
be unified. So far, national strategies are very heterogeneous. Hence a clustering of strategies 
or countries is difficult. 
• DRUID WP6 developed Europe-wide recommendations on withdrawal and conditional 
withdrawal for the general driving population and specific problem groups such as DUI/DUID 
drivers, patients in substitution or other long-term treatment with psychoactive medicines (see 
also D1.4.1).  
• For more details see overview box 7, D1.4.1 and D1.4.2. .  
 
Guidelines for health care professionals (WP7) 
• The implementation of existing protocols and guidelines into existing computer software used 
by health care professionals could be stimulated by e.g. incentives for software companies.  
• For more details see overview box 8.  
 
Risk communication (WP7) 
• The focus of campaigns (content, target group, media etc.) should be selected according to 
the specific characteristic of problem situation and risk group (D7.1.1, D7.3.1). 
• Campaigns are more successful if they are targeted (specific issues, groups, etc.). Therefore, 
large campaigns should be designed as sets of a larger number of activities on a smaller scale 
(D7.1.1, D7.3.1). 
• Campaigns should be evaluated (D7.1.1, D7.3.1). The EU project CAST provides guidelines in 
designing and evaluation campaigns (D7.1.1; D7.3.1). 
• For more details see overview box 8.  
 
More detailed information on legal countermeasures for the policy makers on national level can be 
found in D1.4.1 which recommends different sanctions for different target groups, D1.4.2 which 
discusses how to implement sanctions in regard to per se legislation (e.g. definitions of cut-offs) and 
D1.3.1 which derives risk estimates based on the results of WP1/2.  
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the effects of alcohol on safe driving. DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 1.1.2a 
D1.1.2b: G. Berghaus G., Sticht G., Grellner W., Lenz D., Naumann Th., Wiesenmüller S. (2010): 
Meta-analysis of empirical studies concerning the effects of medicines and illegal drugs 
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including pharmacokinetics on safe driving. DRUID (Driving under the Influence of Drugs, 
Alcohol and Medicines). 6th Framework programme. Deliverable 1.1.2b 
D1.1.2c: Strand M.C., Fjeld B., Arnestad M., Mørland J. (2011): Psychomotor relevant performance: 1. 
After single dose administration of opioids, narcoanalgesics and hallucinogens to drug naïve 
subjects 2. In patients treated chronically with morphine or methadone / buprenorphine. DRUID 
(Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. 
Deliverable 1.1.2c 
D1.2.1: Ramaekers J. (2011): The influence of stimulant drugs on actual and simulated driving. 
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework 
programme. Deliverable 1.2.1 
D1.3.1: (will be available at the end of the DRUID project. Okt. 2011): Concentration- impairment 
functions for the most relevant psychoactive substances based on experimental and 
epidemiological research. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 
6th Framework programme. Deliverable 1.3.1 
D1.4.1: Krismann M., Schöch H., Knoche A., Volker Hargutt V., Klipp S.(2011): Evaluation of legal 
measures to combat DUI / DUID. DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 1.4.1 
D1.4.2: (will be available at the end of the DRUID project. Okt. 2011): Per se limits - Methods of 
defining cut-off values for zero tolerance. DRUID (Driving under the Influence of Drugs, Alcohol 
and Medicines). 6th Framework programme. Deliverable 1.4.2 
D2.1.1: Ravera S., De Gier J.J. (2008): Prevalence of Psychoactive Substances in the General 
Population. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th 
Framework programme. Deliverable 2.1.1 
D2.2.1: Forward S. (2010): Motives behind risky driving – driving under the influence of alcohol and 
drugs. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework 
programme. Deliverable 2.2.1 
D2.2.2:  Walter M., Hargutt V., Krüger H-P. (2011): Prevalence of psychoactive substances and 
consumption patterns in traffic, based on a smartphone survey in Germany. DRUID (Driving 
under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 
2.2.2 
D2.2.3, Part I: Houwing S., Hagenzieker M., Mathijssen R., Bernhoft I. M., Hels T., Janstrup K. Van 
der Linden T., Legrand S.-A., Verstraete A. (2011): Prevalence of alcohol and other 
psychoactive substances in drivers in general traffic Part I: General results. DRUID (Driving 
under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 
2.2.3 Part I 
D2.2.3, Part II: Houwing S., Hagenzieker M., Mathijssen R., Bernhoft I. M., Hels T., Janstrup K. Van 
der Linden T., Legrand S.-A., Verstraete A. (2011) : Prevalence of alcohol and other 
psychoactive substances in drivers in general traffic Part II: Country reports. Review version. 
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework 
programme. Deliverable 2.2.3 Part II 
D2.2.4: Amoros E., Gadegbeku B. and the SAM Group (2010): Prevalence study: Main illicit 
psychoactive substances among all drivers involved in fatal road crashes in France. DRUID 
(Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. 
Deliverable 2.2.4 
D2.2.5: Isalberti C., Van der Linden T., Legrand S.-A., Verstraete A., Bernhoft I., Hels T., Olesen M., 
Houwing S., Houtenbos M., Mathijssen R.,(2011): Prevalence of alcohol and other psychoactive 
substances in injured and killed drivers. DRUID (Driving under the Influence of Drugs, Alcohol 
and Medicines). 6th Framework programme. Deliverable 2.2.5 
D2.3.1: Ravera S., de Gier J.J. (2010): Relative accident risk of patients using psychotropic medicines 
in the Netherlands: A pharmacoepidemiological study. DRUID (Driving under the Influence of 
Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 2.3.1 
D2.3.2: Gadegbeku B., Emmanuelle Amoros E. and the SAM group (2010): Relative risk estimates for 
alcohol and other psychoactive substances impaired drivers in fatal accidents, based on the 
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responsibility approach in France. DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 2.3.2 
D2.3.3: Laapotti S., Keskinen E. (2009): Relative risk of impaired drivers who were killed in motor 
vehicle accidents in Finland. DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 2.3.3 
D2.3.4: Thorsteinsdóttir K., Mühlhäußer J., Paul L., Lottner S., Schick S., Hell W. (2006): 
Responsibility study: Psychoactive substances among killed drivers in Germany, Lithuania, 
Hungary and Slovakia. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 
6th Framework programme. Deliverable 2.3.4 
D2.3.5 (DRAFT): Hels, T., Bernhoft I. M., Lyckegaard, A., Houwing S., Hagenzieker M., Legrand S.-A., 
Isalberti, C., Van der Linden T., Verstraete A. (2011): Risk of injury by diving with alcohol and 
other drugs. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th 
Framework programme. Deliverable 2.3.5 
D3.1.1: Cor K. (2009): Evaluation of oral fluid Screening devices by TISPOL to Harmonise European 
police Requirements (ESTHER). DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 3.1.1 
D3.2.1: Blencowe T., Lillsunde P. (2009): Protocol of “workshop on drug driving detection by means of 
oral fluid screening. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th 
Framework programme. Deliverable 3.2.1 
D3.2.2: Blencowe T., Anna Pehrsson A., Lillsunde P. (2010): Analytical evaluation of oral fluid 
screening deivces and preceding selection procedures. DRUID (Driving under the Influence of 
Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 3.2.2 
D3.3.1: Veisten K., Houwing S., Mathijssen R.(2010): Cost-benefit analysis of drug driving 
enforcement by the police. DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 3.3.1  
D4.1.1: Pil K., Raes E., Van den Neste T., Goessaert A., Veramme J., Verstraete A. (2008): Review of 
existing classification efforts. DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 4.1.1 
D4.2.1: De Gier J.J., S. Ravera S., Monteiro S.P., Álvarez F.J. (2011): Establishment of criteria for a 
European categorisation system for medicinal drugs and driving. DRUID (Driving under the 
Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 4.2.1 
D4.3.1: Gómez-Talegón T., Fierro I., M. Del Río C., Álvarez F.J. (2011): Establishment of framework 
for classification/categorisation and labelling of medicinal drugs and driving. DRUID (Driving 
under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 
4.3.1 
D4.4.1: Álvarez F.J. (2011): Classification of medicinal drugs and driving: a synthesis report. DRUID 
(Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. 
Deliverable 4.4.1 
D5.1.1: Boets, S., Meesmann, U., Klipp, S., Bukasa, B., Braun, E., Panosch, E., Wenninger, U., 
Roesner, S., Kraus, L. & Assailly, J-P. (2008). State of the Art on Driver Rehabilitation: Literature 
Analysis & Provider Survey. DRUID (Driving under the Influence of Drugs, Alcohol and 
Medicines). 6th Framework programme. Deliverable 5.1.1  
D5.2.1: Bukasa B., Klipp S., Braun E., Panosch E., Wenninger U., Boets S., Meesmann U., Ponocny-
Seliger E., Assailly J-P. (2008): Good practice : in-depth analysis of recidivism reasons & 
analysis of change process and components in driver rehabilitation courses. DRUID (Driving 
under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 
5.2.1 
D5.2.2: Bukasa B., Braun E., Wenninger U., Panosch E., Klipp S., Escrihuela-Branz M., Boets S., 
Meesmann U., Roesner S., Kraus L., Gaitanidou L., Assailly J-P. (2008): Development of an 
integrated evaluation instrument for driver rehabilitation measures. DRUID (Driving under the 
Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 5.2.2 
D5.2.3: Klipp S., Escrihuela-Branz M., Boets S., Meesmann U., Roesner S., Kraus L., Panosch E., 
Bukasa B., Braun E., Wenninger U., Siegrist S. (2008): Quality management systems 
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established along with driver rehabilitation schemes. DRUID (Driving under the Influence of 
Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 5.2.3 
D5.2.4: Bukasa B., Braun E., Wenninger U., Panosch E., Klipp S., Boets S., Meesmann U., Roesner 
S., Kraus L., Gaitanidou L., Assailly J-P., Billard A. (2008): Validation of existing driver 
rehabilitation measures. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 
6th Framework programme. Deliverable 5.2.4 
D6.1.1: Kærup S., Larson L., Godler K., Žlender B. (2009): State-of-the-Art Regarding Withdrawal of 
Driving Licence in Connection with Sanctions for Impaired Driving – Results of Questionares. 
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework 
programme.Deliverable 6.1.1 
D6.2.1: Bukasa B., Salamon B., Klipp S., Krisman M., Larsen L., Krašovec B., Merc K., Žlender B., 
Schnabel E. (2011): Recommendations on Withdrawal. DRUID (Driving under the Influence of 
Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 6.2.1 
D7.1.1: Raes E., Pil K., Van den Neste T., Verstraete A. (2007): Task 7.1 Review of guidelines, 
booklets and other resources: state oft he art. DRUID (Driving under the Influence of Drugs, 
Alcohol and Medicines). 6th Framework programme. Deliverable 7.1.1   
D7.2.1: De Gier J.J., Heissing M., Álvarez F.J., Tant M. (2009): Recommendations for improving 
medical guidelines for assessing fitness to drive in patients who use psychotropic medicines. 
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework 
programme. Deliverable 7.2.1 
D7.2.2: Monteiro S., De Gier J.J. (2011): Guidelines and Professional Standards. Report + CD or DVD 
with examples of ICT supported protocols for prescribing and dispensing of medicines affecting 
driving performance, and for informing patients who use other psychoactive substances than 
medicines. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th 
Framework programme. Deliverable 7.2.2 
D7.3.1: Álvarez F.J., Fierro I., Boets S., Meesmann U., Pil K. (2009): Prototypes of booklets, posters, 
messages for risk communication including a script for a TV-clip. DRUID (Driving under the 
Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 7.3.1 
D7.4.1: Margaritis, D., Touliou K., Ravera S., Monteiro S., De Gier J. J., Boets S., Meesmann U., 
Álvarez F.J. (2009): Training Manual for Physicians and Pharmacists on Medicinal drug and 
Driving. Evaluation and implementation of new technologies. DRUID (Driving under the 
Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 7.4.1 
D7.3.2 DRAFT: Meesmann U., Boets S., De Gier J.J., Monteiro S., Álvarez F.J., Fierro I. (2011): Main 
DRUID results to be communicated to different target groups (the one which we are writing). 
DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework 
programme. Deliverable 7.3.2 
D7.4.2 DRAFT: Touliou K., Margaritis D., Spanidis P., Monteiro S., Ravera S., De Gier J.J., Boets S., 
Meesmann U., Tant M. Legrand S.-A., Van der Linden T., Verstraete A., Fierro I., Gómez-
Talegón T., Martin L., Álvarez F.J. (2011): Report on the implementation, evaluation and new 
technologies ofpractice guidelines and information materials. DRUID (Driving under the 
Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 7.4.2 
D7.4.3 DRAFT: Heißing M., Holte H., Schulze H., Baumann E., Klimmt C. (2011) DRUID outcomes 
and risk communication to young drivers. DRUID (Driving under the Influence of Drugs, Alcohol 
and Medicines). 6th Framework programme. Deliverable 7.4.3 
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Annex  
Annex 1: Questionnaire used in the Spanish study 
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Annex 2: Definition of different illicit drug- and medication groups within the DRUID roadside 
survey (D2.2.3) 
•  “The THC substance group is formed by THC only. THC-COOH was detected as well in 
blood, but this inactive metabolite of THC will be regarded as negative. 
• The cocaine group includes both drivers with cocaine and with its metabolite 
benzoylecgonine.  
• The amphetamine drugs group consisted of amphetamine, methamphetamine, MDMA, MDA, 
and MDEA. 
• The illicit opiates group includes drivers that were positive for heroin (6-acetylmorphine) or 
the combination of morphine and codeine where the concentration of morphine is equal to or 
higher than the concentration of codeine. If the concentration of codeine is higher than that of 
morphine, the use was regarded as medicinal opiates and opioids use. 
• The benzodiazepines group consists of diazepam, nordiazepam, oxazepam, lorazepam, 
alprazolam, flunitrazepam, and clonazepam. 
• The medicinal opiates and opioids group consists of morphine, codeine, methadone and 
tramadol. 
• The Z-drugs group consists of zolpidem and zopiclone 
• The group alcohol and drugs (combinations) consist of alcohol 0.1 g/L in combination with 
one or more other psychoactive substances, excluding THC-COOH which is regarded as 
negative. 
• The group drug-drug combinations consist of the combination of two or more other 
psychoactive substances other than alcohol from at least two different groups of drugs, 
excluding THC-COOH which is regarded as negative” (D2.2.3). 
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Annex 3: Substance classes, groups and the analytical findings within DRUID hospital studies 
(D2.2.5 p. 37) 
 
 
“For calculating prevalence, substances of the same type were combined into following substance 
groups: alcohol, amphetamines, cocaine/1, cocaine/2, cannabis/1, cannabis/2, illicit opiates, 
benzodiazepines, Z-drugs, and medicinal opioids. Substance groups are aggregated into the following 
substance classes: alcohol, illicit drugs, medicines and following combinations: drug-alcohol and drug-
drug. This last class is specified as a combination of different substance groups. For example: 
zolpidem + cocaine will be considered a drug-drug combination but zolpidem + zopiclone will be 
considered a single use of z-drugs” (D2.2.5 p. 37).  
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Annex 4: Overview of the estimated European prevalence of psychoactive substances; 
prevalence in percentage; 95% confidence intervals in italics (D2.2.3 PART I p. 9) 
 
 
Source: D2.2.3 PART I p.9 
 
“This table shows the prevalence per substance group and per country as well as the estimated 
European means. The European mean can be used to distinguish per substance whether country 
prevalence is around, below or above this European mean. The table presents the spread of the 
prevalence around the estimated European mean. A yellow colour of a particular prevalence value 
indicates that the European mean lies within the 95% confidence interval of the prevalence. A green 
coloured value indicates that the confidence interval suggests that it is below the European mean, and 
a red coloured value indicates that the confidence interval suggests that it is above the European 
mean” (D2.2.3 PART I p. 5). 
 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
138 
Annex 5: Overview of the main results of all investigated substances in the DRUID road side survey (D2.2.3) and case-control study (D2.3.5)  
 
  ALCOHOL (alone) PSYCHOACTIVE MEDICINES (alone) ILLICIT DRUGS (alone) COMBINED USE 
  
Alcohol 
(≥0.1g/L) 
Alcohol 
(≥0.5g/L) 
Alcohol 
(≥1.2g/L) 
Benzodia-
zepines Z-drugs 
Medicinal 
opiates and 
opioids 
Ampheta-
mines Cocaine THC 
Illicit 
opiates 
Alcohol ( 
0.1g/L) and 
drugs 
Drug-drug  
Mean 
prevalence 
(D2.2.3) 
3.48% 1.49% ca. 0.4% 0.90% 0.09% 0.35% 0.08% 0.42% 1.32% 0.07% 0.37% 0.39% 
Prevalence 
ranking #1 #2 #6 #4 #10 #9 #11 #5 #3 #12 #8 #7 
Highest 
prevalence 
(D2.2.3) 
Italy 
(8.59%) 
Italy 
(5.23%) 
Lithuania 
and Italy 
(about 
1.4%) 
Portugal 
(2.73%) 
Norway 
(0.69%) 
Denmark 
(0.79%) 
Czech 
Republic 
(0.38%) 
Spain 
(1.49%) 
Spain 
(5.99%) Italy (0.3%) Spain (1.14%) 
Italy 
(1.22%) 
Main 
European 
region 
(D2.2.3) 
Southern 
Europe 
No 
specific 
region 
No 
specific 
region 
Southern 
Europe 
Northern 
Europe 
Northern 
Europe 
No specific 
region 
Southern 
Europe 
Southern 
Europe 
Southern 
Europe 
Southern 
Europe 
Southern 
Europe 
Main gender 
effect 
(D2.2.3) 
Male 
drivers   
Female 
drivers 
Female 
drivers 
Female 
drivers 
Differs per 
country 
Male 
drivers 
Male 
drivers 
Male 
drivers Male drivers 
Male 
drivers 
Main age 
effect 
(D2.2.3) 
Differs per 
country   
35 years 
and older 
Drivers 50 
years and 
older 
35 years and 
older 
Young 
drivers (18-
34) 
Drivers (18-
49) 
Young 
drivers (18-
34) 
Drivers 35-
49 
Young drivers 
(18-34) 
Drivers 
younger 
than 50 
Main time 
period effect 
(D2.2.3) 
Weekday 
nights and 
weekends 
  
Daytime 
hours 
Daytime 
hours at 
weekdays 
Daytime hours Differs per 
country 
Differs per 
country 
Differs per 
country  
Night time 
hours 
Differs per 
country 
Relative risk 
of serious 
injury or 
fatality 
compared to 
sober 
drivers 
(D2.3.5) 
5-10x1  20-200x 
2-10x 
(for benzodiazepines + Z-drugs and for 
medicinal opioids) 
5-30x 
2-10x (for 
benzoylecg
onine and 
for cocaine) 
1-3x 2-10x 20-200x 5-30x 
NA = not available; 1 For different concentrations: 0.1 – 0.5g/L: 1-3x; 0.5 - 0.8g/L: 2-10x;  0.8 - 1.2g/L: 5-30x 
 
 DRUID 6th Framework Programme - D 7.3.2 Main DRUID results to be communicated to different target groups  
139 
 
